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Ode to dendritic cells
'What is a dendritic cell, Daddy?'
'A dendritic cell, Son,' said I,
'Is a tall bag of cheese
Plus a Chinaman's knees
And the leg of a nanny goat's eye.'
'How strange is a dendritic cell, Daddy?'
'As strange as strange,' I replied.
'When the sun's in the West
It appears in a vest
Sailing out with the noonday tide.'
'What shape is a dendritic cell, Daddy?'
'The shape, my son, I'll explain:
It's tall round the nose
Which continually grows
In the general direction of Spain.'
'Are you sure there's a dendritic cell, Daddy?'
'Am I sure, my son?' said I.
'Why, I've seen it, not quite
On a dark sunny night
Do you think that I'd tell you a lie?'
With apologies to Spike Milligan and his Bongaloo
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Abstract
Dendritic cells (DCs) are the watchmen of the immune system. They survey the
peripheral tissues and display samples of surrounding antigens for inspection by T
cells. Pathogenic or inflammatory signals trigger DCs to mature, upregulating their
expression ofMHC and costimulatory molecules and converting them into potent T
cell stimulators. The character of the activated DC depends not only on the stimulus
but also on concomitant environmental signals. This thesis tests the hypothesis that
in vitro manipulation of DC function can be used to direct immune responses in vivo.
The work focuses on the cytokine IL-10 and asks whether its impact on DC
maturation can mediate T cell tolerance.
IL-10 has been reported to trap DCs in an immature state, leading to antigen
presentation without full costimulation and consequent T cell anergy. Data presented
here show that DCs do become activated in the presence of IL-10. They
downregulate antigen uptake and, 6 hours after stimulation, display high levels of
MHCII and B7. Their activation is short-lived, with both MHC and B7 expression
returning to baseline within 18h. Even at 6 hours, with high levels of surface MHC
and costimulation, the IL-10 treated DCs express little 1L-12 and fail to elicit strong
T cell proliferation. IL-10 seems not to act by inhibiting DC maturation but instead
by dictating the kinetics and quality of their activation.
The consequence of this DC activation for the responding T cells is also examined.
Both in vitro and in vivo, using co-cultures and adoptive transfers of TCR transgenic
T cells followed by DC-based immunisation, initial contact with IL-10 treated DCs
appears to leave T cells hyporesponsive to subsequent challenge. In a mouse model
of autoimmunity, these DCs suppress disease.
Taken together these data suggest that, rather than preventing DC maturation, IL-10
directs an active DC phenotype that can regulate immune responses. These DCs
have exciting therapeutic potential.
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Chapter 1 - Introduction
1.1 Overview
Dendritic cells (DCs) are potent antigen presenting cells (APCs). In vitro they
stimulate T cell proliferation with 100-1000 times the efficiency of bulk leukocytes
[1 ]; in vivo they are uniquely capable of eliciting a primary antigen specific response
[2, 3], DCs are often described as the sentry guards of the immune system, stationed
throughout the periphery, continuously sampling their environment by phagocytosis
and pinocytosis [4, 5], Antigens are taken in, processed and presented on the cell
surface. As the DCs migrate to the draining lymph node, they upregulate MHC and
costimulatory molecules and mature into specialised T cell stimulators, initiating
adaptive immunity [6, 7].
Their central role in the activation of naive T cells gives DCs a strategic position in
the control of immune responses. Many DC phenotypes exist, reflecting differences
in ontogeny, maturation stage and environment. Both myeloid and lymphoid DCs
have been reported and multiple developmental pathways are described (reviewed in
[8, 9]). Evidence suggests that DC phenotype can be altered by certain cytokines and
a model has been proposed in which different immune responses are thought to result
from equivalent DCs matured in different conditions [10]. DCs are capable both of
influencing the Thl/Th2 balance [11, 12] and inducing either tolerance or immunity
[13, 14], An appreciation of the mechanisms involved in this control might enable
specific manipulation of the immune system. This project set out to examine the
flexibility of DC function, using DCs cultured in the presence of defined stimuli.
The hypothesis is that DCs modified by stimulation in vitro can be used to direct the
outcome of immune responses in vivo.
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1.2 Professional APCs
DCs were first observed by Langerhans in 1868 [15], but it was not until 1973 that
Steinman and Cohn provided a full description [16], They were identified initially
by morphology (fig 1.1): their long cytoplasmic pseudopodia distinguished them
from other large mononuclear cells within a spleen preparation. Electron microscopy
revealed a typically large nucleus, an electron lucent cytoplasm relatively devoid of
small particles and a smooth outer surface, quite different from the ruffled
appearance of the macrophage membrane. Vital dyes and histochemical reagents
also demonstrated characteristic staining patterns. Dendritic cells were declared a
novel cell type, related to but distinct from macrophages [16-19],
Figure 1.1 DC morphology. The main picture shows a DC grown in a glass
chamber well and photographed using phase contrast microscopy, and was
provided by Lynda Stuart (CIR, University of Edinburgh). The smaller pictures are
cytospins, stained with H&E. These DCs were grown from bone marrow
precursors (upper picture; see section 2.3.3) or isolated from spleen (lower picture;
section 2.3.2) and were photographed at magnification xlOOO.
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1.2.1 Antigen uptake
Subsequent use of immunocytochemistry and flow cytometry revealed variations in
DC maturation state [20, 21]. Immature cells such as Langerhans cells (LCs) in the
skin and interstitial DCs in the kidneys, heart and other peripheral tissues [22, 23] are
primed for antigen acquisition. They filter soluble antigens from extracellular fluid
taken up by macropinocytosis at such a rate that they can internalise the equivalent of
their own volume within two hours [4], They are highly phagocytic, engulfing
particulate antigens or whole bacteria via membrane-bound receptors [24],
Phagocytosis is enhanced by opsonisation of pathogens with antibody or complement
[25, 26] and immature DCs have been shown to express both Fc receptors (FcyRI,
RII, and RIII and FceRI and RI1) [27] and the receptor for C3b [28], The CD1 lc
marker often used to identify DCs is a component ofCR4 [29], Scavenger receptors
such as CD36 are also expressed by immature DCs, enabling the phagocytosis of
apoptotic cells or debris [30, 31].
Immature DCs also capture considerable amounts of antigen by receptor-mediated
endocytosis [32]. They possess several lectin receptors, including the DC-specific
ICAM-grabbing non-integrin (DC-SIGN) [33], the DC immunoreceptor (DCIR) [34]
and DEC-205 [35, 36], The natural ligands for DEC-205 are unknown, but anti-DEC
antibodies are internalised and presented to T cells with 100 times the efficiency of
non-specific antibodies [37]. DCs also express the macrophage mannose receptor,
which binds carbohydrates and targets them to lysosomes [38], The low pH of the
lysosomal compartment dissociates the complexes and the receptor then returns to
the cell surface. This rapid recycling allows a limited number of molecules to
internalise a considerable amount of antigen [4], Interestingly, LCs express much
lower levels of the mannose receptor than other immature DCs and their endocytic
and phagocytic activity is relatively impaired [39]. This may be a regulatory
mechanism to dampen reactivity to harmless environmental antigens that contact the
skin.
The binding and intemalisation of antigens is further enhanced by DC receptors that
recognise common molecular structures on the surface of invading microorganisms.
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Janeway first proposed the existence of pathogen-associated molecular patterns
(PAMPs) and complementary pattern recognition receptors (PRRs) before any
examples were identified; he argued that such a system was necessary to distinguish
self from non-self and to prevent autoreactivity of the immune system [40], Since
immunity encourages antigenic variation by selecting against pathogens bearing
recognised motifs, PAMPs are usually structures that are essential for microbial
survival and hence are shared by many different microorganisms. They include cell
wall components of yeasts, gram negative and gram positive bacteria, such as
mannans, lipopolysaccharides (LPS), lipoteichoic acids (LTA) and peptidoglycans
(PDG), as well as flagellin, bacterial CpG DNA motifs and the double-stranded RNA
of viruses [41], Their receptors encompass antigen binding molecules such as DEC-
205 and the mannose receptor, together with a recently discovered family of
specialised PRRs, the Toll-like receptors (TLRs).
The original Toll receptor is a Drosophila protein involved in body patterning and
anti-fungal immunity [42], Ten mammalian homologues have now been identified,
expressed on APCs and other cell types [43, 44] and able to recognise a wide range
of microbial products (table 1.2). The TLRs are implicated in antigen internalisation:
CpG triggering of TLR9 requires an endosomal location [45, 46] and TLR2 is
recruited to phagosomes after challenge with zymosan [47], Both TLR2 and TLR6
accumulated in endosomes containing phagocytosed red blood cells, however,
despite neither being a specific receptor [48]. This may reflect a passive role of the
TLRs as innocent bystanders, swept into the phagosomes by physical proximity to
the receptor actually engaged by the erythrocytes. Alternatively, TLRs may be
actively recruited to the phagosome after internalisation, enabling them to peruse the
phagosomal contents and transmit danger signals when appropriate [48]. This ability
to signal is the basis of much of the interest currently surrounding TLRs: not only do
they bind pathogens but, by concomitantly stimulating DCs, they also form a bridge
between the innate and adaptive immune systems [44].
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TLR Putative ligand Reference
j unknown, [49]
but dimerises with TLR2
2 lipoproteins, peptidoglycans, [48,50-53]
structural variants of LPS,
zymosans
3 double stranded RNA [54]
4 LPS, [55,56]
F protein ofRSV, [57]
HSP-60, fibronectin [58, 59]
5 flagellin [60]
^ unknown, [48,49]
but dimerises with TLR2
7 unknown [61]
g unknown [61]
9 CpG DNA [46]
in unknown [62]
Table 1.2 Mammalian Toll-like receptors and their ligands. Compiled from [44, 63].
1.2.2 DC stimulation
The acquisition of foreign antigens is closely associated with DC activation,
initiating the changes that convert the DC from a dedicated antigen collector into a
specialised presenting cell. As pathogens are bound and internalised, they stimulate
signalling cascades that conventionally lead to upregulation ofMHC and
costimulatory molecules and the release of proinflammatory cytokines [7]. The
TLRs are classic examples of these signalling molecules. The inflammatory
response to most LPS molecules is mediated via TLR4: LPS hyporesponsive
C3H/HeJ mice carry a mutated version of the tlr4 gene [55] and B cells from TLR4"
mice fail to proliferate or to upregulate MHCII after LPS stimulation, despite a
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normal reaction to IL-4 [56]. TLR4 deficient macrophages are similarly affected,
releasing neither TNFa nor nitric oxide in response to LPS stimulation [56],
The TLR4 receptor is a transmembrane homodimer which clusters with both CD 14
and an adaptor molecule, MD-2, to form an LPS activation complex on the DC
surface (fig 1.3)[64, 65], Signals are transmitted into the cell through one of two
adaptor molecules that bind to a Toll/IL-IR (TIR) domain in the cytoplasmic tail of
each TLR4 molecule [66, 67]. MyD88 acts in conjunction with another adaptor,
Tollip, to recruit the IL-1 receptor associated kinase (IRAK) [68], Once activated,
IRAK dissociates from the complex and signals via a TNF-receptor associated factor,
TRAF 6, to initiate a MAP Kinase cascade that results in dephosphorylation of IkB,
release of the NFkB transcription factor and expression of a variety of genes under
Figure 1.3 Signalling through
TLR4. LPS binds the TLR4
homodimer through interaction with
the coreceptor CD 14 and an adaptor
protein, MD-2. Intracellular signalling
then occurs either via the adaptor
molecules MyD88 and Tollip, which
activate the IL-1 receptor associated
kinase (IRAK) and initiate a mitogen
activated protein (MAP) Kinase
cascade to release NFkB from
suppression, or via the alternative
adaptor MyD88-adaptor like (Mai,
also known as TIRAP) which then
signals through IRAK-2 and protein









B7.1, B7.2 ... |->- IL-1, IL-6, IL-12 ...
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the control ofNFkB response elements, including those encoding IL-1, IL-6 and IL-
12 [69, 70]. The second adaptor, named both MyD88 adaptor-like (Mai) and TIR
domain-containing adaptor protein (T1RAP) [71, 72], provides a MyD88 independent
pathway that leads to activation of the transcription factor IFN-regulated factor 3
(IRF-3) and expression of genes such as B7.1 and B7.2 [73, 74],
MyD88 and Tollip also associate with other TLR receptors, including TLR2, 5, 9 and
their heterodimers [48], and several of the downstream molecules such as IRAK and
the TRAF family serve additional receptors on the DC surface [75-77], This
convergence of signalling pathways at least partly explains the similarity of DC
activation in response to quite different stimuli. Huang et al. used microarray
technology to demonstrate that exposure of DCs to Escherichia coli, Candida
albicans and influenza virus each induced the same set of 166 genes, and that this
effect could be reproduced almost exactly by replacing the E.coli with LPS and the
influenza virus with double stranded RNA [78], This suggests that TLR4 and TLR3
use a common signalling pathway, presumably targeting NFkB [78], In addition to
the shared 166 genes, however, E.coli induced another 118 and influenza virus
activated a specific 58. These differences reflect the ability of alternative adaptor
molecules and coreceptors to interact with the TLRs, translating distinct stimuli into
individual blends of genes and appropriately tailored DC phenotypes [79].
The ability of TLRs to bind microbial motifs is a prime example of self:non-self
discrimination, but their specificity is not absolute. Both human heat shock protein
60 and fibronectin have been shown to activate signalling through endogenous TLR4
[58, 59]. Interestingly, fibronectin interacts with TLR4 via its extra domain A
(EDA) region. The EDA region is normally absent and is only expressed as a
product of alternative splicing, induced by tissue injury [80, 81]. The TLRs appear
then to be capable of recognising both foreign invasion and signs of damage or
'danger' within the host [82],
DC activation can also be triggered by other endogenous molecules. Necrotic cells
are potent stimuli of DCs, reflecting both their active production of distress signals
such as heat shock proteins and the passive release of molecules previously
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sequestered within the cell [83]. In the skin, IL-1, GM-CSF and TNFa are all
secreted by keratinocytes in response to physical or chemical disruption of the
epidermis, and all induce activation of local LCs [84-86], Indeed, Bennett et al.
proposed that the DC activation and subsequent immune reaction caused by infection
with Leishmania mexicana is initiated not by the uptake of parasites but rather by IL-
1 or other endogenous stimuli released in response to the bite of the sandfly vector
[87],
1.2.3 DC migration
The Langerhans Cell is often quoted as an illustration ofDC biology [88], DC
precursors enter the skin from the blood, seeding the tissue with a network of
immature DCs [89]. Antigen or inflammation elicits a rapid, local recruitment of
these immature DCs [90], and as the cells respond to the activation signals that they
encounter, they undergo a series of changes in phenotype and function known as
maturation [91], They show a transient upregulation of antigen acquisition [92],
ensuring that the antigens they carry reflect the microenvironment at the point ofDC
activation, before migrating out of the skin, via the lymphatics to the T cell area of
the draining lymph node. As they travel, DCs upregulate expression ofMHC and
costimulatory molecules, and they arrive as powerful T cell stimulators [7],
The emigration of LCs from the skin and their entry to the lymph nodes is controlled
by adhesion molecules and chemokine gradients. Immature LCs are anchored to
surrounding keratinocytes by their expression of E-cadherin [93]. On activation, E-
cadherin is rapidly downregulated [94] and the LCs instead display receptors for
c*6/|3i and integrins [95], encouraging adhesion to the basement membrane.
LCs are capable of protolytic activity and secrete type IV collagenase [96], This
enables them to penetrate the basement membrane and travel through the dermis to
the lymphatic system. The shifting attachments between LCs and connective tissue
are also mediated by changes in the CD44 isoforms expressed by the LCs, a
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consequence of alternative splice variations used at different stages ofmaturation
[25, 91}.
The role of chemokines in directing the movement of DCs is also becoming
increasingly well understood [98]. Chemokines are small, chemoattractive proteins,
often named after the number and spacing of cysteine (C) residues at their N-
terminus [99], Immature LCs are recruited to sites of inflammation by their
expression of the chemokine receptors CCR1, 2, 5 and 6, which recognise molecules
such as macrophage inflammatory protein (MlP)-la, MIP-1|3 and regulated on
activation, normal T cell expressed and secreted (RANTES). LC activation initiates
the downregulation of these receptors and replaces them with high levels of CCR7
which, through its attraction to the chemokines secondary lymphoid-tissue
chemokine (SLC) and MIP-3|3, guides the LCs into the T cell areas of draining
lymph nodes [100, 101]. The importance of this interaction is illustrated in mice
lacking either CCR7 or SLC: both knockout strains are unable to mount primary
immune responses because of inefficient recruitment ofDCs and naive T cells into
secondary lymphoid tissue [102, 103],
Once in the lymph node, the potent ability of DCs to stimulate T cells is also a result
of their maturation. The transient increase in antigen acquisition following LC
stimulation is accompanied by a temporary accumulation of de novo synthesised
MHCII molecules in cytoplasmic vesicles, enabling efficient loading with external
antigens [4, 92], This ends with a marked downregulation of both antigen uptake
and MHC production and instead, existing MHC:peptide complexes are transported
to and stabilised on the cell surface [92, 104], This enhanced antigen presentation is
supplemented by increased expression of adhesion molecules including ICAM-1, 2
and 3 and DC-SIGN, which together strengthen the physical interaction between
DCs and T cells [33, 105], and by marked upregulation of costimulatory molecules
such as B7.1 (CD80), B7.2 (CD86) and CD40, which augment T cell stimulation
[106]. DC maturation also elicits increased secretion of cytokines that promote
effector T cell development, including IL-12, IFNy and perhaps even IL-2 [107,
108] [109]. As a result, the classical outcome of LC activation and maturation is T
cell immunity (fig 1.4)[110].
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T cell expansion
and effector cell differentiation
Figure 1.4 Life cycle of a Langerhans Cell. Haematopoietic progenitors seed the
tissues with immature DCs. Inflammation or antigen stimulates the DC, triggering
maturation and migration to the draining lymph node. There the mature DC stimulates a
vigorous T cell response. Adapted from [398].
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1.2.5 Activation vs maturation
Models ofDC maturation such as this provide considerable insight into the important
stages in DC development, but they also raise several questions. Do all DCs respond
to stimulation in this way? Is maturation an inevitable consequence of DC
activation? The terminology here is confusing: 'activation' and 'maturation' are
often used interchangeably and neither has a clear definition. Strong stimuli such as
LPS or heat-killed bacteria, commonly used to activate DC in vitro, cause DC
maturation and subsequent death [5], In this situation, the two words describe very
similar events. This is not always the case. Both recombinant TNFa and a
Bordatella pertussis antigen have been reported to upregulate MHCII and B7
expression on DCs without eliciting cytokine secretion [111, 112], The DCs are
clearly activated, and yet they have only completed part of the classical maturation
process [113], A more extreme example is provided by DCs cultured overnight in
soluble egg antigen (SEA), derived from the eggs of the parasitic helminth
Schistosoma mansoni. Mice infected with the intact parasite mount a strong Th2
response that is essential for survival [114], DCs treated with SEA and then injected
in vivo induce a similarly powerful Th2 reaction. Importantly, they achieve this
without any detectable increase in expression of B7.1, B7.2, CD40 or ICAM-1 and
with very little upregulation ofMHCII [115], The Th2 response was specific to DCs
pulsed with SEA; it was not reproduced by untreated DCs. SEA therefore appears to
induce DC activation in the absence of any conventional maturation.
It may also be possible to generate mature DCs that are no longer activated. DC
activation is rapid. Export ofMHCII complexes to the DC surface is observed
within 2h of LPS stimulation [116] and IL-12 release can be detected within at 4h
[117], The process is also transient. Langenkamp et al. described the DC phenotype
after activation as 'exhausted'. Their LPS stimulation triggered classical maturation
in the DCs, but once that initial activity had passed, the capacity of the cells to
secrete cytokines, particularly IL-12, was spent [118], Reis e Sousa and colleagues
reported a similar phenomenon, which they called 'paralysis' [119], The timing of




1.3.1 Origins and Lineage
DCs are CD45+ leukocytes, originating in the bone marrow. This was neatly
demonstrated in allogeneic bone marrow transplants: donor strain MHCII was
expressed by Langerhans cells in the recipients' skin [120], Early analysis of the DC
phenotype noted the presence of certain monocyte and macrophage markers,
including CD14 and F4/80 [19, 20], The myeloid lineage ofDCs was generally
accepted, and the debate then was whether DCs represented an independent cell type
or were merely veiled macrophages [121], Steinman and colleagues demonstrated
the shared ontogeny ofDCs and macrophages in a series of colony forming assays:
single cells gave rise to mixed populations [122], Standard protocols for obtaining
DCs in vitro involve their differentiation from monocyte precursors [91, 123], and
the same appears to occur in vivo [124-126],
The paradigm of a myeloid, immunogenic DC is not always a valid one, however.
Thymic DCs are thought to effect negative selection of developing T cells and
contribute to tolerance rather than immunity [127, 128]. A significant number of
these thymic DCs in mice display the CD8 surface marker typical of lymphoid cells
[129]. The CD8 was shown to be endogenously produced, suggesting a lymphoid
origin. This was supported by adoptive transfer experiments in which early T cell
precursors, still capable of developing into B lymphocytes but not to erythroid or
myeloid cells, formed both DC and T cell progeny when used to reconstitute an
irradiated thymus [130, 131].
Although these key thymic reconstitution experiments were not clonal, formally
leaving open the possibility that trace contamination by myeloid progenitors might
account for the DCs that developed, the evidence for a lymphoid lineage is strong.
DCs have been observed with B as well as T cell characteristics. Grouard et al. first
described the human 'plasmacytoid T cell', which expresses the lymphoid marker
CD4, resembles a plasma cell in appearance, and yet will readily differentiate into a
DC when cultured in conditioned medium [132], CD 19 positive pro-B cells can
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acquire a DC phenotype in vitro [133], and a subset ofDCs found in murine
lymphoid tissues has recently been identified by expression of the common B cell
marker B220 [134, 135],
Further support for two distinct lineages ofDCs was provided by the analysis of
transcription factor mutants, which revealed differences in signalling requirements
between DC subsets (table 1.5). PU.l is an efe-family transcription factor expressed
in early haematopoietic progenitors [136]; PU.l knockout mice have CD8+
'lymphoid' but not CD8- 'myeloid' DCs [137], RelB is a component ofNFkB
Transcription factor
removed
Cells disrupted Cells surviving Reference
PU.l CD8- myeloid DCs CD8+ lymphoid DCs [137]
RelB All myeloid cells
inc. most DCs
CD8+ DCs in spleen,
thymic DCs
[138] [139]
Ikaros (dominant negative) Lymphocytes, most
DCs
Myeloid cells, LCs [141, 142]
Ikaros (C terminal null) B cells, NK cells,
most DCs
Myeloid cells, LCs,
T cells, CD8+ DCs
[143]
Table 1.5 Lymphoid and myeloid specific deficiencies in transcription factor knockout mice.
complexes and RelB null mice lack CD1 lc+ myeloid cells including the majority of
DCs [138], Wu et al. noted a residual population of splenic CD8+ DCs in these
mice, and suggested that normal development of thymic DC would occur were the
thymic medulla not so defective [139], Conversely, Ikaros is a lymphoid specific
transcription factor and a dominant negative mutant, Ik7, blocks the in vitro
development ofDC from human lymphoid precursors [140], DC differentiation
from peripheral monocytes was unaffected. The same dominant negative mutation in
transgenic mice severely disrupts both lymphocyte and DC development. Myeloid
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cell and epidermal LC populations survive intact [141, 142], A null mutation at the
C-terminus of Ikaros, specific to Ikaros and not affecting related genes, similarly
depletes B and NK cells but some T cell development leaks through. Importantly,
this is accompanied by the appearance ofCD8+ DCs in the thymus [143],
These data strongly support the existence of lymphoid well as myeloid DCs, but the
observations are not unambiguous. The extent of DC disruption in Ikaros deficient
mice indicates either that all DCs other than LCs are lymphoid in origin, or that
Ikaros is also involved in the development of some myeloid cells. A similar story
emerges from an analysis of the cytokine dependence of different DC populations.
Saunders et al. [144] have reported the unique ability of lymphoid DCs to develop in
culture without GM-CSF, and they argue that the common use ofGM-CSF as a
support factor for DC growth in vitro may skew results towards apparently myeloid
origins. The cytokine cocktail needed to replace GM-CSF was complex, however,
and notably included IL-3 and 1L-7. In the absence of these interleukins, GM-CSF
regained its influence as a growth factor. The receptors for IL-3 and GM-CSF share
a common (3 chain and may stimulate the same signalling networks [145], Mice in
which the GM-CSF gene is disrupted show little deficiency in DC number [146],
Again, this could reflect either the lymphoid origin of the majority ofDCs, or merely
the redundancy of cytokine function in vivo.
1.3.2 DC subsets
A discussion ofDC lineage becomes largely academic without some implication of
functional consequence. The evidence for an ontogenic influence on DC function in
vivo is not yet clear. Thymic DCs are CD8+, are almost certainly lymphoid [130,
147] and mediate tolerance rather than immunity [148, 149], but the T cell outcome
here may well reflect the developmental stage of the thymocytes rather than any
inherent quality of the DCs [150], CD8 expression is also a feature of a subset of
DCs in the spleen, lymph nodes and certain non-lymphoid organs (fig 1.6) [129],
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Figure 1.6 DC subsets of mouse lymphoid organs. Splenic DCs comprise three major
subpopulations, defined by their expression of CD8aa and CD4. Lymph nodes contain the
same three subsets with two additional populations, thought to arrive through the lymphatic
system. One of these expresses low levels of CD8 but is Langerin positive and probably
represents the mature form of epidermal Langerhans cells. The other is distinguished from
CD8-CD4- double negative DCs by its expression of DEC-205, and is believed to be the
mature version of tissue interstitial DCs. The arrows here denote only phenotypic divisions
and do not indicate any lineage relationship.
that their CD8 expression is lineage specific. Splenic CD8+ DCs do not originate in
the thymus: they are present as normal in athymic nu/nu mice [149]. They cannot
then share the same lymphoid precursor as thymic DCs. Shortman and colleagues
argue that equivalent lymphoid progenitors might exist in the bone marrow [153], but
other researchers have demonstrated that splenic CD8+ DCs can derive from a highly
purified CD8- DC population in vivo [154]. This suggested a shared and perhaps
sequential myeloid lineage. Kamath et al. have used bromodeoxyuridine (BrdU)
staining to assert the opposite [155], however, and the case is still undecided.
Langerhans cells have been shown to upregulate CD8 expression on maturation,
essentially converting from a CD8- to a CD8+ phenotype [156], and two other
reports have described the emergence ofCD8+ DCs from myeloid precursors [157,
158],
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Although CD8 has disadvantages as a lineage marker, it does separate distinct
functional populations. In keeping with the role of thymic DCs in central tolerance,
CD8+ DCs in the spleen and lymph nodes were originally proposed to mediate
peripheral tolerance [151]. Shortman and colleagues demonstrated suppression of
both CD4 and CD8 T cell responses by CD8+ DCs. CD4 inhibition was associated
with T cell apoptosis, perhaps due to the expression of FasL by CD8+ DCs [159];
CD8 suppression was due to failure of IL-2 induction [160, 161]. More recently,
O'Connell et al. increased cardiac allograft survival by pretreating mice with donor
strain CD8+ DCs [162], and Heath and Carbone have identified the APC responsible
for cross-tolerance of the CD8+ T cell pool as a CD8+ DC [163, 164], The same cell
has been previously implicated in cross-priming [165], however, so factors other than
DC subset are clearly involved.
In contrast to any tolerogenic role, several groups have reported the preferential
induction of Thl reactions by CD8+ DCs [152, 166, 167], and it is now widely
accepted that CD8+ DCs are the dominant producers of IL-12 [168, 169]. Both
conclusions serve to emphasise the influence of subset divisions on DC function, but
otherwise reconciling tolerance with strong Thl responses is difficult. The
explanation may lie in the regulatory functions of Thl cytokines such as IL-2 and
IFNy. IL-2 is a prototypic T cell growth factor, supporting the clonal expansion of
activated T cells by both autocrine and paracrine routes [170], IL-2 knockout mice
are not immunodeficient, however, but instead display profound lymphocyte
hyperplasia and symptoms of autoimmunity. Other cytokines appear to be able to
compensate for its growth factor function, but its presence as an inhibitor is
absolutely necessary to prevent anti-self responses [171]. IL-2 may potentiate Fas-
mediated apoptosis [172-174], which is in keeping with the deletional tolerance seen
among CD4 T cells responding to CD8+ DCs in vitro [159]. The Thl cytokine IFNy
has also been reported to drive T cell apoptosis: cells lacking IFNy are protected
from activation-induced cell death [175], T cell tolerance and Thl proliferation may
then be two sides of a fine balance, and in this situation, minor discrepancies in the
cell purities and model antigens used in individual laboratories might be sufficient to
generate quite different outcomes.
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Distinct lineages and subsets of DCs exist in man as well as in mouse (reviewed in
[169, 176]), although how exactly the populations correlate between species remains
unclear [9]. Human DCs lack the CD8 marker seen in mice, but they do express CD4
[132] and the CD4+ CD3- CD1 lc- "plasmacytoid" DCs that emerge from cytokine
stimulation of peripheral blood are probably lymphoid in origin [132, 177, 178],
Functionally, monocyte-derived, CD4- CD1 lc+ "DC1" cells respond to bacterial
stimuli with a vigorous release of proinflammatory cytokines such as IL-12, TNFa
and IL-6 [11, 179]. The plasmacytoid "DC2" cells and particularly their precursors,
the pre-DC2s, are instead a major source of type 1 interferons [180, 181] and hence
form an important anti-viral defence [182]. lFNa/(3 producing DCs have also been
identified recently in mice [183]. The correlation between human and murine DCs is
complicated by the difficulty of accessing equivalent tissues. Most human studies
use peripheral blood, a scant resource in mice. Shortman and colleagues have
recently begun a heroic investigation of the DC subsets in mouse blood (Shortman,
2002, NIH/NIAID meeting, Airlie, Virginia, USA) and, with support from rare
descriptions of the DC populations in human spleen and tonsils [184-186], they
maintain that a direct comparison of DCs in mice and men will reveal close
similarities [9],
1.3.3 DCplasticity
The great attraction of DCs for immunotherapy is their ability to assess the nature
and context of an antigen and to tailor the immune response appropriately. DC
subsets make a substantial contribution to this flexibility, providing the total DC
population with a variety of possible functions. Several mechanisms exist to target
antigens to relevant DCs. Human, monocyte-derived 'DC1' cells express a different
range of antigen recognition receptors from their plasmacytoid 'DC2' counterparts.
DC Is display high levels ofmannose receptors, favouring the uptake of
polysaccharide antigens, while DC2 cells instead express a unique lectin molecule
recognised by the antibody BDCA2 [132, 187], In the mouse, separate DC
populations have been defined by differential expression of the lectin DEC-205 [188-
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190], The TLR family of receptors also show subset specificity, with TLRs 2 and 4
predominantly expressed on DC1 cells and TLRs 7 and 9 restricted to DC2s [191,
192], Such distinctions may extend to the level of antigen presentation: DC1 cells
are particularly rich in CD 1 molecules, enabling more efficient presentation of lipid
moieties [193].
That said, the need to match each antigen with a particular DC seems surprisingly
inefficient. It is improved by appropriate tissue localisation of the DC subsets. The
best example of this is the dominance of tolerogenic lymphoid DCs in the thymus
[190, 194], but other tissues also show characteristic immune responses and this too
could be a result of polarised DC compositions. The LCs of the skin are classic
examples of immunogenic DCs [20] and, correspondingly, antigen delivery by a
subcutaneous route favours strong immunity [195]. DCs isolated from Peyer's
Patches appear to be inherently skewed towards Th2 induction [196, 197], which
may reflect the contribution of Peyer's Patches in providing access for intestinal
antigens to the immune system. The liver is also an inherently tolerogenic organ
[198, 199] and considerable effort has been made to identify and exploit the DC
characteristics that contribute. Liver-derived DCs cultured with IL-3 and anti-CD40
were recently shown to induce regulatory T cells in vitro and prolong allograft
survival in vivo [200],
Another unique quality of the liver is its cytokine microenvironment. Hepatocytes
secrete TGF|3 and IL-10 [201-203], both ofwhich are reported to inhibit DC
maturation and suppress T cell responses [204, 205], The influence of these
cytokines implies that the flexibility ofDC function is not just a population effect but
also a feature of individual cells. Indeed, Kalinski et al. have proposed a model in
which equivalent myeloid DCs are matured and polarised by environmental signals,
generating very different T cell outcomes [10]. The supporting evidence is strong.
IFNy has been shown to enhance DC production of IL-12 and skew responding T
cells towards a Thl phenotype, while prostaglandins suppressed IL-12 release and
produced a Th2 response [10, 12]. Sato et al. stimulated DCs in vitro with GM-CSF,
IL-3 and IL-12 and achieved a clear Thl response; replacing the IL-12 with IL-4
instead promoted Th2 proliferation [206], Human plasmacytoid DCs, which when
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cultured with IL-3 will preferentially drive a Th2 reaction, are capable of eliciting
IFNy and 1L-10 from T cells when stimulated with herpes simplex virus [182, 207].
Similarly, murine bone marrow-derived DCs can distinguish bacterial and parasitic
antigens and stimulate type 1 and type 2 immunity accordingly [115, 208], even
discriminating between the yeast and hyphae of the fungus Candida albicans [209].
The plasticity ofDC function is not restricted to regulation of the Thl/Th2 balance.
Kalinski's model also described 'type 3' DCs, generated in the presence of IL-10
[10]. IL-10 is an immunosuppressive cytokine, originally described as a product of
polarised a Th2 clone [210] and now known to be released by a variety of cells
including keratinocytes, B cells, macrophages and DCs [211, 212], It downregulates
the APC function ofmacrophages and DCs, reducing surface MHC and
costimulation and inhibiting cytokine production [213-215], Its effect on DCs is
described as an inhibition ofmaturation: IL-10 is thought to prevent the upregulation
of activation markers such as MHCII and B7.2, causing the DC to arrive in the
lymph node and interact with T cells while still essentially immature [205, 216],
Although capable of forming surface MHC:peptide complexes [217], the low levels
ofCD40, B7.1 and B7.2 on these cells are thought to result in antigen presentation
without adequate costimulation, leading to T cell tolerance [10, 216],
Other reagents have also been reported to inhibit DC maturation, including
corticosteroids [218], vitamin D3 derivatives [219] and malaria-infected erythrocytes
[30]. All appear to suppress T cell responses in vitro. The function ofDCs is clearly
influenced by their maturation state: immature DCs are thought to induce tolerance;
mature DCs, immunity [220], Their activation state may also be significant. In their
characterisation of post-activation 'exhaustion', both Langenkamp et al. and Reis e
Sousa et al. described the contrasting T cell reactions induced by DCs at different
times after stimulation. The peak of activation was associated with a Thl outcome;
post-activation quiescence with Th2 [118, 119]. The importance of timing was
























iDC "DC1" "DC2" "DC3" dead
Figure 1.7 Models of DC differentiation. DCs show considerable flexibility of
function. This could be a result of (A) the contribution of distinct subsets, (B) the
influence ofpolarising signals and (C) the kinetics of DC activation.
The plasticity ofDC function is apparent at several levels. Subsets, context and
kinetics all contribute (fig 1.7). Despite the great debate between proponents of
lineage and environment in the late 1990s [222], none of these influences are
mutually exclusive. It may be, for instance, that the ontogeny of a DC dictates the
extremes of its possible functions and the cytokine signals received during activation
then determine where within that range the DC operates. The potentials of different
DC populations may be overlapping but not necessarily identical. Indeed,
Maldonado-Lopez et al. recently reported that the distinct functions of CD8+ and
CD8- DCs can be partly but not wholly reversed by prior treatment with the
cytokines IL-10 and IFNy [12], Similarly, Edwards et al. have described the ability
of yeast extracts to elicit IL-10 release from all three splenic DC populations,
CD8+CD4-, CD8-CD4+ and CD8-CD4-, while bacterial stimuli could only induce
IL-12 secretion in two. The CD8-CD4+ DCs activated with Mycobacterium extract
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were inhibited in their expression of IL-10 but could not make the full transition to
IL-12 production [223].
1.4 DC : T cell interaction
The flexibility provided by a DC system ofmultiple subsets and individual plasticity
enables immune responses to be moulded to fit their specific challenge. The
translation of each DC phenotype into a qualitatively different immune reaction
relies on a series of cell surface and soluble signalling events that occur during the
initial DC:T cell interaction.
1.4.1 TCR engagement
As nai've T cells circulate through secondary lymphoid tissue, they form weak and
transient attachments with waiting APCs through the interaction of leukocyte
function antigen (LFA) -1 and CD2 on the T cell surface and ICAM-1,2 and 3 and
LFA-3 on the DC. DC-SIGN is also important, contributing to the positioning of
DCs in the T cell area [224] and reinforcing the early DC:T adhesion [33]. These
events are thought to slow the passage ofT cells through the lymph node, allowing
TCRs time to sample the contents ofMHC grooves on display. Signalling through
the TCR further enhances T cell expression of adhesion molecules and induces a
conformational change in LFA-1 that markedly increases its binding affinity for
ICAM-3, stabilising cellular attachment [225].
This initial engagement of the TCR is followed within minutes by remodelling of
both cell membranes to form a focus of tight contact, known as the immunological
synapse [226, 227]. TCRs and costimulatory molecules become concentrated in a
central supramolecular cluster (the cSMAC), surrounded by a ring of larger adhesion
molecules such as CD2, LFA-1 and CD45, which are physically squeezed to the
periphery (the pSMAC)[228], Cytoskeletal rearrangements polarise the cells
towards the synapse, bringing together receptor and signalling molecules and
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enabling the efficient, directional secretion of cytokines [229], The synapse
facilitates the extended TCR signalling needed to commit the T cell to proliferation
and IL-2 production. While effector or memory T cells can achieve this activation
within 30 minutes, naive cells can take between 6 and 30+ hours [230]. During this
time, specific MHC:peptide complexes on the DC are thought to be repeatedly
engaged and disengaged by a rapid turnover of TCRs on the T cell surface. In
optimal conditions, 100 MHC:peptide complexes can bind and downregulate up to
CD4
Figure 1.8 The TCR receptor. Peptide:MHC complexes on the
DC are recognised and bound by the T cell receptor a(3
heterodimer. Signalling occurs via ITAM motifs in the e, 6, y and
especially £ chains of CD3. The CD4 and CD8 coreceptors deliver
src-family kinases to initiate the phosphorylation cascade.
20 000 TCRs within 5hours [231, 232], This serial triggering causes an
accumulation of downstream signalling events inside the T cell, eventually exceeding
an activation threshold and inducing proliferation and effector cell differentiation
[233],
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The TCR clusters on the T cell surface with a CD3 complex, comprising y,6,e and
intracellular t, chains (fig 1.8)[234], The CD4 or CD8 coreceptor also associates,
delivering the protein tyrosine kinase Lck which, together with a related kinase, Fyn,
initiates the signalling cascade that translates TCR engagement into T cell activation.
Lck and Fyn phosphorylate key sites in the immunoreceptor tyrosine-based
activation motifs (ITAMs) contained within the tails of the CD3 complex, leading to
ZAP-70 recruitment and downstream activation of adaptor molecules (reviewed in
[235]). This results in cytoskeletal reorganisation and altered gene expression,
coordinated by transcription factors such as NF-AT, AP-1 and NFkB [236, 237],
1.4.2 Costimulation
In naive cells, the coupling of TCR engagement to downstream signal transduction
pathways is relatively inefficient [238], Costimulation serves to stabilise and
amplify the signals emanating from the TCR by recruiting kinases and adaptor
proteins to the synapse [239], The best characterised of the costimulatory
interactions is that between the B7 molecules B7.1 and B7.2 on the DC and CD28 on
the T cell. Antibodies against B7.2 inhibit a mixed leukocyte reaction and negate a
primary antigen specific response [106, 240], Other molecules also contribute.
Activated DCs express 4-IBB ligand [241], which binds the 4-IBB receptor
expressed on both CD4 and CDS T cells and preferentially drives CD8 proliferation
and IFNy release [242], and the TNF family members CD40 and OX40L, which both
have receptors on activated T cells [243, 244], Costimulation is not restricted to
contact dependent mechanisms. A recent report described IL-2 release by DCs, and
this could act as a soluble mediator to initiate and support IL-2 production in
responding T cells [109, 245],
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Dendritic cell T cell
Figure 1.9 DC:T cell dialogue. Interaction between B7 on the DC and CD28 on the T
cell augments peptide:MHC signalling through the TCR, and leads to T cell upregulation
of CD40L. This binds CD40 and increases DC activation, inducing surface expression of
OX40L. Signalling through OX40 increases T cell stimulation and encourages
polarisation of the T cell response.
Costimulation is a two-way conversation. Activated T cells express TNF-related
activation induced cytokine (TRANCE), which interacts with its receptor, receptor
activator ofNFkB (RANK), on the DC to potentiate cytokine release and prolong
survival [246,247], Signalling via B7 can also regulate DC function: in vivo therapy
with the high affinity B7 ligand CTLA-4-Ig was recently shown to regulate an
immune response not just by blocking the binding ofB7 to CD28 but also through its
impact on DC metabolism [248, 249], One of the T cell consequences ofB7:CD28
communication is the enhanced expression ofCD40 ligand, which then engages
CD40 on the DC and elicits further DC activation, particularly increasing the
production of cytokines such as IL-12 [243]. The additional stimulus given to the
DCs also upregulates their expression ofOX40L and so reinforces T cell
costimulation through OX40L:OX40 interaction (fig 1.9)[244, 250],
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1.5 T cell outcomes
1.5.1 ThlvsTh2
Thl and Th2 subsets were first identified by Mosmann and Coffman in 1986 [251].
They are defined by their distinct cytokine production and effector functions: Thl
cells secrete IL-2 and IFNy and are potent activators of macrophages; Th2 cells
release IL-4, IL-5 and IL-13 and support humoral immunity [252], The two cytokine
profiles are mutually antagonistic. IFNy inhibits Th2 development; IL-4 and IL-10
both limit Thl differentiation and dampen macrophage activity [253, 254], The
polarised phenotypes that result are echoed in CD8 T cells, B cells and even NK cells
[221, 255-257]. Many factors influence the decision between Thl and Th2
dominance of an immune response, and there is increasing evidence that DCs
contribute by instructing the T cells at the moment of priming (reviewed in [168]).
IL-12 and IL-4 are critical driving factors for Thl and Th2 reactions respectively.
DC production of IL-4 has been reported [209], although not yet been reproduced.
In contrast, the ability ofDCs to synthesise and release considerable quantities of IL-
12 has been widely observed. Some IL-12 can be induced by strong activation
signals such as LPS and other bacterial components [119, 258], but this response is
potently enhanced by T cell interaction or anti-CD40 treatment [107, 259, 260],
Interestingly then, CD40 costimulation has recently been implicated in the
development of a Th2 biased response. CD40~/~ DCs were shown to be fully capable
of supporting a Thl reaction against bacterial antigens from Propionibacterium
acnes, but were unable to elicit Th2 cytokines in response to an extract from
Schistosoma mansoni [261], The role ofCD40-CD40L signalling appears
dispensable for the activation of Thl cells, but critical to Th2 differentiation.
Other costimulatory molecules are also thought to influence Thl and Th2 responses.
A dominance of B7.2 signalling over that of B7.1 has been reported to favour a Th2
reaction [262, 263]. OX40 costimulation is also associated with Th2 development,
and anti-OX40 stimulation of naive T cells in vitro induces IL-4 expression [264],
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Lane and colleagues [250, 265] have argued that T cells receiving a strong signal
through OX40 will respond by upregulating the chemokine receptor CXCR5, which
acts as a homing receptor to guide them into B cell follicles. Once there, they
provide cognate help for B cells, encouraging IL-4 release and class switching to the
Th2 associated IgGl isotype. OX40 costimulation is clearly also involved in the
optimal function ofThl cells, however, since an OX40-Ig fusion protein that blocks
the T cell signal also prevents the development of inflammatory diseases such as
inflammatory bowel disease (IBD) and experimental autoimmune encephalomyelitis
(EAE) [266, 267], Lane's explanation is that the fusion protein also binds to OX40L
expressed on vascular endothelium [268], and so prevents activated Thl cells from
entering the inflamed tissues to perform their effector functions [265]. It remains
controversial. Normal T cells transferred into OX40L deficient mice will home to
sites of inflammation; Chen et al. argue that the impaired hypersensitivity responses
in these mice reflect the importance of OX40-OX40L interaction in the priming of
Thl cells [269],
The potential of OX40 signalling to direct Th2 reactions contrasts with the notion of
Th2 as a default response that occurs in the absence of IL-12 [10]. Evidence
suggests that a Th2 phenotype can occur by default: IL-127" DCs elicit IL-4 in vivo
[152] and, in culture, 'exhausted' DCs that can no longer produce IL-12 will also
trigger IL-4 release from responding T cells [118]. The lack of IL-12 is not always
sufficient, however, and particularly in experiments using pathogen-derived antigens,
a Th2 response also appears to involve positive induction. Jankovic et al. recently
reported that, although IL-12~/_ mice produce only limited IFNy in response to
antigen from Toxoplasma gondii, an intracellular parasite that normally generates
powerful Thl immunity, there was no compensatory increase in IL-4 expression
[270]. This contrasted with results from MyD88 deficient animals which, when
given the same challenge, displayed a strong Th2 response involving IL-4, IL-5, IL-
10 and IL-13 [270], These data suggest either that some component of the T. gondii
extract signals to induce a Th2 response, which only becomes evident when the
dominant Thl response is completely inhibited, or that IL-12 is involved in Th2 as
well as Thl development [271]. Similar data had been provided by Kaisho et al.,
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who demonstrated that activation ofMyD88"" DCs leads to a Th2 bias in a
subsequent MLR and argued that this cannot be explained solely by the lack of pro¬
inflammatory cytokines made by these impaired DCs. MyD88 sufficient DCs
derived from IL-12_/", IL-18-/~ or double knockout mice failed to induce IFNy in the
MLR, but did not skew towards Th2 [272], Kaisho et al. proposed that Th2
induction results from TLR signalling via the MyD88 independent pathway (fig 1.2).
Others have argued for the existence of an independent family of PRRs, equivalent to
the TLRs but specific for parasitic antigens, which are poised to direct the
development of appropriate Th2 responses [273],
1.5.2 Immunity vs tolerance
The outcome of the DC influence on an immune response can be a Thl or Th2 bias,
or either immunity or tolerance [13, 14], 'Tolerance' was originally used by Burnet
to describe the negative complement to immunity necessary to protect against self
destruction [274], but while Burnet referred only to the deletion of autoreactive T
cell clones in the thymus, such central tolerance is now known to be incomplete.
Self-reactive T cells with low affinity receptors or those specific for antigens not
expressed in the thymus can escape into the periphery, and so additional mechanisms
must act outside the thymus in order to prevent autoimmunity [82, 275], This
peripheral tolerance also serves to inhibit other unwanted immune responses, such as
reactions to antigens within food or shed by commensal bacteria [276],
One form of peripheral tolerance is T cell ignorance: some self antigens are
sequestered away from the immune system, hidden behind physical defences such as
the blood-brain and blood-ocular barriers (BBB and BOB, respectively). These
barriers are constructed from specialised vascular endothelia and close junctional
complexes that together form a tight sieve to regulate the passage of
macromolecules, pathogens and cells into the parenchyma of the brain or eye. They
confer a status of 'immune privilege' on these tissues, reflecting the organs'
importance for survival and their inability to regenerate [277-279]. The exclusion
thought to be responsible for this 'privilege' was argued to prevent autoreactive T
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cells from encountering their antigen, and to deny access to effector cells activated
elsewhere. The implied risk was that any breach of the barrier, perhaps through
traumatic insult, might allow ensuing autoimmunity to destroy whatever tissue the
initial injury had left intact [280], Limited lymphatic drainage and immune
surveillance of the CNS and the eye does occur [281, 282], and other mechanisms
contribute to the immune suppression in these sites. The tissues of the retina and
cornea express FasL, causing Fas-mediated apoptosis of activated T cells in situ
[283], DCs populate the neural parenchyma only very sparsely [284, 285], and
although resident microglia can upregulate MHCII expression upon activation [286],
this is apparently in the absence of costimulatory molecules and so prohibits
immunity [287, 288].
Antigen presentation without adequate costimulation is a classical method of
tolerance induction [289, 290], The T cell response is characterised by limited
proliferation, a lack of cytokine production, particularly of IL-2, and the persistence
of this hyporesponsiveness even after subsequent stimulation with fully competent
APC. The phenomenon is known as T cell anergy, and it was first described in
response to free peptide, presumably presented in a paracrine way by the MHCII+
human T cells to which it was given [291]. Other early demonstrations used fixed
splenocytes [292] or purified MHCII molecules [293]. While a costimulation
blockade is an effective method of disabling specific T cell responses in vitro [294],
the inability to transcribe IL-2 is easily overcome by exogenous cytokine [295] and it
seems a surprisingly fragile mechanism to be employed in vivo. Indeed, Matzinger
[82] has argued that functional hyporesponsiveness can only be at best a temporary
state that tolerised T cells pass through on their way to death, and at worst an in vitro
artefact. Pape et al. have demonstrated the long-term survival of tolerised T cells in
vivo, however, and they argue that neither immune deviation nor active suppression
are responsible [296], Whether purely experimental or also physiological, it appears
that anergy can be an in vivo phenomenon.
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1.5.3 Regulatory T cells
The contribution of active suppression to peripheral tolerance is currently the focus
of renewed interest, with the recent publication of a wealth of new and largely in vivo
data describing the existence of regulatory T cells [297]. Thl and Th2 cells have
long been reported to downregulate each other's function [254], so both could be
described as 'regulatory' in certain situations. Indeed, immune deviation is a
recognised form of T cell tolerance [298] and a Th2 balance has been shown to be
protective in Thl-driven transplant rejection and autoimmune reactions [299, 300],
The use of immune deviation as a therapy is a risky one, however. Th2 reactions are
not null responses and lupus is a crippling example of antibody-mediated pathology
[301],
In contrast, one of the therapeutic attractions of the newly defined regulatory T cells
is their potential to suppress both Thl and Th2 responses [302], The existence of a
natural population of inhibitory cells was elegantly demonstrated by Powrie and
colleagues, who reconstituted lymphocyte deficient SCID mice with T cells depleted
of their CD45RB10 component and saw severe colitis develop 6-8 weeks later. The
CD45RB10 cells alone did not induce colitis and, moreover, were able to prevent
disease when the two populations were transferred together [303, 304]. The
CD45RB10 population was functionally heterogeneous, containing memory and
effector cells as well as those with regulatory action. Other groups reported a
naturally occurring CD4+CD25+ regulatory T cell population [305, 306] and indeed
CD25 was found to correlate more closely with inhibitory function in the colitis
model than either of the CD45RB or CD38 markers used previously [307, 308], The
difficulty with all three of these molecules is that their expression is shared with
activated CD4+ T cells irrespective of function, and to date the only definitive
marker of regulatory T cells is their suppressive action [309],
The mechanisms by which regulatory T cells operate are uncertain. CD4+CD25+
"Tregs" are anergic in phenotype: they proliferate only poorly in response to
stimulation [306]. They also appear to induce anergy in their target cells: they inhibit
IL-2 expression in cocultured CD25- cells, and the constraint that this imposes on T
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cell proliferation can be overcome by addition of exogenous 1L-2 [310], How
exactly the suppression of 1L-2 is achieved remains controversial. It was suggested
that the constitutive expression of CD25 enables them to act as IL-2 'sinks',
depriving otherwise responsive cells of access to sufficient IL-2 to initiate the
autocrine amplification [170], but recently activated T cells expressing equivalent
levels of CD25 do not suppress proliferation [310], Regulatory T cells also require
activation through their TCR in order to assume their inhibitory phenotype [310-
312], although their targets do not need to share the same antigen specificity or even
MHC restriction [310]. Physical contact between CD25+ Tregs and target cells is
essential, as transwcll separation eliminates suppression [310]. Although this
suggests that soluble cytokines are not primarily responsible for CD25+ regulation,
Nakamura et al. have proposed that surface bound TGF(3 is critical [313]. They
report that CD25+ T cells activated in vitro display a reactivity with an anti-TGF|3
antibody that is not shared by their CD25- counterparts, and they argue that
contradictory accounts of the inability of anti-TGF(3 antibodies to abrogate
suppression [310] are due to the failure of the antibodies to penetrate the tight contact
between interacting cells. Perhaps conclusive data here is provided by TGF(3r/_
CD25+ T cells, which appear unhampered in their ability to suppress proliferation of
cocultured cells (quoted as unpublished data in [314]). It is interesting to note,
however, both that the TGF(3 knockout mice from which these suppressive T cells
were derived died prematurely from severe inflammatory disease [315], and that
Powrie's original work with CD45RB10 cells in vivo suggested a role for both TGF|3
and IL-10. Neutralising antibodies abolished the protection against colitis that these
cells otherwise provide [316].
Other descriptions of probably distinct regulatory T cell phenotypes have also cited
the involvement of IL-10 and TGF|3. T regulatory type 1 cells, Trls, were originally
generated in vitro by repetitive stimulation ofCD4 T cells in the presence of IL-10
[317]. They were characterised by limited proliferation but considerable secretion of
IL-10 and IL-5, without IL-2 or IL-4. Trl clones inhibit proliferation of naive [317]
and perhaps also memory CD4 T cells in vitro (quoted as unpublished data in [311]).
In vivo, ova-specific Trl cells can prevent the colitis induced by CD45RBhl cells in
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SCID animals, although only when the mice are fed ovalbumin [317], This implies
that, like CD45RB10 or CD25+ regulatory T cells, Trl cells also require recent TCR
triggering to become active, and that their effect is then non-specific. The
suppression that these ova-specific Trl cells mediate acts against an immune
response focussed on the self antigen or gut flora component that drives
inflammatory bowel disease [318],
The action ofTrl cells in vitro can be inhibited by either anti-IL-10 or anti-TGF|3,
and most potently by the two antibodies in combination [317, 319, 320]. This
distinguishes them from Th3 cells, a CD4 population proposed to suppress
neighbouring cells by TGF|3 alone [312, 321], Th3 cells were first described as a
result of experimental oral tolerance: EAE-prone SJL/J mice were fed low doses of
myelin basic protein (MBP) and their mesenteric lymph nodes then used to generate
T cell clones. Cells were identified which shared TCR specificity with potentially
encephalitogenic Thl clones, but which secreted TGF|3 upon stimulation [322, 323],
These cells prevented the proliferation and cytokine production ofThl clones in
vitro and suppressed symptoms ofEAE in vivo. A proportion of these 'Th3' clones
also expressed IL-10 and IL-4, however, so their distinction from classical Th2 cells
was not always clear. Indeed, Weiner has argued that the nature of a regulatory T
cell is a product of the environment in which it functions, thus ensuring a degree and
a mechanism of suppression pertinent to each situation [324], Clean definitions of
Th2, Th3 and Trl cells may only ever be artificial distinctions.
Can any cell become a suppressor, then, if stimulated in the right circumstances?
'Regulation' is not a unique feature of CD4 T cells. Suppressive versions of CD8
cells, NKT cells and B cells have all been reported [325-327]. They share common
mechanisms: all rely at least partly on IL-10 as an effector molecule. An
understanding of the signals required to initiate suppressive function in these effector
cells would be a powerful therapeutic asset.
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1.5.4 Tolerogenic DCs
The ability ofDCs to influence the decision between tolerance and immunity was
neatly illustrated by Hawiger et al, who targeted antigen to undisturbed DCs in vivo
by conjugating it to an anti-DEC-205 antibody. The hybrid antibody alone induced
systemic tolerance; the same fusion protein given with an anti-CD40 antibody that
stimulates the DCs, instead primed strong immunity [328], This led to an
understanding that immature DCs constitutively migrate into lymph nodes and
establish and maintain tolerance to the self antigens that they present. As a
consequence, the T cell reaction to an infection is focussed only on the foreign
antigens and not against the self peptides that DCs inevitably also display [220],
This model is supported by two other reports of in vivo tolerance induction mediated
by immature DCs [325, 329].
Activated DCs can also induce tolerance if directed by the environment or antigen.
DCs harvested from the draining lymph nodes of the lung displayed high levels of
surface MHCII, B7 and CD40 and yet elicited only minimal T cell proliferation in
vitro [330], They expressed IL-10, detected by both PCR and intracellular staining,
and the limited T cell response was proposed to be a result of Trl induction. In
contrast, DCs taken from mesenteric lymph nodes produced TGF(3 and generated
TGF|3-secreting T cells [330], McGuirk et al. have described the ability of
filamentous haemagglutinin (FHA) from Bordatella pertussis, a respiratory tract
pathogen, to stimulate a DC phenotype that gives rise to Trl cells [112]. The authors
offered two possible explanations: either the pathogen has evolved to exploit DCs to
minimise the immune attack that it will face, or the host has deliberately employed
tactics aimed to protect against the pathology of an unmitigated response. FHA
deficient B.pertussis is cleared from the lung more rapidly than its wildtype
equivalent. This is partly due to the loss of adhesion normally provided by FHA, but
it also reflects an enhanced Thl response from the host and is associated with
increased damage to the airways (Mills, 2002, BSI congress, Harrogate, UK).
Evidence also suggests that the action of regulatory T cells can be mediated by DCs.
DCs are not essential: activated CD4+CD25+ T cells will suppress CD8 cells in the
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absence ofAPC [331], A typical lymph node contains a prominent population of
DCs, however, and both CD4 and CD8 regulatory T cells have been reported to act
via induction of a tolerogenic DC phenotype [332, 333].
1.6 Summary
The importance ofDCs in stimulating T cell responses gives them a powerful
influence over the outcome of immune reactions. They combine information from
their subset affiliation, the cytokine environment, the nature of the antigen and the
strength of stimulation, and translate it into T cell stimulation through antigen
presentation and costimulation. They can direct both Thl or Th2 immunity and
anergic or active tolerance. This functional flexibility provides DCs with
considerable promise for therapeutic manipulation of the immune system.
1.7 Aims
This project originated in 1999, shortly after Kalinski et al. published their model of
environmental instruction of DC function [10] and raised the possibility of
manipulating DC phenotypes for therapeutic gain. With the hypothesis that in vitro
conditioning ofDCs could be used to direct immune responses in vivo, I began by
activating DCs in the presence of different cytokines. These early experiments
highlighted IL-10 as an immunosuppressive reagent capable of inducing a DC
phenotype that elicited only limited T cell proliferation. This observation generated
several questions:
• Is the influence of IL-10 on DCs an inhibition ofmaturation?
(Chapter 3)




• Can this in vitro effect also be seen if the DCs are administered in vivo?
(Chapter 5)
• Do these DCs have any therapeutic benefit when applied to a disease model?
(Chapter 6)
In attempting to address these issues, 1 hope this thesis offers some novel insight into
the workings of dendritic cells and their potential to be exploited as immunotherapy.
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Chapter 2 » Materials and Methods
2.1 Animals
All mice were maintained under specific pathogen free conditions in the animal
facilities of the Faculties of Medicine and Science and Engineering at the University
ofEdinburgh. BALB/c and C57B1/6 mice were either purchased from B&K
Universal (Hull, UK) or bred in house; DO 11.10 TCR transgenics (H-2Ad restricted,
OVA peptide 323-339 specific) [334] were all bred in house. Mice were used at 6-
12wk of age, and were sex and age matched within experiments. All experiments
involving animals were performed under guidance from the appropriate Home Office
personal and project licenses.
2.2 Media
Unless otherwise specified, medium was RPMI 1640 (Sigma-Aldrich, Poole, UK)
supplemented with 5% foetal calf serum (FCS) (Labtech International, Andover,
MA, USA), 2mM L-glutamine (Gibco BRL, Life Technologies, Paisley, UK), 50pM
|3-mercaptoethanol (2-ME) (BDH Merck, Poole, UK) and 50U/ml penicillin plus
50pg/ml streptomycin (Gibco).
Ex vivo cells were prepared and washed in Hanks Balanced Salt Solution (HBSS)
(Sigma) with 2% FCS and antibiotics as above.
PBS was made in house by dissolving 137mM NaCl, 8.2mM NaH2PO4.2H20, 2.7mM




2.3.1 Splenic DCs by MACSpurification
Spleens were removed from BALB/c mice and crushed between two glass slides to
obtain a single cell suspension. Red blood cells were removed by incubation in red
blood cell lysis buffer (Sigma) for 5min at room temperature. Cells were washed,
resuspended at 108cells/900pl and mixed with lOOpl of CD1 lc microbeads (Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany), as per the manufacturer's instructions.
They were then incubated on ice for 15min, washed, resuspended and loaded onto
pre-wet miniMACS MS columns in a miniMACS magnetic separator (Miltenyi). A
maximum of 4xl08 cells were applied to a single column. The column was washed
to dislodge unlabelled contaminants, then removed from the magnet and the positive
fraction eluted using the supplied plunger.
2.3.2 Splenic DCs by plastic adherence
BALB/c spleens were removed and a single cell suspension prepared as above. Cells
were resuspended in 10ml medium per spleen and distributed into 60mm, tissue
culture grade petri dishes (Nalge Nunc International, Roskilde, Denmark) using 5ml
cell suspension per plate. These were incubated at 37°C for 90min to enable
macrophages and DCs to adhere. The plates were rinsed, using pre-warmed medium
and gentle pipetting, until it could be seen that the majority of the non-adherent
contaminants had been removed. The plates were given 5ml fresh culture medium,
without GM-CSF, and returned to the incubator overnight. This long incubation
allowed transiently adherent DCs to detach and they were harvested the following
morning by more vigorous washing. Strongly adherent macrophages were left on the
plates. Yields at this stage averaged 2-3x106 cells per spleen and were 30-40%
CD1 lc+MHCII+ DCs, as assessed by flow cytometry. The majority of the
contaminants were CD 19+ B cells.
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To further enrich the DCs, cells collected after overnight adherence were depleted of
B cells, T cells and granulocytes using Dynabead technology (Dynal, Oslo, Norway).
Cells were resuspended at 2xl07/ml and incubated with uncongugated antibodies
against CD19 (10pg/ml), Thyl.l (5pg/ml) and Grl (5p,g/ml) (all from Pharmingen,
San Diego, CA, USA) for 30min at 4°C on a rotating mixer. Excess antibody was
removed by washing in cold culture medium. Dynabeads were prepared for use by
washing to remove the azide preservative and finally resuspended at lxlO7 beads/ml.
Antibody-labelled cells were added to the bead suspension to give 6 beads per
o
labelled cell and 4x10 beads/ml, and the mixture incubated, rotating, for 30min at
4°C. Beads were then removed using a strong magnet (Dynal) and the unbound cells
collected from the supernatant.
2.3.3 Bone marrow-derived DCs
DCs were grown from early bone marrow progenitors under the influence of GM-
CSF, using a protocol based on that of Inaba et al. [335]. Bone marrow was flushed
from the femurs and tibias of BALB/c mice using medium and gentle pressure from
a 2.5ml syringe and a 25G needle. Cell clusters were dispersed by passage through a
second 25G needle. Red blood cells were removed using lysis buffer (Sigma) and
the remaining cells seeded into 24 well tissue culture plates at 3.75xl05cells/ml and
lml per well. The culture medium was as normal, but using 10% FCS and without
2-ME. GM-CSF was added in the form of 5% supernatant from the transfected cell
line X63-gmcsf [336], providing 10-15ng/ml GM-CSF. Levels of IL-10 in the
supernatant were low (~90pg/ml) and those of IL-12 and TNFa were undetectable
(Lynda Stuart, CIR, University of Edinburgh, personal communication). Cultures
were washed at day 3 and day 6 to remove non-adherent granulocytes and
lymphocytes. This involved swirling the plates before removing lml from each well
and replacing it with fresh medium. On day 7, loosely adherent DCs were harvested
by more vigorous washing, leaving firmly adherent macrophages attached to the
plate. Preparations were 85-90% CD1 lc+, MHCII+ DCs (fig 3.1), and the remainder
of the cells were predominantly Grl+ granulocytes.
When bone marrow derived DCs (BMDCs) were used in vivo, the presence of FCS
in their culture medium caused unwanted immune responses against serum antigens
adsorbed onto the DC surface. The protocol was therefore modified to reduce the
amount of FCS involved. Bone marrow suspensions were initially plated in 10%
FCS, as above, to establish proliferation, but on days 3 and 6, this was replaced with
1% normal mouse serum (Harlan Sera Labs, Loughborough, UK). The GM-CSF
supernatant, from a hybridoma grown in the presence of FCS, was identical in both
cultures.
The bones from a single mouse typically released 2-3x107 BM precursors and so
could be used to seed approximately two 24 well plates. If the culture was
performed in FCS throughout, the expected yield from these two plates was 1-
1,5xl07 immature DCs. The yield was reduced in the presence ofmouse serum,
averaging 0.5-lxl07 DCs. In vivo experiments therefore began with 2 plates of DCs
for every 5 mice to be injected.
2.3.4 Deactivation
Immature DCs were harvested from bone marrow cultures at day 7 and replated at
lxl06cells/ml and 1ml per well in fresh 24 well plates, using DC culture medium
with GM-CSF. LPS from E.coli 055 :B5 (Sigma) was added at 0.1|ig/ml. Cytokines
were recombinant mouse proteins; IL-10 and IL-4 (both from R&D systems,
Abingdon, UK) were used at 50ng/ml. Human prostaglandin E2 (PGE2) was a kind
gift from ProfRodney Kelly (MRC Centre for Reproductive Biology, University of
Edinburgh). It had previously been shown to cross-react with mouse, and was used
at 0.1 pM.
2.3.5 Cytospins
5xl04 DCs were resuspended in 200pl ofmedium or PBS containing 10% FCS, and
spun onto Superfrost plus glass slides (BDH Merck, Poole, UK) using a Shandon
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Cytospin 3 centrifuge (Shandon Inc, Pittsburgh, PA, USA) at 300rpm for 3min. The
slides were dried in air for approximately lOmin and then stained using Diff-Quick®
reagents (Gamidor Ltd, Abingdon, UK). Staining comprised 2min in methanol, 2min
in Diff-Quick I® (eosin) and lmin in Diff-Quick II® (haematoxylin). Slides were
then rinsed in tap water, air dried and coverslips mounted in Pertex mounting
medium (CellPath, Newtown, UK).
2.4 Other cell preparations
2.4.1 Unfractionated spleen and lymph nodes
Single cell suspensions of spleen were prepared in HBSS / 2% FCS, by crushing
between glass slides and passage through a 25G needle. Red blood cells were
removed with red blood cell lysis buffer (Sigma). Lymph nodes (popliteal, inguinal,
brachial, axillary, superficial cervical, peri-aortic and mesenteric) were harvested,
pooled and a single cell suspension prepared as for the spleens, but without red blood
cell lysis. Both preparations were washed in medium and a viable cell count
performed in 0.05% trypan blue (Sigma).
2.4.2 T cellpurification
CD4+ T cells were purified from pooled spleen and lymph nodes by removing
MHCII and CD8 positive contaminants with a MACS depletion column (Miltenyi).
Cell preparations were stained with biotin-conjugated antibodies against MHCII
(clone M5114; I-A specific; grown in house and used at 1:100) and CD8 (53-6.72;
1:100). Staining was for 15min on ice. The cells were washed and incubated with
streptavidin-conjugated microbeads (Miltenyi) for 15min on ice, before being loaded
onto a CS MACS column in a varioMACS magnet (Miltenyi). A single column was
used for up to 2xl08 total cells. The column was washed and unbound cells
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collected. They were routinely >80% CD3+ CD4+ (fig 5.2), and yields averaged
2xl07 cells per mouse.
2.4.3 Blood mononuclear cells
To monitor specific T cell expansion in vivo during DO 11.10 adoptive transfer
experiments (section 2.9) or to confirm reconstitution of irradiated bone marrow
chimaeras (section 2.10), peripheral blood mononuclear cells were harvested and
stained for analysis by flow cytometry. 50pl of tail blood was collected into an equal
volume of heparin (lOOOU/ml; CP Pharmaceuticals, Wrexham, UK) and layered over
500pl LympholyteM (Cedarlane Laboratories Ltd, Hornby, Ontario, Canada). After
centrifugation at 2000rpm for 20min, mononuclear cells were harvested from the
interface and washed before use.
2.5 Flow cytometry
Samples were analysed with a FACScalibur flow cytometer and CellQuest software
(Becton Dickinson, Mountain View, CA, USA), using a live cell gate set by forward
and side scatter characteristics (see fig 3.5, for example).
2.5.1 Surface staining
Cells were taken from culture or directly after isolation and placed in a 96well, V-
bottomed plate for staining. l-2xl05 cells were used routinely to collect 10 000
events on the flow cytometer. When the target population was small, as in the
DOl 1.10 adoptive transfer experiments (section 2.9), lxl06 cells were stained and
100 000 events collected. The cells were washed and resuspended in lOOpl of
antibody diluted in PBS supplemented with 2% FCS. Details of the specific
antibodies and dilutions are listed in table 2.1. The cells were stained for 20min on
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19.19.1 In house 1:800 unknown
I-Ad/I-Ed - FITC 2G9 Pharmingen 1:200 rIgG2a
CDllc-PE HL3 Pharmingen 1:50 HsIgG,
j CD lie- FITC N418 In house 1:400 HsIgG,
B7.1 -PE 16-10A1 Pharmingen 1:100 HsIgG2
B7.2-PE GL1 Pharmingen 1:100 rIgG2a
CD40 - PE 3/23 Pharmingen 1:100 rIgG2a
ICAM-1 - PE 3E2 Pharmingen 1:200 HsIgG i
T cell
markers
CD4 - FITC GK1.5 In house 1:250 rIgG2b
ova specific
TCR - biotin
KJ-126 In house 1:100 mIgG2a
ova specific
TCR - FITC
KJ-126 In house 1:400 mIgG2a
CD69 - PE H1.2F3 Pharmingen 1:100 HsIgG,
CD25 - PE 7D4 In house 1:100 IgM
CD45RB -
FITC
16A In house 1:100 rIgG2a
CD62L - PE MEL-14 In house 1:100 HgG2a
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Antibody Clone Source Dilution Isotype
Other cells
Ly-6C (Grl)-PE RB6-8C5 Pharmingen 1:100 rIgG2b
CD 19 - FITC ID3 In house 1:100 rIgG2a
CD8 - biotin 53-6.72 In house 1:100 rIgG2a
Cytokines
IL12p40/p7 - PE C15.6 Pharmingen 1:100 rlgGi
IL-10-PE JES5-2A5 Pharmingen 1:100 rlgG,
IL-4 - PE BVD6-24G2 Pharmingen 1:100 rlgGi
IFNy - PE XMG1.2 Pharmingen 1:100 rlgG,
Secondary
reagents
Streptavidin - PE Calbiochem 1:1500
Isotvpe
controls
PE control R35-95 Pharmingen UgG2a
I
PE control A95-1 Pharmingen rIgG2b
PE control A19-3 Pharmingen HsIgG
FITC control R35-95 Pharmingen r!gG2a
Table 2.1 Antibodies used in flow cytometry. Monoclonal primary antibodies were
supplied by Pharmingen, Caltag Laboratories (Burlingame, CA, USA) or grown and
conjugated in house (section 2.6). Streptavidin-PE was bought from Calbiochem
(Nottingham, UK). Isotype controls from Pharmingen were used at the same concentration
as the test antibody, and in house antibodies were matched with an irrelevant antibody of the
same isotype at the same concentration. Abbreviations in isotype column: r, rat; Hs,
hamster; m, mouse.
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ice in the dark, washed and, if necessary, stained with a secondary antibody. Cells
were resuspended in 200pl PBS / 2% FCS and analysed immediately.
To assess the surface phenotype ofBMDCs, the membrane-impermeant dye ToPro3
(Molecular Probes, Leiden, The Netherlands) was included for the final 5min of
staining at a final concentration of lpM. This enabled the live cell gate to be set
more accurately, using ToPro3 exclusion in addition to forward and side scatter
characteristics.
2.5.2 Dead cell analysis
To quantify cell death, unstained cells were resuspended in lpM ToPro3
immediately before acquisition. The analysis gate was set to exclude debris, and the
proportion of ToPro3+ 'dead' cells calculated as a percentage of total cells within
this population.
2.5.3 Antigen uptake assay
DCs were harvested after activation, washed and 2xl05 cells resuspended in 50pl
PBS or FITC-dextran (2mg/ml in PBS; MW 70 000; Molecular Probes Inc, OR,
USA) in a 96well, round bottomed plate. Cells were incubated at 37°C for 45min, to
allow antigen intemalisation, or on ice as a negative control. They were then flooded
with 200jxl ice cold PBS for 5min, washed twice and resuspended in 1%
paraformaldehyde for analysis by flow cytometry.
2.5.4 Intracellular cytokine staining
BMDCs were activated with LPS or with LPS and IL-10 for 6h (as in section 2.3.5)
in the presence ofGolgiStop™ (Pharmingen) at a dilution of 1:1500, as
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recommended by the manufacturer. Cells were stained with N418-FITC to detect
surface CD1 lc expression, washed and then fixed and permeabilised by
resuspending in Cytofix/Cytoperm™ reagent (Pharmingen) for 20min on ice. Cells
were washed in permeabilisation buffer (provided in the Cytofix/Cytoperm™ kit) and
stained with either anti-IL-12 or anti-IL-10 for 30min on ice. Subsequent washes
were again performed in permeabilisation buffer and the cells then resuspended in
PBS / 2% FCS for analysis by flow cytometry.
T cells from DC cocultures (section 2.7.2) were analysed for cytokine expression 7d
after their original stimulation. Cells were harvested and replated in the presence of
50ng/ml phorbol 12-myristate 13-acetate (PMA), 500ng/ml ionomycin (both from
Sigma) and GolgiStop™ (Pharmingen, as above) for 4 hours, before being stained
with KJ-126-FITC and IFNy, IL-4 or IL-10-PE, using the same protocol as described
for DCs.
2.5.5 CFSE staining
T cell proliferation was visualised using CFSE (5, 6 carboxyfluoroscein diacetate
succinimidyl ester) (Molecular Probes), a membrane permeant dye that binds
covalently to cytoplasmic proteins and is distributed equally to each daughter cell
upon division. The mean fluorescence therefore halves progressively as the cells
divide [337], Spleens and lymph node cells taken from mice immunised with ova
peptide (section 2.9) were labelled with CFSE at lOnM for 8min at room
temperature, washed and cultured in the presence of 0.5p,g/ml ova peptide.
Background fluorescence was determined for each sample 16-18h later, using flow
cytometry. Cell division was assessed on day 3.
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2.6 Antibody preparation
Supernatants from antibody-secreting hybridomas were collected and fdtered to
remove cells. Immunoglobulin was precipitated with ammonium sulphate, using
29 lg per litre of supernatant, and then dissolved in PBS and extensively dialysed
against PBS. Antibodies were purified by binding to a protein G - sepharose column
(Amersham, Buckinghamshire, UK) with elution at pH 2.8. Antibody concentration
was estimated by measuring absorbance at 280nm.
Purified antibodies were conjugated to biotin by reacting each lmg of protein with
75pg of succinimidyl-6 (biotinamido) hexanoate (EZ-Link™ NHS-LC-Biotin; Pierce,
Rockford, IL, USA) in dimethyl formamide (Sigma). FITC conjugation was
performed by reacting each lmg of antibody with 50ng FITC Isomer I (Sigma) in a
0.15M sodium chloride / 50mM sodium carbonate buffer at pH9. Conjugated
antibodies were then dialysed extensively against PBS to remove excess label.
Antibodies were filter sterilised and stored frozen at -20°C.
2.7 Proliferation assays
2.7.1 Assessment ofDCfunction
The stimulatory capacity of different DC populations was assessed by measuring the
DOl 1.10 TCR transgenic (Tg) T cell proliferation elicited by antigen pulsed DCs.
DCs were harvested after activation, washed and pulsed with graded doses of ova
peptide (323-ISQAVHAAHAEINEAGR-339; Albachem Ltd., Edinburgh, UK) for
90min at 37°C. Pulsed DCs were washed and plated in 96well, round bottomed
plates with CD4+ DOl 1.10 T cells at lxl04 DCs plus 1x10s T cells per 200pl well.
Proliferation was measured by 3H-thymidine incorporation during the last 16h of a
3d culture (section 2.7.4).
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2.7.2 Assessment ofT cellfunction
To assess whether the initial DC interaction affected the subsequent function of the
responding T cells, DCs were pulsed with ova peptide as above (section 2.7.1) and
mixed with CD4+ DOl 1.10 T cells in a 48well plate, using lxlO^ DCs and lxlO6 T
cells per 1ml well. After 3 days, all cells were recovered and centrifuged through
LympholyteM to purify live T cells. These were returned to culture at 2x106
cells/well in 1.5ml in a 24well plate, using medium supplemented with 1%
supernatant from an IL-2 secreting hybridoma (a transfected cell line, X63-IL2
[338]). This supernatant was assessed by ELISA to contain 200ng/ml IL-2 when
undiluted.
The T cells were collected again on day 7 of culture and either stained for cytokine
detection (section 2.5.4) or plated with irradiated APC to measure their proliferation
in response to restimulation. Spleens were taken from syngeneic BALB/c mice and
irradiated whole with 4000rads from a caesium source irradiator. Single cell
suspensions were made and plated at 5xl05 cells/well of a 96well, flat bottomed
plate. 5x104 T cells were added to each well in the presence of graded doses of ova
peptide, to a final volume of 200fxl. Proliferation was measured by 3H-thymidine
incorporation during the last 16h of a 3d culture.
2.7.3 Spleen and lymph node restimulation assays
Spleens and lymph nodes from immunised mice were harvested and single cell
suspensions plated at 6xl05 cells/well of a 96well, flat bottomed plate in 200ql final
volume. Graded doses of ova peptide were added and proliferation measured by 3H-
thymidine incorporation during the last 16h of a 3d culture.
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2.7.4 Cell harvesting and scintillation counting
Proliferation was measured by the addition of 0.5pCi of 35Ci/mmol [3H]-thymidine
(ICN, Basingstoke, UK) to each well, 16h before the end of culture. Plates were
harvested onto filter mats (Printed Filtermat A; Wallac, Turku, Finland) using a
96well MachHIM Tomtec harvester (Wallac). The mats were dried on a hot plate
and a solid scintillation wax melted into them (Meltilex™ A; Wallac). When the wax
had re-solidified, the mats were read using a Trilux 1450 Microbeta liquid
scintillation and luminescence counter and software (Trilux, Arnsberg, Germany).
2.8 Polymerase chain reactions
2.8.1 RNA extraction
Total RNA was isolated using Trizol® reagent (Gibco) and a standard phenol-
chloroform extraction. lxlO6 DCs were resuspended in 500pl Trizol® and stored
frozen at -80°C. Samples were thawed, incubated at room temperature for 5min and
mixed with lOOpl chloroform. After centrifugation, the upper aqueous phase was
added to 250pl isopropanol, mixed and incubated at room temperature for lOmin.
Precipitated RNA was washed in 75% ethanol before being resuspended in 30pl
nuclease-free water (Promega, Madison, WI, USA). RNA concentrations were
estimated by measuring absorbance at 260nm.
2.8.2 RT-PCR
cDNA was synthesised using the Expand1M Reverse Transcriptase kit (Roche
Diagnostics, Lewes, UK) according to the manufacturer's instructions. Oligo(dT)
primers were annealed to denatured RNA and reverse transcription then performed in
a 20pl reaction containing lOOmM DTT, 3.3mM each dNTP (Promega), 20U RNasin
(Promega) and 0.05U Expand RT enzyme. Reactions were incubated for 60min at




Sense primer 5 '-ATGGCCATGTGGGAGCTGGAGAAAG-3'
Antisense primer 5' -GTGGAGCAGCAGATGTGAGTGGCT-3'
Programme Denaturation - 94°C, 30s
Annealing - 62°c, 30s




Sense primer 5' -GATCATGAAGACATCACACGG-3'
Antisense primer 5'-AGAATGATCTGCTGATGGTTG -3'
Programme Denaturation - 94°C, 30s
Annealing - 65°c, 30s




Sense primer 5 '-GCACCACACCTTCTACAATGAG-3'
Antisense primer 5 '-GTCTAGAGCAACAT AGCAC AGC-3'
Programme Denaturation - 94°C, 30s
Annealing - 62°c, 30s
Extension - 68°C, 30s
25 cycles
Product 409bp
























Table 2.3 Primers and probes used for real-time RT-PCR. See section 2.8.3.
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PCR used Taq Supreme™ polymerase and buffers from Helena Biosciences
(Sunderland, UK). 20pl reactions contained 2pl cDNA, 0.3mM each dNTP, 0.2mM
each primer, 1.5mM MgCb and 1U Taq Supreme™ enzyme. PCR was performed in
a PTC-200 DNA Engine (MJ Research, Watertown, MA, USA). Primers and
programmes are listed in table 2.2. PCR products were visualised on 2% agarose
gels (ultraPURE agarose; Gibco) containing 0.5pg/ml ethidium bromide (Sigma).
2.8.3 Real time RT PCR
RNA samples were treated with DNasel (Gibco). cDNA was synthesised using
random hexamers and the TaqMan Reverse Transcription kit (Perkin-Elmer Applied
Biosystems, Foster City, CA) as directed. Real-time RT-PCR was performed as
described [339]. Relative quantification was done on an ABI PRISM 7700 Sequence
Detector (Perkin-Elmer) using pre-developed TaqMan reagents according to the
manufacturer's instructions. Each reaction involved multiplex amplification of 18S
rRNA to account for differences in the quantity or quality ofRNA present. Thermal
cycling conditions for all reactions were 2min at 50°C and lOmin at 95°C, followed
by 40 cycles of 2-step PCR consisting of 15s at 95°C and lmin at 60°C. All samples
were amplified in triplicate. The threshold cycle Ct, which correlates inversely with
target mRNA levels, was defined as the cycle number at which the emitted reporter
fluorescence increased above a threshold level. For each sample, the amount of
target mRNA was expressed as an «-fold difference relative to the amount of target
mRNA expressed by unstimulated DC (designated the calibrator). The formula used
to calculate these values is 2"AACt, where ACt is determined by subtracting the average
18S rRNA Ct value from the average target Ct value. AACt then involves subtraction
of the ACt calibrator value from the target ACt value.
Primers and probes, to provide specific fluorescence, were designed by Dr Lynn
Forsyth (CIR, University of Edinburgh) using Primer Express software (ABI Prism,
Perkin-Elmer). They are listed in table 2.3.
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2.9 Injections and immunisations
2.9.1 Adoptive transfer ofDO11.10 cells
DO 11.10 lymph node cells were filtered through parachute silk and injected i.v. into
BALB/c recipients, using 5xl06 cells/mouse in 200pl PBS. The lymph nodes from
one donor mouse usually yielded sufficient cells to transfer into 5-6 BALB/c hosts.
2.9.2 DC immunisation
Recipients of DO11.10 adoptive transfers were immunised 24h later with DCs coated
with ova peptide. BMDCs were harvested at day 7 of culture and replated in
medium alone, with LPS or with LPS and IL-10 for 6h (section 2.3.5). They were
then washed and pulsed with 50pg/ml ova peptide for 90min at 37°C. Cells were
washed again, counted and resuspended at 2.5xl06/ml in PBS, before being filtered
through parachute silk. Mice were injected with 5xl05 DCs, either i.v. in 200pi or
i.p. in 250ql (see section 5.6). Both routes were effective in inducing DOl 1.10 T
cell expansion in the spleens and lymph nodes of the recipients.
2.9.3 CFA immunisation
Some mice receiving a DOl 1.10 adoptive transfer and subsequent DC immunisation
were later rechallenged in vivo with ova peptide emulsified in complete Freund's
adjuvant (CFA). lmg/ml peptide was combined with an equal volume ofCFA
containing heat killed Mycobacterium tuberculosis H37RA (Sigma), vortexed and
sonicated. 50pl volume was injected s.c. into each hind leg, thereby delivering 50pg
ova peptide into each mouse, split between the two sites. Responses were assessed
by harvesting the draining inguinal lymph nodes, processed as described in section
2.4.1.
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2.10 Bone marrow chimaeras
Recipient BALB/c mice were lethally irradiated by exposure to 950rad over 45min,
using a caesium source irradiator. 24h later they were reconstituted with pooled
bone marrow cells from BALB/c and DOl 1.10 mice. A single cell suspension of
each bone marrow population was prepared as in section 2.3.3 and depleted ofThy 1+
T cells by staining with a biotinylated anti-Thyl antibody (T24 biotin, produced in
house), streptavidin-conjugated microbeads and subsequent removal on a MACS
depletion column (Miltenyi, section 2.4.2). This aimed to prevent graft-versus-host
disease in the recipient mice. BALB/c and DOl 1.10 cells were then combined at a
ratio of 9:1, filtered through parachute silk and 5xl06 injected i.v. into each irradiated
host. The chimaeras were left 8 weeks before use, to allow reconstitution of the
immune system. This was confirmed by a normal ratio of B to T cells in the
peripheral blood, measured by flow cytometry (section 2.4.3).
2.11 EAE induction
2.11.1 Immunisation with MOG35.55
C57B1/6 mice were immunised with lOOpg MOG35.55 peptide (Advanced
Biotechnology Centre, Imperial College, London, UK) emulsified in CFA, given as
two 50(^,1 s.c. injections, one into each hind leg (see section 2.9.3). Mice also
received 200ng of pertussis toxin i.p. in 500pl PBS on the same day and two days
later.
2.11.2 Clinical scoring
Clinical signs of EAE were assessed daily using a discrete 0-6 scoring system [327],
0, no signs; 1, flaccid tail; 2, impaired righting reflex or unstable gait; 3, partial hind
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limb paralysis; 4, total hind limb paralysis; 5, hind limb paralysis with partial fore
limb paralysis; 6, moribund or dead. Mice at grade 5 for two consecutive days or at
grade 6 were humanely killed and their scores recorded as grade 6 throughout the
remainder of the experiment.
2.11.3 Cytokine ELISA
Spleen and inguinal lymph node cells ofmice recovered from EAE, 30d after
immunisation, were cultured with MOG35.55 peptide and their cytokine production
measured by a cell-based ELISA protocol [340]. Single cell suspensions were plated
at 6xl05 cells/well in a 96well, flat bottomed plate. Graded doses ofMOG35.55
peptide were added to a final volume of 200pl, using X-Vivo 15 serum free culture
medium (BioWhittaker, Maidenhead, UK) supplemented with 2mM L-glutamine and
50pM 2-ME. After 48h, lOOpl of cells were transferred to MaxiSorb microtiter
plates (Nalge Nunc), precoated with anti-cytokine antibody and blocked in PBS / 1%
bovine serum albumin (ELISA grade; Sigma). The cells were cultured at 37°C for a
further 24h before the plates were washed, incubated with biotinylated detection
antibodies for lh at room temperature, extravidin-peroxidase (Sigma) for 30min and
then developed with 10% w/v tetramethylbenzidine (TMB) substrate (Sigma) diluted
in substrate buffer (0.05M sodium phosphate, 0.025M sodium citrate, pH5) with
0.03% hydrogen peroxide. Reactions were stopped with 2M H2SO4, and plates were
read at 450nm using a MultiSkan Ascent reader and software (Thermo Labsystems,
Vantaa, Finland). Paired antibodies and recombinant cytokine standards were
bought from Pharmingen, and are listed in table 2.4.
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Cytokine detected Capture Ab Standard Detection Ab
IL-2 JES6-1A12 Recombinant mouse IL-2, JES6-5H4
2pg/ml beginning at 5ng/ml 0.5p.g/ml
IL-4 11B11 Recombinant mouse IL-4, BVD6-24G2
2pg/ml beginning at 5ng/ml 0.5|ag/ml
IL-10 JES5-2A5 Recombinant mouse IL-10, SXC-1
2pg/ml beginning at lOOng/ml 0.5p.g/ml
IFNy R4-6A2 Recombinant mouse IFNy, XMG1.2
2pg/ml beginning at lOOng/ml 0.5p.g/ml
Table 2.4 Antibodies and cytokines used for cell-based ELISA assays. See section 2.11.3.
2.12 Statistics
Statistics were calculated using GraphPad Prism® (version 3.0, GraphPad software,
San Diego, CA, USA, www.graphpad.com). following the recommendations made
by this programme. Results were considered significant ifP<0.05.
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Chapter 3 - DC activation in the presence of IL-10
3.1 Introduction
DCs can elicit very different immune responses. Langerhans cells classically
promote the development of strong immunity and contact hypersensitivity [89, 341],
while thymic DCs establish central tolerance by deleting responding T cells [150,
342]. The factors that control such diverse functions remain the matter of some
debate [222], Shortman and colleagues originally argued that thymic DCs develop
from lymphoid precursors distinct from the myeloid cells thought to give rise to other
DC types [130], A subset of DCs in spleen and lymph node were also identified as
lymphoid in origin, and it was suggested that these too might tolerise T cells by Fas-
mediated deletion [159, 189]. The story has been complicated by the description of
many more DC subsets, but the idea that the function of a DC is fixed by its lineage
has persisted. Moser [152] and others [167] have reported that only CD8a+ DCs are
able to release the IL-12 that can drive IFNy production and a Thl response.
Pulendran et al. described differences in DC localisation and antigen uptake that
correlated with lineage [188],
Intuitively, it is hard to accept that the performance of a DC is determined solely by
its ontogeny. This seems unfeasibly rigid in an immune system that must respond
appropriately to innumerable different insults. There is a growing body of evidence
that DCs are plastic, capable of reading external signals and tailoring the immune
response appropriately. Cytokines can polarise DC function: IFNy enhances DC
production of IL-12, thereby skewing the T cell response towards a Thl phenotype,
while prostaglandins suppress IL-12 release and allow the development of Th2 cells
[343, 344], Different pathogens are also influential. DCs can distinguish between
bacterial and parasitic antigens and stimulate type 1 or type 2 immunity accordingly,
even discriminating between the yeast and hyphae of the fungus Candida albicans
[115,208,209],
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One of the attractions ofDC plasticity is that it implies that DCs are open to
modulation, and so could be used to manipulate the immune system. If the presence
of different cytokines or other agents during DC activation can determine their
function, these cells have considerable therapeutic promise. With the aim of
generating tolerogenic DCs for use in vivo, I began by stimulating DCs with LPS in
the context of IL-10, IL-4 or PGE2. This chapter describes the different phenotypes
that were achieved. While PGE2 reduced the ability of DCs to stimulate T cells, IL-4
surprisingly enhanced it. The effect of IL-10 was most pronounced, however. DCs
activated in the presence of IL-10 showed an early upregulation ofMHC and
costimulatory molecules, followed by rapid downregulation. The induction of these
surface markers occurred in the absence of full IL-12 expression and without
detectable IL-10 production. IL-10 appears to act not by holding DCs in immaturity,
but rather by dictating the kinetics and quality of their activation.
3.2 Approach
Initial experiments identified bone marrow-derived dendritic cells as a source of DCs
open to manipulation. When the cells were harvested at day 7 of culture, they had a
largely immature phenotype, with little MHCII or B7.2 on their surface. These cells
were replated into medium containing both LPS and different cytokines, to drive DC
maturation in the presence of putative polarising signals. The DCs were harvested at
various times afterwards and either phenotyped by flow cytometry and PCR or
assessed functionally in T cell proliferation assays.
3.3 Results
3.3.1 Dendritic cell sources
In order to obtain a population of dendritic cells to study, splenic DCs were first
compared with those grown in vitro from early bone marrow progenitors (fig 3.1).
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Initial attempts to purify splenic DCs used MACS technology to positively select
CD1 lc+ cells. Yields were unpredictable (0.5 to 6 xlO6 DC/spleen), however, and
their viability predictably poor (typically <50%). As an alternative, plastic adherence
was used to enrich DCs to ~30-40% of splenocytes. The majority of contaminants
were B cells, and subsequent depletions of B cells, T cells and granulocytes left a
highly purifed DC population (-95% CD1 lc+ MHCII+; fig 3.1C). Cell death was
still considerable (see fig 3.IB), but viable yields averaged 5xl05 DC/spleen. Given
that DCs are thought to comprise 1-1.5% ofmouse spleen [284, 345], this suggests
reasonably efficient recovery.
The major disadvantage of these splenic DCs was that, probably due to both their
origin in secondary lymphoid tissue and the protracted isolation procedure, the cells
had an extremely mature phenotype: staining for both MHCII and B7.2 was intense
(fig 3.1C, D). Mature DCs are reported to be resistant to polarising signals [205,
346], and so in order to manipulate DCs by maturing them in the presence of
different cytokines, a source of immature cells was needed. Bone marrow-derived
DCs (BMDCs) offered a more malleable population. Harvesting BMDCs at day 7 of
culture yielded cells that were predominantly alive (fig 3.IF), were 85-90% pure (fig
3.1G) and, importantly, expressed only low levels ofMHCII and B7.2 on their
surface (fig 3.1G, H). The numbers ofDCs generated in this way were also several
fold higher than those isolated from spleen. The femurs from a single mouse
typically released -2x107 bone marrow precursors, which could produce 1 - 1.5xl07
immature DCs by day 7.
While the extended culture period required to obtain BMDCs may make them less
physiologically relevant than ex vivo splenic DCs, equivalent protocols exist for
growing DCs from myeloid precursors in human blood [25] [347], BMDCs
therefore have a strong therapeutic relevance. For this reason, and because they




Figure 3.1 Comparison of spleen- and bone marrow-derived DCs. DCs were
either purified from mouse spleen using plastic adherence and depletion of
contaminating lymphocytes and granulocytes, or grown from bone marrow
precursors in the presence of GM-CSF and harvested at day 7 of culture. This
figure depicts their phenotype immediately after isolation or harvest. (A&E)
Photographs of cytospins stained with haematoxylin and eosin. Magnification,
xlOOO. (B&F) Forward and side scatter profiles, assessed by flow cytometry.
Note the different scales, linear vs log, on the side scatter axes. The live cell gate
used for subsequent analysis is shown. (C&G) Double staining for CDllc and
MHCII, used as an estimate of dendritic cell purity. The numbers give the
percentage of live cells falling in the top right quadrant. (D&H) B7.2 expression.
Open peaks indicate isotype controls. Data in all panels are representative of at
least five separate experiments.
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3.3.2 DC maturation
The maturation process of dendritic cells was mimicked in vitro by stimulating them
with LPS from E. coli bacteria, an archetypal activation signal. Murine bone marrow
derived DC are notoriously prone to spontaneous maturation and indeed the
unstimulated population already displayed a reasonable level ofMHC and
costimulation on their surface. This probably reflects both the age of the cells and
the disruption involved in their replating. 24 hours' culture in LPS, however, further
increased expression of both MHCI andMHCII and the costimulators B7.1, B7.2,
CD40 and ICAM-1 (fig 3.2A). When the DC were coated with peptide and
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Figure 3.2 Dendritic cell maturation. DCs were harvested at day 7 of culture and replated in
medium alone (unstimulated) or in the presence of LPS (O.lpg/ml). (A) Surface marker
expression 24h after stimulation, measured by flow cytometry. Open peaks represent isotype
controls. (B) T cell stimulatory capacity, also at 24h. DCs were pulsed with ova peptide and
mixed with CD4+ cells purified from DO11.10 TCR Tg mice. Proliferation was measured by
3H-thymidine incorporation during the last 16h of a 3d culture. Data is shown as the mean of
triplicate cultures ± SEM. Both panels are representative of at least three different experiments.
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Figure 3.3 DCs are responsive to environmental signals. DCs were harvested at day 7 of
culture and stimulated with LPS for 24h either alone or in combination with IL-10 (50ng/ml),
PGE2 (0.1 gM) or IL-4(50ng/ml). (A) Surface phenotype, assessed by flow cytometry. Open
peaks indicate isotype controls. (B) T cell proliferation. DCs were pulsed with ova peptide at
lpg/ml and mixed with DO11.10 T cells. Proliferation was measured by 3H-thymidine
incorporation during the last 16h of a 3d culture. Data represents the mean of triplicate cultures
± SEM. (C) DC IL-12 expression, assessed by RT-PCR. H20 control. All panels are
representative of three independent experiments.
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3.3.3 Polarisation by cytokines
E. coli LPS alone generates strongly immunogenic DCs that secrete IL-12 and favour
a Thl response [7, 348], To elicit a contrasting phenotype, DCs were activated with
LPS in the presence of IL-10, PGE2 or IL-4.
The data here support the argument for DC plasticity: different phenotypes and, at
least in terms of T cell stimulation, different functions were achieved from a single
DC prep (fig 3.3). The influence of the individual cytokines was interesting. At this
24h timepoint, IL-10 caused a profound downregulation of both MHC and
costimulator expression and consequent T cell proliferation. PGE2 suggested a
similar effect, but its downregulation was less severe and this discrepancy could not
be overcome by increasing its concentration. The action of the two cytokines was
clearly not identical. Most surprising was the impact of IL-4. IL-4 is a model Th2
cytokine and I expected it to suppress the immunogenicity and the Thl inducing
capacity of DCs. In contrast, its effect was a slight enhancement of LPS-induced
activation, seen in terms of the surface phenotype of the DCs (fig 3.3A), the







Figure 3.4 IL-10 alone is not a DC activation signal. DCs were replated at day 7
and cultured for 24h with or without LPS, in the presence or absence of IL-10.
Their surface phenotype was assessed by flow cytometry. Open peaks represent
isotype controls. Data is representative of three separate experiments.
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3.3.4 Activation in the presence ofIL-10
While the synergy between LPS and IL-4 was intriguing, I wanted to obtain a DC
phenotype that could be used to regulate T cell responses. 1L-10 appeared the best
candidate. The marked suppression of surface MHC and costimulation and of T cell
proliferation seen in figure 3.3 has been understood as an inhibition ofmaturation:
the presence of 1L-10 negates the effect of LPS and prevents upregulation of
activation markers [205, 349]. The impact of IL-10 appears more profound,
however. After 24 hours' stimulation, IL-10 suppressed both MHCII and B7.2
expression to a level not equal to, but consistently below that of the unstimulated
control (compare figs 3.2 and 3.3; also evident in fig 3.4). While IL-10 alone seems
to do little to disturb immature cells - it is not itself an activation signal (fig 3.4) -
the downregulation caused by LPS and IL-10 together suggests the DCs have made
some kind of active response to the combined signal. In support, at just 6 hours post-
stimulation, both IL-10 treated and LPS alone populations were activated: their
expression ofMHCII and B7.2 was high, and higher than that seen at 24h with LPS
alone (fig 3.5). This is exciting first because it demonstrates that LPS-driven
activation is transient, with MHCII and B7.2 up- and then down-regulated within
24h, and second because it demonstrates that activation does occur in the presence of





Figure 3.5 IL-10 treated DCs respond to stimulation. DCs were replated and stimulated
with LPS, in the presence or absence of IL-10. This figure shows their surface phenotype 6h
after activation; compare with figure 3.4, taken at 24h. Open peaks indicate isotype controls.
Data is representative of five different experiments.
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3.3.5 Downregulation ofantigen acquisition
To confirm the maturation status of IL-10 treated DCs, their ability to internalise a
fluorescent antigen was assessed. The switch from antigen uptake to antigen
presentation is, at least in vitro, a hallmark ofDC maturation [4, 350]; this allows
antigen uptake to be used as a convenient measure of immaturity. Unstimulated,
'immature' DCs contained a population of cells that actively internalised FITC-
dextran and became brightly fluorescent. Cells that had been matured in LPS for 24h
acquired less antigen: in the experiment shown, the mean fluorescence of this
population fell from 200 to 66 (fig 3.6). DCs stimulated with LPS and IL-10 also
showed reduced antigen uptake, their fluorescence matching that of the mature, LPS-







Figure 3.6 IL-10 treated DCs downregulate antigen uptake. DCs were given
LPS and IL-10 for 24h before being washed and pulsed with FITC-dextran.
Internalisation was assessed by flow cytometry. (A) Forward and side scatter
plot showing the live cell gate used for analysis. (B) Background
autofluorescence, measured on unstimulated cells pulsed with PBS alone. (C)
Antigen uptake assay. Open peaks indicate background uptake at 0°C, filled
peaks specific uptake at 37°C. Numbers give the mean fluorescent intensity for
cells within the marker shown. Data is representative of three independent
experiments.
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3.3.6 Acceleration ofactivation kinetics
The presence of IL-10 during DC activation does not prevent the early upregulation
of surface markers, nor the loss of an immature phenotype, but it does suppress the
levels ofMHC and costimulation seen 24h after stimulation. Intrigued by the
transience of activation, the expression of these markers was followed over time.
The results are shown in figure 3.7. They reveal a clear wave of activation, with
expression increasing, peaking and falling again within the 24h period. The variation
was most striking for B7.2 but also occurred for MHCII and, to a lesser degree, for
B7.1. Expression of all three markers peaked at 6-12h with LPS alone and was
beginning to fade by 24h. Cells stimulated with LPS plus IL-10 achieved equivalent
levels of expression, but the peak occurred earlier, around 3-6h, and downregulation
was much more advanced by 24h. Throughout the timecourse, the expression of the
DC marker CD1 lc was stable and comparable for both populations of cells. Thus, in
terms of surface phenotype, the effect of IL-10 is to drive LPS activated DCs more
quickly into and out of activation. Its influence is kinetic.
Figure 3.7 IL-10 accelerates DC activation kinetics. DC were stimulated with LPS or LPS plus
IL-10 and samples removed from the culture at various times afterwards for analysis by flow




The lifespan ofDCs arriving in a lymph node is short; the final consequence of
activation is death [155], The rapid kinetics of IL-10 treated DCs could either speed
them into an early death, or result in an extended post-activation 'exhaustion' with
the cells then dying at the same time as those stimulated by LPS alone. To
distinguish the two possibilities, the percentage of dead or dying cells was measured
at various times after activation (fig 3.8). Unstimulated cells lived longer than either
population given LPS; IL-10 treated DCs again behaved as mature cells. At early
timepoints, however, their death rate was higher than that of cells in LPS alone,







Figure 3.8 Cell death following activation. DCs were stimulated with or without LPS
and EL-10 and stained with the membrane impermeant dye ToPro3 at various times
afterwards. (A) An example of staining, taken after 24 hours' stimulation. The boxed
region was used to define dead cells. (B) Percentage cell death as a function of time.
Data is representative of four separate experiments.
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3.3.8 Delayed addition ofIL-10
Several groups have reported that DCs become resistant to the effects of IL-10 as
they mature [205, 346, 351], This is consistent with an inhibition of maturation, but
it needed to be reconsidered in light of the kinetics of DC activation. DCs were
stimulated with LPS and IL-10 was added either immediately or at various times
afterwards. All cultures were analysed by flow cytometry 24 hours after the initial
LPS (fig 3.9). As seen earlier, the LPS signal alone induced a relatively high level of
B7.2 expression. When the LPS was given together with IL-10, that expression was
downregulated. As the time delay was increased between the LPS stimulus and the
addition of IL-10, the extent of suppression diminished.
Unstimulated plus LPS
MHCII B7.2 MHCII B7.2
Figure 3.9 IL-10 can downregulate LPS-activated DCs. DCs were stimulated with LPS, or not,
at Oh. IL-10 was added to both types of culture either immediately or at various times afterwards.
Cells were harvested at 24h and their expression of surface markers measured by flow cytometry.
Open peaks indicate isotype controls. Data is representative of two independent experiments.
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This result is perhaps unsurprising given the experimental design: IL-10 added 18
hours after the LPS had considerably less time in which to act before the cells were
taken for staining, compared to IL-10 given at the start of the timecourse. It does
suggest, however, that shortly after stimulation DCs remain at least partially
responsive to IL-10 mediated suppression. This window of opportunity appears to
include the 6-8h timepoint at which LPS stimulated DCs are at the peak of their
activation.
3.3.9 Cytokine deficiencies
To see whether IL-10 affected the quality of activation as well as its kinetics, DCs
were examined first for their production of IL-12. IL-12 is a key dendritic cell
cytokine, often used as an indicator of activation [352] [353] and proposed by
Kalinski et al. to be the determinant of Thl vs Th2 polarisation [10]. As seen by RT-
PCR, both IL-12 p40 and p35 genes were strongly induced by LPS stimulation, with
or without IL-10 (fig 3.1OA). The response was short-lived, with downregulation of
both genes apparent by 14h post-stimulation. Although these kinetics were affected
by IL-10, with expression peaking earlier in its presence, the dominant effect was
one of scale. This was reinforced when the samples were quantified by real-time
RT-PCR (fig 3.10B). DCs activated in the presence of IL-10 did show a brief, early
upregulation of IL-12 p40. Expression was maximal 2h after stimulation, 2000-fold
above the pre-stimulation background, and had returned to baseline by 6h. This
response was dwarfed by that seen with LPS alone, however; peak expression then
was 10-fold higher. The p35 subunit showed a similar pattern: although transcription
was induced in the presence of IL-10, the effect was stronger in its absence.
When intracellular cytokine staining was used to visualise protein production during
the first 6 hours post stimulation, the same IL-12 deficiency was apparent on two
levels (fig 3.10C). The number of DCs making any IL-12 was lower in IL-10 treated
cells than in those given LPS alone, and the IL-10 DCs also made less IL-12 on a per
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Figure 3.10 IL-12 expression. (A&B) DCs were stimulated with LPS and IL-10 and
samples taken for RNA extraction at various times afterwards. (A) Expression of the two
IL-12 subunits assessed by RT-PCR, using B-actin for comparison. (B) Quantitative real¬
time RT-PCR. Y-axis scale indicates an «-fold increase above gene expression at Oh. Data
is represented as the mean of triplicate reactions ± SEM. (C) Protein production was
measured 6h after stimulation using intracellular cytokine staining. Numbers give the
percentage of live CDllc+ dendritic cells positive for IL-12, ie. falling in the top right
quadrant, and the y-axis mean fluorescent intensity of these cells. Data is representative of
three independent experiments.
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assays. One caveat to the protein data is that the staining antibody recognises the
p40 subunit of IL-12 but cannot distinguish between monomers, bioactive
heterodimers or potentially inhibitory homodimers.
That said, the main observation here appears to be that DC stimulated in the presence
of IL-10, even when phenotypically activated, still make little IL-12. Reis e Sousa
and colleagues have described an IL-12:IL-10 axis in which DC stimulated to
produce one cytokine make little of the other [223], McGuirk [112] and others [216,
354] have reported that IL-10 producing DCs induce a regulatory or anergic T cell
response. I was interested therefore to see if the lack of IL-12 in my cells
corresponded with an increase in IL-10. Figure 3.11 suggests not, neither at the level
of gene expression nor of protein production. DCs activated by LPS alone express
some IL-10 message but translate little protein; DCs stimulated in the presence of IL-
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Figure 3.11 IL-10 production. DCs were stimulated with LPS and IL-10 and
samples taken for RNA extraction or cytokine staining, as in figure 8. (A) IL-10
expression, assessed by real-time RT-PCR. Y-axis scale indicates an w-fold increase
above gene expression at Oh. Data is shown as the mean of duplicate reactions. (B)
Protein production, measured 6h after stimulation. Numbers give the percentage of
CDllc+ cells positive for IL-10, and the mean fluorescent intensity of these cells.
Data is representative of three separate experiments.
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3.4 Discussion
Although it is clear that distinct DC subsets have distinct functions, this probably
reflects a combination of lineage [189, 355, 356], stimulus [348], activation state
[118] and environment [10, 12]. In a paper detailing five discrete DC populations
separated according to degrees of expression of CD8a and CD1 lb, Pulendran et al.
emphasised the complexity of the system [188], He wrote,
'The data presented here highlight the need to view DC development ...
as an interplay of distinct ontologic lineages with a maturational
dependence on specific microenvironmental signals.'
By demonstrating different phenotypes in response to different cytokine signals, this
chapter supports the argument for DC flexibility. The bone marrow derived DCs
used were fairly heterogeneous, however, as evident in the range ofMHCII
expression on unstimulated cells (see fig 3.3, for example). Several alternative
culture methods have been suggested in order to generate a more homogeneous,
reliably immature source of DCs [357, 358], but in all of them, factors such as the
gentleness of handling and the batch of culture medium can cause considerable
variation. While my DCs were negative for CD8a and CD4 and, by virtue of their
growth in GM-CSF, were most likely myeloid cells, it is a formal possibility that the
different phenotypes arise not because of plasticity at the level of single cells, but in
response to selective outgrowth of distinct precursors. In defence, there is very little
proliferation of DC after day 7 of culture [335], which covers the lifespan studied
here. Kapsenberg et al. tried to address this issue by skewing a DC population
towards one extreme phenotype and then trying to reverse that function in the same
cells. They found that, though initially open to polarisation, the DC became fixed
and resistant to any opposing function. Their conclusion, however, was simply that
DCs are one-shot cells with a limited lifespan (Kapsenberg, 1999, Metchnikoff
lecture, Edinburgh, UK). The question remains open.
PGE2 was described as a DC2 generating factor in Kalinski's seminal proposal of DC
polarisation [10]. It is an inflammatory mediator associated with the enhancement of
84
humoral immunity [359, 360]. Its action results at least in part from its potent
suppression of IL-12 production by APC [361, 362], which may [363] or may not
[362] be due to induction of endogenous IL-10. In contrast to IL-10, however, PGE2
has been reported to synergise with other inflammatory mediators in enhancing DC
activation, specifically by augmenting upregulation ofMHC and costimulatory
molecules in response to IL-1 (3 and TNFa. PGE2 is also thought to be an important
component of the ill-defined monocyte conditioned medium (MCM) used by
Bhardwaj and colleagues as a positive control in the induction of DC maturation
[83]. By looking only for PGE2-mediated changes in the expression of DC markers
or in the consequent proliferation of T cells, I perhaps missed the real impact of this
reagent. Cytokine analysis would have been more revealing.
The same may be true ofmy assessment of IL-4. I observed slightly elevated
expression ofMHCII and B7.2 and T cell stimulation and saw hints of increased IL-
12 by PCR. Since then, three reports have described IL-4 mediated promotion of IL-
12 release by DCs, leading to a Thl bias in the T cell response [364-366]. Although
initially surprising, this may have evolved as a regulatory loop to prevent extreme
Th2 reactions. A similar effect has been attributed to IL-13 [366]. There is
supporting data in vivo too. IL-4 knockout mice are deficient in Thl as well as Th2
responses [367], Recombinant IL-4, rather than treating Thl type autoimmunity,
instead exacerbates symptoms in both experimental arthritis and uveoretinitis [368,
369]. In human atopic dermatitis, the T cell activity in the skin that is initially
characterised by Th2 type cytokines later becomes dominated by IL-12 and IFNy
[370],
In contrast to IL-4, IL-10 is one of a number of factors reported to modulate DC
function by trapping the DC in an immature state [205, 206, 346, 349, 351, 371].
Data presented here have shown that DC activated in the presence of IL-10 do
respond to the LPS stimulus, downregulating antigen uptake and increasing
expression ofMHC and B7, but this activation is transient. The immunosuppressive
action of IL-10 appears then to accompany some degree ofDC maturation. The
discrepancy may be explained by the different timescales examined. Beulens,
Steinbrink, Kalinski and Sato all reported the apparently immature phenotype of IL-
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10 treated DCs 48h or more after addition of IL-10 [205, 206, 346, 371], While the
kinetics of DC activation in human monocyte-derived DCs may be slower than in
mouse bone marrow equivalents [117], this is still in full agreement with the
observations presented here. That expression of activation markers is low at a
particular time after stimulation does not necessarily mean that it has been low
throughout the intervening period.
This is an idea that has been hinted at previously. Beulens et al. recorded uninhibited
expression of the human DC maturation marker, CD83, in the presence of IL-10
[371], De Smedt et al. noted that in splenic DC, IL-10 treatment did not prevent the
upregulation of surface B7 or CD40 but did skew towards a Th2 outcome in vivo
[372], Rea et al. demonstrated that suppression ofDC function by the steroid
dexamethasone was concomitant with DC maturation [373], The association
between DC immaturity and tolerance, "signal 1 without signal 2" [374], was further
challenged recently. Albert et al. reported that both cross-priming and cross-
tolerance require mature DCs [375]. With both TCR engagement and costimulation
in place, the T cell response was determined by an additional "signal 3". Like the
data presented here, this suggests that DC maturation state alone does not dictate
tolerance or immunity. In support, TNFa-matured DC have been shown to express
high levels ofMHC and costimulation and yet to elicit tolerance in vivo [111].
Maturation driven by a B. pertussis antigen gives a similar DC phenotype, and these
cells guide the development of Trl regulatory T cells [112], DC activated in the
presence of IL-10 may share the same phenotype.
The nature of signal 3 remains uncertain. It was originally defined as a cytokine
signal, directing the Thl/Th2 balance of the T cell response [10], DC derived
cytokines may contribute to T cell activation as well as polarisation [376], with IL-2
an intruiging new example [109, 245], Both Menges [111] and McGuirk [112] used
DC that were phenotypically activated but secreted little cytokine. The IL-10 treated
DCs used here were also deficient in both IL-12 and IL-10. Lutz and Schuler [113]
term such DC "semi-mature", a description that befits their poor performance in both
cytokine release and T cell stimulation. The data presented in this chapter add a
kinetic perspective: the high levels ofMHC and B7 on our IL-10 treated DC are not
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maintained. Their decline is rapid, with downregulation almost complete within 24h
in the presence of IL-10. The surface ofmature DC is considered relatively stable:
the half-life ofMHCII has been measured at over 100 hours [92], This implies that
the reduction in marker expression is an active process, not a passive loss. If the
interaction between DC and responding T cells is normally a lengthy conversation
[377], then the premature downregulation of key DC molecules may be sufficient to
limit T cell proliferation. Their activation would literally be aborted [378],
IfDC regulation was purely kinetic, the T cell outcome would be dictated by the
stage of differentiation that the DC had reached as it arrived in the lymph node. If it
met a specific T cell at the height of activation, then strong immunity would result; if
it was past its peak, the consequent immune response would be different, perhaps
even tolerant. This is an extension of Lanzavccchia et al.'s description ofDC
exhaustion [118, 379]. Simplistically, it predicts that the same activation should
occur in the presence and absence of IL-10 with the only difference being one of
timing. This is indeed what happens in terms of surface phenotype, but analysis of
the IL-12 expression of the two DC populations revealed qualitative differences.
Temporal regulation and alternative activation may be complementary. The kinetic
profiles of the individual costimulatory molecules differ: the variation in expression
is more pronounced for B7.2 than B7.1, for example. The balance of costimulation
signals provided by DC will consequently change over time, influencing the T cell
outcome [262, 263]. A similar argument can be made for IL-12. Bioactive IL-12 is
a 70kD heterodimer comprised of p40 and p35 chains, encoded by separate genes. In
DCs, regulation appears to focus on the p35 subunit [365, 380] and an excess of p40
can form inhibitory homodimers [381], Data in this chapter suggests that the
induction of p35 expression in response to LPS is delayed relative to that of p40.
The changing ratio of the two subunits will determine the amount of functional IL-12
produced over time.
How long does it take for a DC to respond to pathogenic signals in the periphery and
to arrive in the lymph node? Norbury et al. observed antigen-laden DCs in the
draining lymph node within 6h of injecting virus into the footpad [382], Both DC
number and antigen presentation then declined rapidly, suggesting a relatively short
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timescale. Experiments using an adoptive transfer ofDO 11.10 T cells reported
maximal production of IL-2 by lymph node T cells 6h after intravenous
administration of peptide [383], and by 12h following subcutaneous injection of
protein antigen [384], The low levels ofMHCII and B7 on the surface ofDC 24h
after stimulation in the presence of IL-10 appear less relevant than the high levels
that we see at 6h. The establishment of tolerance by IL-10 treated DC [205, 351]
may not be a default response caused by the immaturity of the DC, but a reaction to
definite signals from fully differentiated APC.
In summary, IL-10 has a powerful influence on DC function. The data presented in
this chapter suggest that this is achieved not by preventing DC maturation, but by
controlling the kinetics and cytokine profile of their activation. I next wanted to
assess the impact this might have on the responding T cells.
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Chapter 4 - The T cell response to IL-10 DCs in vitro
4.1 Introduction
Adaptive immunity is distinguished by its vast repertoire of antigen specificities.
This creates a formidable defence against pathogens, but it comes at a cost: the
random generation of antigen receptors allows the development of self-reactive
lymphocytes, capable of attacking the body's own tissues with the same destructive
efficiency normally used to purge infections. Tolerance mechanisms have evolved
alongside immunity to protect us from such 'horror autotoxicus' [220, 385], Central
tolerance prevents the development of autoreactive cells by deleting those that
respond to self peptides displayed in the thymus [386, 387], The system is leaky,
however, and cells with low affinity receptors or whose specific antigen is absent
from the thymus can survive and escape into the periphery [82, 275], Peripheral
tolerance exists to prevent the activation of these survivors. It comes in several
guises. Deletion [388, 389], anergy [290], suppression [390] and deviation [298]
have all been described.
The inhibition ofT cell responses is currently a topic of intense interest. Several
populations of regulatory T cells have recently been described, including CD25+
Treg cells, IL-10 dependent Trl cells and TGF|3 secreting Th3s [305, 317, 323],
While their surface markers and their means of suppression appear to be different, all
three groups are characterised by a limited proliferation in response to antigen. This
is reminiscent of T cell anergy, defined as a long-term state of hyporesponsiveness
[292] and also proposed as a mechanism of peripheral tolerance [289], Anergy was
originally understood to be a result of signal one without signal two, TCR triggering
without adequate costimulation [391]. Immature DCs express sufficient MHC to
engage TCRs [217], but with very little B7.1, B7.2 or CD40 [358], Thus, while the
activation of dendritic cells initiates immunity, the steady-state migration of
immature DCs is thought to maintain peripheral tolerance [328].
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The link between IL-10 treated DCs and T cell tolerance, then, appears to be a simple
one: IL-10 inhibits the maturation ofDCs, preventing their upregulation of
costimulatory molecules and rendering responsive T cells anergic [205]. The data
presented in chapter 1 suggest that this may not be the whole story. Six hours after
activation, DCs stimulated in the presence and absence of IL-10 both express high
levels ofMHCII, B7.1 and B7.2. This chapter considers the impact of these DCs on
an in vitro population of responding T cells. Experiments show that even early after
stimulation, with high levels ofMHC and B7, IL-10 treated DCs fail to prime T cells
as effectively as their LPS-matured counterparts. This initial interaction with an IL-
10 treated DC appears to limit both the proliferation and the cytokine production of
the T cells upon subsequent rechallenge. Although both DC populations are
phenotypically activated, they direct quite different T cell responses.
4.2 Approach
Immature DCs were harvested on day 7 of culture and stimulated for 6 or 24h with
LPS or LPS and IL-10. They were washed, pulsed with ova peptide and mixed with
CD4+ cells from DO 11.10 TCR Tg mice. The resulting T cell proliferation and
activation marker expression in these primary co-cultures was analysed by 3H-
thymidine incorporation and flow cytometry. In addition, some T cells were kept in
culture for 7d, in the presence of exogenous IL-2, before being recovered and
restimulated. These secondary cultures were assessed by recording their
proliferation in response to peptide presented on irradiated APCs, and by analysing
their cytokine expression after stimulation with PMA and ionomycin.
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4.3 Results
4.3.1 T cell stimulation at 24h
As described in chapter 3, DCs activated with LPS and IL-10 retained only very low
levels ofMHC and B7 on their surface 24h later (see fig 3.3). Correspondingly, they
elicited only limited T cell proliferation (figs 3.3 and 4.1). Like their surface marker
expression, their T cell stimulation was below that of the unstimulated controls, and
although the range of peptide concentrations did not reach saturation, this deficiency
was not overcome by increasing the antigen dose (fig 4.1). In contrast, DCs





Figure 4.1 IL-10 treated DCs fail to stimulate T cell proliferation. DCs were
harvested at day 7 of culture and replated in medium alone (unstimulated), with LPS
or with LPS and IL-10. After 24h cells were pulsed with ova peptide and mixed with
CD4+ cells from DO11.10 TCR Tg mice. Proliferation was measured by 3H-
thymidine incorporation during the last 16h of a 3d culture. Data is shown as the
mean of triplicate wells ± SEM and is representative of three independent
experiments.
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4.3.2 T cell stimulation at 6h
The lack of proliferation seen in response to DCs activated in the presence of IL-10
for 24h or more has been widely reported [205, 346, 351, 392] and is easily
explained in terms of their limited expression ofMHC and costimulatory molecules.
At 6h post-activation, however, the surface phenotype of these DCs appears largely
equivalent to that of DCs matured with LPS alone (see fig 3.5). Surprisingly then,
even when the DCs were mixed with T cells 6h after activation, the IL-10 treated
population still displayed a marked deficiency in T cell stimulation. The responding
T cells proliferated no more than they did in response to unstimulated DCs, whereas
LPS-activated DCs induced much stronger T cell proliferation (fig 4.2).
[ova peptide] (ug/ml)
-m- LPS alone
—k— LPS + IL-10
~k~ Unstimulated
Figure 4.2 Even at 6h, IL-10 treated DCs stimulate a limited T cell response.
The different DC populations were assessed in a T cell proliferation assay as in
figure 4.1, but here the DCs were stimulated with LPS ± IL-10 for only 6h before
being pulsed and mixed with T cells. Proliferation was measured by 3H-thymidine
incorporation during the last 16h of a 3d culture. Data is shown as the mean of
triplicate wells ± SEM and is representative of four independent experiments.
4.3.3 Addition ofexogenous 1L-12
Since IL-10 treated DCs stimulated only limited T cell proliferation at 6h post
activation, despite high levels ofMHCII, B7.1 and B7.2, some other aspect of the
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DC phenotype had to be responsible. IL-12 was an obvious candidate: it is a key
component ofDC activation and it was expressed at clearly different levels by DCs
stimulated in the presence or absence of IL-10 (see fig 3.10). IL-12 was originally
described as a T cell growth factor [393, 394] and it has also been shown to support
B cell proliferation [395],
Figure 4.3 shows, however, that IL-12 is not the explanation for the lack of T cell
proliferation seen here. The addition of exogenous IL-12 to the cytokine deficient,
IL-10 treated DCs did not enhance their T cell stimulation, and the addition of
blocking antibodies against IL-12 to the cytokine sufficient, LPS-activated DCs did
not inhibit theirs (fig 4.3).
[ova peptide] (ug/ml)
LPS DCs
»■••• LPS DCs + anti-IL-12
—- LPS+IL-10 DCs
....... LPS+IL-10 DCs + IL-12
—Unstimulated DCs
Figure 4.3 IL-12 does not affect T cell proliferation. DCs were harvested at day 7
of culture and replated in medium alone, with LPS or with LPS and IL-10. After 6h
DCs were pulsed with ova peptide and mixed with DO11.10 CD4+ cells. Some co-
cultures were supplemented with either recombinant IL-12 or with an anti-IL-12
blocking antibody, as indicated. Data is shown as the mean of triplicate wells ± SEM.
4.3.4 T cell activation markers
The low level ofT cell proliferation in response to IL-10 treated DCs could indicate
either inefficient priming, leaving a higher percentage ofT cells ignorant and naive,
or an active suppression of the T cell response. To distinguish the two possibilities,
the T cells were assessed first in terms of their expression of activation markers.
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Figure 4.4 T cell activation markers. DCs were harvested at day 7 of culture and replated
in medium alone, with LPS or with LPS and IL-10. After 6h DCs were pulsed with ova
peptide and mixed with DOl 1.10 CD4+ T cells. Samples were removed from the co-cultures
for analysis by flow cytometry either 24 or 96h later, as indicated. "Naive" cells were CD4+
T cells purified from a DOl 1.10 mouse and stained immediately. All histogram plots are
gated on Rl, which was set on forward and side scatter characteristics to include all live
lymphocytes, both resting and blasting. It is shown at the top of the figure. Percentages
give the proportion of gated cells falling within the marker shown, and mfi refers to the
mean fluorescent intensity of all gated cells. Data is representative of three separate
experiments.
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Naive T cells were mixed with antigen-pulsed DCs that had been stimulated for 6h,
and samples then taken for analysis by flow cytometry. After 24h of co-culture, all
three groups ofDCs had induced markers of T cell activation: CD69 and CD25 were
upregulated and CD45RB and CD62L downregulated, in comparison to freshly
isolated naive CD4+ cells (fig 4.4). The degree of activation fitted well with the
proliferation data shown earlier (fig 4.2). The T cell population stimulated by LPS-
matured DCs contained more CD69hl, CD25hl and CD62L10 cells than the populations
stimulated by DCs given LPS and IL-10 or DCs left in medium alone (fig 4.4). The
latter two groups appeared similar in phenotype, as they did in proliferation, despite
the difference in expression ofMHC and B7 on the dendritic cells.
To assess the phenotype of the T cells later in their response, samples were also
taken after 96 hours of co-culture. Expression of CD69 and CD62L mirrored that
seen at 24h, with a greater percentage of activated T cells in the group stimulated by
LPS DCs than in either of the others (fig 4.4). The CD25 staining was particularly
interesting. Transient display ofCD25, the a chain of the IL-2 receptor, is
commonly used as a T cell activation marker [396], but sustained expression has
been associated with a population of regulatory T cells shown in vitro and in vivo to
suppress other T cell responses [305, 397], While almost all cells in fig 4.4
expressed some CD25 at 96h, the intensity of staining was higher in the unstimulated
and LPS+IL-10 groups than in the LPS alone set. Although intruiging, this trend was
not consistent between experiments.
4.3.5 T cell restimulation
To distinguish further between a failure to prime and an active suppression, T cells
responding to IL-10 treated DCs were maintained in culture in the presence of
exogenous IL-2, before being recovered and rechallenged with peptide presented on
irradiated APC. The reasoning was that if the T cells had been left ignorant by
inefficient priming, then the competent APC should elicit normal, primary-type
proliferation, whereas if the T cells had been tolerised, then their response should be
inhibited. The result is given in figure 4.5. While T cells recovered from culture
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with unstimulated DCs showed surprisingly strong proliferation, above even that of
the LPS-activated DCs, T cells originally stimulated by IL-10 treated DCs were
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Figure 4.5 Recovered T cells respond differently to restimulation. DCs were
harvested at day 7 of culture and replated in medium alone, with LPS or with LPS and IL-
10. After 6h DCs were pulsed with ova peptide and mixed with DOl 1.10 CD4+ cells. 3d
later, the cells were spun through lympholyte and replated in fresh medium containing IL-
2 (see section 2.7.2). 7d after the original co-culture, cells were collected, counted and
mixed with irradiated splenocytes. Ova peptide was added and proliferation measured by
3H-thymidine incorporation during the last 16h of a 3d culture. Data is shown as the mean
of triplicate wells ± SEM and is representative of three independent experiments. The
corresponding primary response curve is shown in fig 4.2.
4.3.6 Cytokineprofiles
To see whether the initial interaction with IL-10 treated DCs affected the cytokine
secretion of the responding T cells as well as their proliferation, T cells were
recovered and restimulated with PMA and ionomycin in the presence of a Golgi
block. Their cytokine patterns were then assessed by intracellular staining. T cells
stimulated by LPS DCs predominantly produced IFNy and expressed little IL-4 or
IL-10 (fig 4.6), in keeping with the IL-12 made by these DCs (see fig 3.10). T cells
co-cultured with unstimulated DCs, which expressed very little IL-12, exhibited a
Th2 profile, with a marked reduction in IFNy and increased levels of both IL-4 and
IL-10. In contrast, while the IL-12 secretion ofDCs stimulated with LPS and IL-10
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Figure 4.6 T cell cytokine profiles. DCs were harvested at day 7 of culture
and replated in medium alone, with LPS or with LPS and IL-10. After 6h
DCs were pulsed with ova peptide and mixed with DOl 1.10 CD4+ cells. 3d
later, the cells were spun through lympholyte and replated in fresh medium
containing IL-2 (see section 2.7.2). 7d after the original co-culture, cells
were stimulated with PMA and ionomycin and their cytokine expression
measured by intracellular staining and flow cytometry. All dot plots are
gated on Rl, set by forward and side scatter to include blasting lymphocytes
and shown at the top of the figure. Numbers give the percentage of gated
events falling in the top right quadrant and the y-axis mean fluorescent
intensity of these cells. Data is representative of three separate experiments.
was intermediate between that of the unstimulated and LPS-matured groups, the
responding T cells were characterised by a general cytokine deficiency. Their
expression of IFNy, IL-4 and IL-10 was well below that of either of the other groups.
4.4 Discussion
Even early after activation, despite their similarly high expression of surface MHC
and B7, DCs activated in the presence and absence of IL-10 are not equivalent. This
was demonstrated in relation to the DC in chapter 3 and is illustrated here by its
influence on the T cell response. IL-10 treated DCs stimulate only limited T cell
proliferation and the responding T cells display low levels of activation markers, are
less sensitive to restimulation and make little cytokine.
There are several possible interpretations of this data. Looking at early expression of
T cell activation markers suggested that both unstimulated and IL-10 treated DCs
prime inefficiently, leaving a significant number of unactivated, naive T cells.
Unstimulated or immature DCs are not prepared for T cell interaction. The classical
Langerhans Cell paradigm has immature DCs in the periphery physically separated
from naive T cells in the lymph node [88, 89], and some form of stimulation is
required to trigger the DC to change its chemokine receptors and migrate [398].
CCR7 expression, which controls entry to the T cell zones of secondary lymphoid
tissue, is only upregulated on mature or maturing DCs [398, 399], In addition, the
adhesion molecules, TCR ligands and costimulators that a T cell must see on an APC
in order to connect, engage and signal are all expressed at low levels on immature
DCs [7]. Maturation is associated with a ten-fold escalation of transport of new
MHCII molecules to the plasma membrane [ 104] and a further ten-fold increase in
the half-life ofMHCII once there [92], The opportunity for conversation between an
immature DC and a T cell may only be fleeting.
In contrast, IL-10 treated DCs express high levels ofMHC and B7 and yet still fail to
stimulate strong T cell proliferation. Why? What is the purpose of upregulating
these molecules if not to engage T cells? One explanation may lie in the design of
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the experiment. The 6h timepoint was identified as the peak of B7.2 expression in
IL-10 treated DCs by giving LPS and IL-10 simultaneously. If signalling through
the IL-10 receptor happens more slowly than the rapid LPS response [400] then the
first message received by the nucleus will be a direction to upregulate activation
markers, and the downmodulatory influence of IL-10 will only come later. The early
burst ofMHC and B7 would not then represent a decisive activation state but more
an inevitable consequence of cell physiology.
A more appealing explanation is that the presence ofMHC and B7 enables a
productive interaction with the T cell, but one that delivers a non-proliferative signal.
Several examples of negative signalling have been described. The best characterised
is the interaction between B7.1 and B7.2 on the APC and CTLA4 on the T cells
[401]. CTLA4 binds the B7 ligands with greater affinity than CD28 [402, 403], but
CD28 is constitutively expressed while the appearance ofCTLA4 requires T cell
activation [404] [405], The first contact is therefore between B7 and CD28,
enhancing T cell activation, driving an initial burst of proliferation but also causing
upregulation of CTLA4 and consequent termination of the T cell response [406,
407], The mechanisms used by CTLA4 to suppress T cell activation are still being
elucidated. As an alternative receptor for B7.1 and B7.2, it competes with CD28 for
the same ligands. Downstream signalling from CTLA4 uses the same
phosphatidylinositol 3-kinase (PI-3K) and serine-threonine phosphatase molecules as
required by CD28, so competition also occurs intracellularly [408], CTLA4
signalling can directly inhibit TCR signal transduction, by activating an enzyme that
removes phosphates from the ITAM motifs in the TCR complex [409]. Finally,
CTLA4 inhibits T cell progression through the cell cycle, particularly elongating S
phase [410], Engagement of CTLA4 is a positive signalling event with a negative
outcome on proliferation.
Recently new members of the B7 costimulator family have been described and some
of these too have been attributed regulatory function. B7h (also known as B7RP-1
and B7H2) is widely expressed on DCs, other APC and non-haematopoietic cells
[411,412], Its ligand, ICOS, is upregulated on T cells after activation and hence is
thought to be important in directing effector function rather than during priming
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[413], Its role in T cell regulation is less clear. Blocking ICOS costimulation during
the induction of autoimmunity exacerbates EAE [414, 415], This may reflect the
lack of Th2 polarisation thought to be encouraged by the B7h-ICOS interaction
[416], ICOS signalling has also been shown to contribute to Thl induction [417],
however, and while the EAE studies were performed in vivo, the in vitro data is
contradictory. Priming myelin specific T cells in vitro in the absence of ICOS
signalling reduced their ability to elicit EAE when transferred back into mice. This
was associated with an inhibition ofboth IFNy and IL-10 responses [418], The
discrepancy is puzzling. Two review articles have suggested that it indicates a role
for ICOS costimulation in the induction of regulatory T cells in vivo [419, 420].
Perhaps more exciting are the molecules PD-L1 (also known as B7H1) and PD-L2
(also called B7DC), both expressed on DC and both shown to interact with PD-1 on
the T cell [421, 422], Stockl et al. recently described the use of anti-PDLl blocking
antibody to manipulate T cell responses. While IL-10 treated DCs induced T cell
anergy, coating these DCs with anti-PDLl restored proliferation (Stockl, 2002, ENII
conference, Lez Embiez, France). This is strong evidence that the T cell response to
IL-10 treated DCs is not simply due to a lack of costimulation. Screening these DCs
for expression of B7 homologues and other inhibitory signals would be very
interesting.
Analysis of DC cytokines other than IL-12 and IL-10 might also be revealing.
TNFa, IL-6, IL-1 (3 and IL-2 are all released from classically activated DCs and are
therefore good candidates for a missing signal from IL-10 treated DCs [423, 424],
IL-2 is particularly significant because one of the defining characteristics of T cell
anergy is the inability to transcribe IL-2 [425]. Addition of exogenous IL-2 has been
shown to overcome anergy in vitro [426]. This has two important implications. It
may explain why my demonstration of "hyporesponsiveness" was somewhat muted.
The T cells from IL-10 DCs did show a reduced proliferation in response to
rechallenge, and their cytokine expression was limited, but particularly in a
transgenic system where almost all the T cells are of a single specificity, a whole
population effect would have been more convincing. In both types of restimulation
assay, however, exogenous IL-2 was added to the T cell cultures (see section 2.7.2).
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This may have undermined any ability of the DC to induce anergy, and a comparison
of cultures with and without IL-2 would have been useful. The importance of IL-2
also questions the relevance of this type of anergy to peripheral tolerance in vivo,
however. If the IL-2 produced during any normal immune response could trip
anergic, self-reactive T cells into action, then it is surprising that more of us do not
suffer autoimmunity.
Functional inactivation has found favour once again with the current interest in
regulatory cells [297, 302], CD25+ regulatory cells are naturally selected in the
thymus and form 5-10% of circulating peripheral T cells [427]. Thymectomy of 3
days old mice, before CD4+ CD25+ cells have emerged into the periphery, leads to
widespread autoimmunity [428, 429]. Pathogens have also been reported to subvert
DC function to generate inhibitory T cells [112], This is not only a cunning survival
strategy for the pathogen, it also has considerable potential for therapeutic
exploitation. The induction of a regulatory T cells by IL-10 treated DCs is an
attractive idea. The difference in proliferation between restimulated T cells from IL-
10 treated and LPS-matured DCs could just be the difference between a primary and
a secondary response, if the original lack of T cell stimulation by the IL-10 treated
DCs was a failure to prime, but it could also represent the limited proliferation seen
in anergic [391] and regulatory T cell populations [317]. The use ofCFSE staining
may have been enlightening here, since unlike 3H-thymidine, CFSE can distinguish
between few cells dividing normally and many cells dividing only once.
The limited rechallenge response of T cells stimulated by IL-10 treated DCs was also
characterised by reduced cytokine production. The difference in the T cell reactions
to unstimulated and IL-10 treated DCs here was interesting: while unstimulated DCs
gave rise to a Th2 biased profile, IL-10 DCs elicited little T cell cytokine of either
type. Do the IL-10 DCs make enough IL-12 to prevent the outbreak of a Th2
response but too little to drive a strong Thl differentiation? Is that sufficient to make
them suppressive? Figure 4.3 suggests not, since supplementing IL-10 treated DCs
with exogenous IL-12 does not enhance their T cell stimulation, but T cell function
may not be a direct correlate of proliferation. Importantly, the T cells recovered
from cultures with IL-10 treated DCs did not secrete high levels of IL-10, despite the
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association between this cytokine and inhibitory T cells [317]. Limited cytokine
production is a feature of anergic T cells, however [289, 296],
The real need here is for some functional assessment of the recovered T cells.
Testing for suppressive action by titrating them into another proliferation assay
would reveal much about their phenotype. It may be that several rounds of
restimulation in vitro are needed to generate a truly inhibitory population [317, 329].
This is the mixed blessing of in vitro data: the systems are simple, offering exact
control of variables and the potential to tease apart complex mechanisms. As a
consequence, though, the culture conditions used have a major influence on the
results obtained. Although enlightening, their relevance to physiology can be
debatable. To address this, it was decided to establish an adoptive transfer system to
test the different DC phenotypes in vivo.
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Chapter 5 - The T cell response to IL-10 DCs in vivo
5.1 Introduction
The ability to generate substantial numbers of dendritic cells from bone marrow or
blood-borne precursors [335, 347, 358] made therapeutic application an exciting
possibility [430, 431], Early experiments exploited the potent immunogenicity of
mature DCs to augment vaccination regimes [432] and boost anti-tumour responses
[433, 434], DCs are multifunctional cells, however, capable of directing a variety of
T and B cell responses [10, 435], In vitro manipulation before injection offers the
potential to deliberately engineer the outcome of an immune response. Data
presented in chapters 3 and 4 suggest that DCs stimulated in the presence of IL-10
rapidly acquire an active phenotype that fails to elicit strong T cell proliferation.
This chapter begins to assess their therapeutic promise by asking first whether IL-10
treated DCs can limit T cell expansion in vivo as shown in vitro, and second whether
this initial DC:T cell interaction has any lasting consequence for T cell activity.
The first experiment was theoretically simple: I wanted to activate DCs with LPS
alone or with LPS and IL-10, pulse both populations with antigen and inject them
into mice, allowing them to interact with T cells in vivo. The difficulty with this
approach lay in detecting the response. The frequency of T cells of any given
specificity is extremely low in a wildtype animal; Tse et al. estimated that T cells of
a single specificity make up less than '/iooooo of the circulating pool, rising to only
'/ioooo even after immunisation [436], To analyse 1000 of these T cells would
n
require a starting population of -1x10 cells for each data point, the equivalent of the
draining lymph node cells from one immunised mouse [437], One of the attractions
of TCR transgenic mice, then, is that they have T cells of almost entirely a single
specificity. In DOl 1.10 mice, approximately 75% ofT cells express both chains of
the transgenic receptor [334, 438]; in DOl 1.10 mice on a Rag"/_ or a SCID
background, preventing endogenous rearrangement of the TCR-Va chain, the figure
is almost 100% [439]. Immune responses are not made any easier to detect,
however. Intact TCR transgenic mice respond very poorly to attempts to induce
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either immunity or tolerance [195, 440], The overwhelming frequency of responsive
T cells appears to inhibit normal development of immune responses.
Marc Jenkins and colleagues devised a clever compromise. By transferring a limited
cohort of DOl 1.10 T cells into a wildtype BALB/c recipient, they achieved a
situation where -0.5% of T cells in the lymph nodes carried the transgenic specificity
[195, 437, 439], This is still above a typical baseline for peptide-specific responses,
but it is not dissimilar to the frequency of alloreactive T cells in a normal individual
[441] and, crucially, it allows the development of both immunity and tolerance [195],
One of the key advantages of this adoptive transfer system is the availability of a
monoclonal antibody, KJ126, which specifically recognises the transgenic TCR of
DOl 1.10 mice [442], Using KJ126, both flow cytometry and immunohistochemistry
can be exploited to follow the progress of an immune response in vivo [195, 443,
444], In the experiments presented here, DOl 1.10 transfers were used to examine
the responses generated by DCs stimulated in the presence or absence of IL-10. The
T cell expansion triggered by IL-10 treated DCs was shown to be smaller than that
induced by DCs activated by LPS alone, mirroring the differences seen in vitro in
chapter 3. This initial contact with IL-10 treated DCs in vivo also appears to render
T cells hyporesponsive to subsequent antigenic challenge.
5.2 Approach
A DOl 1.10 adoptive transfer system was established, working largely from Jenkins's
published protocols [195, 439] with DC immunisation procedures adapted from
Pulendran et al. [166] and Maldonado- Lopez et al. [152], To examine the
performance of the different DC phenotypes, DCs were harvested after 7 days of
culture and stimulated for 6h with LPS or LPS+IL-10. The cells were washed,
pulsed with ova peptide, washed again and injected into mice that had been
adoptively transferred 24h earlier with a cohort of DOl 1.10 T cells. The
experimental outline is illustrated in fig 5.1. Mice were either killed at day 5 after
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Figure 5.1 Experimental outline. An adoptive transfer system was established in which
Balb/c mice received a cohort of DO 11.10 TCR Tg T cells before being immunised with
different DC populations, each coated with ova peptide. The mice were either sacrificed
after five days or rechallenged in vivo and sacrificed at day 17. Their response to ova was
measured by recording any expansion of the DO 11.10 population and assessing its ability
to respond to ova peptide in vitro.
priming to assess T cell expansion at the peak of the primary response, or left intact
and instead rechallenged in vivo on day 7. This second immunisation was given as a
duplicate shot of LPS-activated DCs or as a s.c. injection of peptide in CFA, and in
both cases peak expansion of the secondary response was measured 3 days later, on
day 10. Some mice were kept until day 17 and their spleen or lymph node cells then
restimulated in vitro.
5.3 Results
5.3.1 DO11.10 T cells before and after transfer
To identify a convenient source of transgenic T cells, an initial comparison was made
of adoptive transfers of either unseparated lymph node cells or CD4+ enriched
splenocytes. The lymph nodes ofDO 11.10 mice were collected, pooled and
immediately prepared for injection. Spleens from the same animals were lysed of
red blood cells and depleted ofCD8+ and MHCII+ contaminants by magnetic
separation (see section 2.4.2). The purities of the two preps are illustrated in fig 5.2.
Both populations were transferred into wildtype BALB/c recipients by i.v. injection
into the tail vein. Two concentrations ofCD4+ splenocytes were used. The
transferred mice were sacrificed 24h later and their spleens and lymph nodes (pooled
popliteal, inguinal, brachial, axillary and cervical) examined by flow cytometry (figs
5.3 and 5.4). While the percentage of CD4+ KJ126+ cells in an untransferred
BALB/c mouse was undetectable, each of the transfer recipients displayed a small
but distinct double positive population. The transfer had worked.
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Figure 5.2 T cell purity before transfer. DO11.10 T cells were prepared for
transfer either by pooling lymph nodes or by depleting splenocytes of CD8+ and
MHCII+ contaminants with a MACS column. A sample was taken from each, stained
with antibodies against CD4, CD8 and CD 19 and analysed by flow cytometry.
Forward and side scatter characteristics were used to define live cells, and the
numbers give the percentage of these cells which fall within the marker shown.
























Figure 5.3 Detecting DO11.10 cells 24h after transfer, in the spleen. Mice received an
adoptive transfer of different numbers of either lymph node cells or CD4+ enriched
splenocytes. 24h later, their spleens were harvested, stained and analysed by flow cytometry.
The numbers give the percentage of KJ126+ cells within the CD4+ population, using a live
lymphocyte gate (R2) set on forward and side scatter characteristics as indicated at the top of
the figure. The two plots represent the two mice in each group.
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Figure 5.4 Detecting DO11.10 cells 24h after transfer, in the lymph nodes. As in
figure 5.3, mice received an adoptive transfer of either lymph node cells or CD4+
enriched splenocytes and were sacrificed 24h later. Peripheral lymph nodes were
collected, pooled and analysed by flow cytometry. The numbers give the percentage of
KJ126+ cells within the CD4+ population, using a live lymphocyte gate (R2) set on
forward and side scatter characteristics and shown at the top of the figure. The two
plots represent the two mice in each group.
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While the crude lymph node prep contained a lower percentage of CD4+ cells
(61.3% ± 2.3, n=4) than the purified splenocytes (80.7% ± 3.0, n=5)(fig 5.2), the
time needed to harvest and prepare the LNCs was considerably shorter. This had an
edge of convenience, but it also meant that the cells were fresher and probably
healthier when transferred into the recipient mice. The protocol of transferring 5xl06
LNCs into each recipient was therefore used in all subsequent experiments.
5.3.2 Without immunisation, survival of transferred cells is limited
To assess how long the transferred cohort ofDO11.10 T cells lasted in the intact
BALB/c host, mice were adoptively transferred with DO11.10 LNCs and killed at
various limes afterwards (fig 5.5). Early experiments had suggested that the
transferred population was stable during the first 48h after transfer and indeed, the
percentages seen 24h after the transfer of 5x106 cells (although splenocytes rather
than LNCs) in figs 5.3 and 5.4 are below those given for day 3 in fig 5.5. After day
3, however, this stability waned and the transgenic population declined steadily,
becoming almost undetectable by day 28 post transfer. This was also reported by
Jenkins and colleagues [437] and is probably due to homeostatic competition with
Figure 5.5 Loss of transferred T cells over time. DO 11.10 lymph node cells were
transferred into Balb/c recipients and two mice sacrificed at various times afterwards. The
number ofKJ126+ cells in their spleen and peripheral lymph nodes was measured by flow
cytometry and is expressed as the percentage of live CD4+ cells in each tissue. Data is
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Figure 5.6A DO11.10 expansion in response to DC immunisation. DOl 1.10 LNC
were transferred into mice 24 hours before immunisation with PBS, LPS-activated DCs
or LPS-activated DCs pulsed with ova peptide. 5 days after immunisation, the mice
were sacrificed and the percentage of DOl 1.10 cells in their spleens measured by flow
cytometry. The raw data is shown here. The numbers give the percentage of KJ126+
cells within the CD4+ population, using the live cell gate shown at the top of the figure.




































Figure 5.6B DO11.10 expansion in response to DC immunisation. These graphs
illustrate the raw data shown in fig 5.6A, together with equivalent data from the lymph
nodes of the same mice. The y-axis values give the percentage of KJ126+ cells within the
live CD4+ population, and each point represents an individual mouse.
normal BALB/c T cells emerging from the thymus [445]. Practically, it meant that
any immunisation of adoptively transferred mice had to be done within 48-72h of the
initial transfer.
5.3.3 DC immunisation expands the transferredpopulation
To confirm that DC immunisation could elicit an antigen specific immune response,
immature DCs were harvested at day 7 of culture and stimulated with LPS for 6h.
Half the cells were then pulsed with ova peptide and halfmaintained in medium
alone. The two populations were injected i.v. into mice that had been adoptively
transferred with DOl 1.10 LNCs 24h earlier. The mice were sacrificed 5 days later
and the percentage of CD4+ KJ126+ transgenic cells in their spleens and lymph
nodes measured by flow cytometry. The raw data is shown in fig 5.6A and
summarised in fig 5.6B. In both tissues, there was a clear and antigen specific
expansion of the DOl 1.10 cells in response to the peptide-loaded DCs. Mice
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receiving unpulsed DCs and those mock-injected with PBS displayed a low level of
KJ126 staining consistent with unimmunised transfers 6d after delivery of the T cells
(see fig 5.5).
5.3.4 Theprimary response peaks at day 5
Pulendran et al. [166] and Maldonado-Lopez et al. [152] recommended measuring
the immune responses triggered by antigen-loaded DCs 4-5 days after immunisation.
Figure 5.7 confirmed that day 5 also caught the peak of the primary response in the
DC-immunised adoptive transfers used here. The data also revealed an interesting
disparity between the two lymphoid tissues studied. Systemic administration of
antigen-loaded DCs induced more extensive expansion of the DO11.10 population in





Figure 5.7 The primary response peaks at day 5. Adoptive transfers were immunised
with LPS-activated DCs pulsed with ova peptide and two mice sacrificed at 3, 5 and 7
days later. The number of KJ126+ cells in their spleen and peripheral lymph nodes was
measured by flow cytometry and is expressed as the percentage of live CD4+ cells in each
tissue. Data is shown as the mean of the two samples at each timepoint.
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5.3.5 IL-10 treated DCs stimulate limited T cell expansion in vivo
Having established that DO 11.10 T cells could be transferred successfully and would
respond to ova peptide, I wanted to test whether DCs activated by LPS in the
presence of IL-10 would generate the same degree of T cell expansion as DCs given
LPS alone. Both DC populations were stimulated for 6h, pulsed with ova peptide
and injected i.v. into mice adoptively transfered with DO 11.10 LNCs 24h earlier.
The percentage ofCD4+ KJ126+ T cells in their spleens was measured 5d later by
flow cytometry. Unstimulated DCs induced a moderate T cell response, but
activating them with LPS significantly enhanced the T cell expansion (P<0.0001, fig
5.8). When the LPS was given together with IL-10, this increase disappeared
(P=0.03, fig 5.8). This is very similar to the effect of IL-10 treated DCs seen in vitro
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Figure 5.8 IL-10 treated DCs stimulate a limited T cell response in vivo. Mice received an
adoptive transfer of DO 11.10 LNC 24h before being immunised with unstimulated DCs
(medium alone), DCs activated with LPS for 6h or DCs stimulated with LPS in the presence of
IL-10, all pulsed with ova peptide. As negative controls, mice were included that had been
immunised with DCs not pulsed with antigen and that had been mock-injected with PBS alone.
Mice were sacrificed 5 days after immunisation and the number of KJ126+ cells in their
spleens measured by flow cytometry. Data is expressed as the percentage of KJ126+ cells
within the live CD4+ population and each point represents an individual mouse. The graph is
representative of seven independent experiments, each using 4-5 mice per group. *, P = 0.044;




As in vitro, the limited T cell expansion generated by IL-10 treated DCs could reflect
either inefficient priming or an active suppression of the T cell response. To
distinguish the two possibilities, mice that had received an adoptive transfer of
DOl 1.10 LNCs were immunised with the different DC populations and their spleens
harvested at day 5, the peak of the primary response, and restimulated in vitro.
Unfortunately proliferation in these cultures proved resoundingly non-specific: there
was no reduction in counts as the ova peptide was titrated out and even wells without
peptide scored upwards of 70000 cpm (fig 5.9A). Importantly, the spleens of mice
given mock injections of PBS proliferated very little while those from mice
immunised with unpulsed DCs showed the same high background as the three
experimental groups. This suggested that the problem was not an isolated feature of
the in vitro culture, but more likely a secondary response to another antigen
unwittingly loaded onto the DCs alongside the ova peptide.
Serum antigens were obvious candidates, especially as the emergence of high
background proliferation coincided with a change in serum supplier. Despite
extensive investigation of the batch variability of commercial mouse serum, though,
the explanation remained elusive. Mismatching the sera and even the media used for
the preparation of the DCs with that involved in the restimulation culture was
unsuccessful. There was no evidence of superantigen contamination of media or
other reagents and indeed simple in vitro proliferation assays with DOl 1.10 T cells
remained ova-dependent. One possibility was that the tail vein injection of
transgenic T cells just 24 hours before delivering DCs into the same site created a
damaged or inflammatory environment that at least contributed to the unexpected
response. Fig 5.9B suggests otherwise. These mice were immunised without any
prior adoptive transfer and yet their background proliferation remained high. The
extent of the problem was illustrated by CFSE labelling of the restimulation cultures
(fig 5.10). Two colour staining with KJ126 allowed the ova-specific DOl 1.10 cells
to be distinguished from the BALB/c majority, and neatly demonstrated that while
both the expansion of the DOl 1.10 cells in vivo and their division in vitro required
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Figure 5.9 High background proliferation. (A) Mice received an adoptive transfer of
DOl 1.10 LNCs and were immunised 24h later with DCs pulsed with ova peptide. Their
spleens were harvested 5d after immunisation and plated in vitro with graded doses of
antigen. (B) Wildtype mice were immunised with DCs without any prior adoptive
transfer. Their spleens were harvested at day 5 as above. In both cases, proliferation
was measured by 3H-thymidine incorporation during the last 16h of a 3d culture. Data
is shown as the mean of triplicate wells ± SEM and the two lines per immunisation
represent the two mice per group.
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Figure 5.10 Non-specific proliferation illustrated by CFSE staining. Mice received
an adoptive transfer of DO 11.10 LNCs and were immunised 24h later with LPS-
stimulated DCs either coated with ova peptide or left without antigen. Their spleens
were harvested 5d after immunisation and labelled with CFSE before being cultured in
vitro for a further 4 days. These cells were counterstained with KJ126-PE and their
fluorescence assessed on a flow cytometer. Dividing DOl 1.10 cells fall into the top left
quadrant.
5.3.7 Restimulation at day 5
The problem of high background proliferation in in vitro restimulation cultures was
surprisingly solved by moving the mouse serum from the freezer to the fridge for
routine storage. The beauty of the peptide dependent responses seen at last in fig
5.11 therefore masked the disappointing similarity of the experimental groups. Mice
that had been adoptively transferred with a cohort ofDOl 1.10 LNCs were
immunised with DCs that were attempted in figure 5.9, adoptive transfers had been
immunised with DCs that were either unstimulated, activated with LPS or treated
with LPS and IL-10 together. Their spleens were harvested at day 5 and cultured
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Figure 5.11 Ex vivo restimulation at day 5. Mice received an adoptive
transfer of DO11.10 LNCs 24h before being immunised with untreated DCs,
LPS-activated DCs or DCs stimulated with LPS+EL-10, all coated with ova
peptide. Mice that received an adoptive transfer but were immunised with LPS-
activated DCs without antigen or a mock-injection of PBS were included as
negative controls. Mice were sacrificed 5d after immunisation and their spleens
pooled within groups and plated for in vitro culture with graded doses of ova
peptide. Proliferation was measured by 3H-thymidine incorporation during the
last 16h of a 3d culture and data is shown as the mean of triplicate wells ± SEM.
The graph is representative of two independent experiments, each with 5 mice
per group.
DC treatments resulted in equivalently strong in vitro recall responses. Given the
higher percentage ofDO 11.10 T cells found in the spleens ofmice immunised with
LPS-activated DCs on day 5 (see fig 5.8), their proliferation per KJ126+ cell at this
stage was in fact lower than that achieved by either unstimulated or IL-10 treated
5.3.8 Secondary expansion in vivo is small
The similarity of the proliferation curves in fig 5 .11 was perplexing. While it was
certainly possible that the limited T cell expansion generated by IL-10 treated DCs
was due to inefficient priming, leaving the majority of the DO11.10 cells as fully
DCs.
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capable of responding to antigenic challenge as any other naive population, I still
expected immunisation with LPS DCs to result in a stronger, secondary-type
response to the in vitro restimulation. This was not the case. One possible
explanation was that by harvesting and restimulating the spleens at the peak of the
primary response, the T cells activated by the DC immunisation were left refractory
to the second stimulation. The proliferation seen in fig 5.11 might then be a primary
response ofDOl 1.10 cells left unactivated by the original, in vivo challenge.
To address this, the time between primary and secondary challenge was increased
and, importantly, the restimulation was also delivered in vivo. Mice that had been
adoptively transferred with DOl 1.10 LNCs were immunised with DCs that had been
cultured in medium alone, with LPS or with LPS and IL-10 together. 7 days later, all
three groups were reimmunised with LPS-activated DCs. To measure their T cell
expansion in response to the second challenge, mice were either sacrificed or bled 3
days later, on day 10. The percentage ofDOl 1.10 cells in their CD4+ pool was
































Figure 5.12 T cells show little expansion to secondary challenge in vivo. Adoptive transfers were
immunised with untreated DCs, LPS-activated DCs or DCs stimulated with LPS+IL-10, all coated with
ova peptide. Transfers receiving LPS-activated DCs without antigen were included as a negative
control. Seven days later, mice were rechallenged with LPS-activated DCs pulsed with peptide. The
negative control group again received DCs without antigen (No Ag), and a positive control group was
set up with an adoptive transfer 24h before being given only the same LPS DC + ova 'rechallenge'as
the experimental mice (Rechallenge only). Mice were sacrificed 3d after rechallenge,on day 10 of the
experiment, and the number of KJ126+ cells in their spleens measured by flow cytometry. Data is
expressed as the percentage of KJ126+ cell within the live CD4+ population and each point represents
and individual mouse. The graph is representative of five independent experiments, each using 4-5
mice per group. There is no significant difference between any of the experimental groups, using an
unpaired students t-test.
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immunised twice with unpulsed DCs illustrated the background level of DO 11.10
chimaerism established by the adoptive transfer. The positive control group, animals
that were given the second round of LPS-stimulated DCs as a primary challenge,
showed some T cell expansion but at only 3 days after immunisation, they were still
in the early stages of their response. In contrast to the large secondary expansion I
had anticipated from at least those immunised with LPS DCs, all three experimental
groups showed very little increase above background. Although initially surprising,
this inhibition of secondary proliferation was also reported in the original description
of the adoptive transfer technique [195] and has recently been shown to be imposed
by external factors, perhaps persisting antigen, within the immunised host [383],
5.3.9 Restimulation at day 17
To overcome the lack of T cell expansion, Merica et al. recommended measuring
responses to in vivo rechallenge by purifying the DO 11.10 population and re-
transferring them into a fresh, unimmunised host [383]. As an alternative approach,
here the experimental mice were kept until day 17, lOd after the second DC
injection, and then their spleens taken for in vitro restimulation. The delay until day
17 ensured that the DOl 1.10 expansion had returned to baseline in all groups (fig
5.13A), and was designed to avoid any refractory behaviour from the responding T
cells. The resulting proliferations are shown in fig 5.13B. Differences between the
groups were small, but on the two separate occasions that the experiment was
performed, splenocytes from mice originally immunised with IL-10 treated DCs
proliferated less than those from mice given either unstimulated or LPS-activated
DCs. The initial interaction with DCs stimulated in the presence of IL-10 appeared
to inhibit the T cell response to subsequent challenge.
This result was even clearer when the in vivo rechallenge was given as a s.c. injection
of peptide in CFA, in place of the second dose of antigen-loaded DCs (fig 5.14). As
above, adoptive transfers were immunised with the different DC populations,
rechallenged on day 7 and sacrificed on d 17. Cells from the lymph node which
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Figure 5.13 In vivo rechallenge with LPS DCs. As in figure 5.10, adoptive transfers were
immunised with untreated DCs, LPS-activated DCs or DCs stimulated with LPS+IL-10, all
coated with ova peptide, and rechallenged 7d later with LPS DCs pulsed with peptide. The
positive control group (Rechallenge only) received an adoptive transfer 24h before being given
the same DC + ova as the experimental mice. The negative controls (No Ag) were given LPS
DCs without antigen at both immunisation and rechallenge. Mice were sacrificed lOd after
rechallenge, on day 17 of the experiment. (A) The number of KJ126+ cells in their spleens was
measured by flow cytometry. Data is expressed as the percentage of KJ126+ cell within the live
CD4+ population and each point represents an individual mouse. There is no significant
difference between experimental groups, using an unpaired student's t-test. (B) The remaining
splenocytes were pooled within groups and plated for in vitro culture with graded doses of ova
peptide. Proliferation was measured by 3H-thymidine incorporation during the last 16h of a 3d
culture. Data is shown as the mean of triplicate wells ± SEM. Both panels are representative of
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Figure 5.14 In vivo rechallenge with peptide in CFA. Adoptive transfers were
immunised with untreated DCs, LPS-activated DCs or DCs stimulated with LPS+IL-10,
all coated with ova peptide, and rechallenged 7d later with ova in CFA. The positive
control group (Rechallenge only) received an adoptive transfer 24h before being given
the same ova in CFA as the experimental mice. The negative controls (No Ag) were
given LPS DCs without antigen at immunisation and PBS in CFA at rechallenge. Mice
were sacrificed lOd after rechallenge, on day 17 of the experiment. (A) The number of
KJ126+ cells in the draining lymph nodes was measured by flow cytometry. Data is
expressed as the percentage of KJ126+ cell within the live CD4+ population and each
point represents an individual mouse. There is no significant difference between
groups, using an unpaired student's t-test. (B) The remaining lymph node cells were
pooled within groups and plated for in vitro culture with graded doses of ova peptide.
Proliferation was measured by 3H-thymidine incorporation during the last 16h of a 3d
culture. Data is shown as the mean of triplicate wells ± SEM. Both panels are
representative of two independent experiments, each using 4-6 mice per group.
drained the site ofCFA injection were stained to measure the percentage of DO 11.10
T cells present and plated with peptide to assess their proliferative response to
restimulation. Again the T cell expansion triggered by the in vivo rechallenge was
limited (fig 5.14A), but this had the advantage of ensuring a similar number of
transgenic T cells in each well of the restimulation assay. Lymph node cells from the
different groups of mice showed distinct proliferative responses, however (fig
5.14B). LNCs from adoptive transfers first immunised with LPS activated DCs
proliferated strongly, typical of a primed response. Those from transfers immunised
with unstimulated DCs also responded strongly; the discrepancy between this and
that of the LPS DCs might be explained by the slight difference in percentage of
DO 11.10 cells present (see fig 5.14A). Importantly though, very little proliferation
was achieved by LNCs from mice first given DCs stimulated with LPS and IL-10
together. These DCs clearly inhibited subsequent T cell responses.
5.3.10 Restimulation in bone marrow chimaeras
Although still in need of repetition, the data shown in figs 5.13 and 5.14 together
suggest that immunisation with DCs activated in the presence of IL-10 can be
sufficient to tolerise a cohort of specific T cells in vivo. An exciting question was
then whether these T cells were simply inactivated, perhaps anergised, or whether an
active suppression was involved. One way to address this would be to purify the
non-proliferative T cells, transfer them into a fresh BALB/c host at the same time as
another cohort of nai've DOl 1.10 LNCs, and test whether they can inhibit expansion
of the nai've cells. An alternative approach, and the one adopted here, is to immunise
and rechallenge a group of mice that are chimaeric for the DO 11.10 transgene at the
level of their bone marrow rather than just in the periphery, as in the adoptive
transfers. These chimaeric mice were created by lethally irradiating BALB/c
recipients before reconstituting them with a mixture of BALB/c and DOl 1.10 bone
marrow. The ratio of BALB/c to DOl 1.10 cells was chosen to ensure that 1-2% of
mature T cells carried the Transgenic TCR (Simon Fillatreau, ICAPB, University of
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Figure 5.15 Outline of bone marrow chimaera experiment. BALB/c hosts were lethally
irradiated and, 24h later, injected with bone marrow from both BALB/c and DO11.10 mice,
combined at a 9:1 ratio. The mice were left 8 weeks to allow reconstitution of the immune
system. They were then immunised with different DC populations, each coated with ova
peptide. 5 days later, they were rechallenged in vivo with LPS-activated DCs also pulsed with
peptide. Mice were sacrificed at day 10, and their response to ova measured in an in vitro
assay.
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Figure 5.16 In vivo rechallenge in bone marrow chimaeras. Chimaeric mice were created
by reconstitution of an irradiated BALB/c host with 90% BALB/c and 10% DO 11.10 bone
marrow (see section 2.10 and fig 5.15). These mice were immunised with untreated DCs,
LPS-activated DCs or DCs stimulated with LPS+EL-10, all coated with ova peptide, and
rechallenged 5d later with LPS DCs pulsed with peptide. The positive control group
(Rechallenge only) were immunised with LPS DC + ova only on day 5. The negative controls
(No Ag) were given LPS DCs without antigen at both immunisation and rechallenge. Mice
were sacrificed 5d after rechallenge, on day 10 of the experiment. Their spleens were
harvested and plated for in vitro culture with graded doses of ova peptide. Proliferation was
measured by 3H-thymidine incorporation during the last 16h of a 3d culture. Data is shown as
the mean of triplicate wells ± SEM and the two lines represent the two mice in each group.
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chimaeras, an initial injection of IL-10 treated DCs may inactivate the population of
DO 11.10 T cells present at that time but more Transgenic cells will emerge from the
thymus before administration of the in vivo rechallenge. Again, any suppression of
these naive cells would suggest an active role for the originally tolerised T cells.
Chronologically this was the first in vivo experiment performed; bone marrow
chimaeras were made routinely in the lab while the adoptive transfer system took
time to establish. As such, the timing of the successive immunisations lacked some
of the refinement later used in the experiments described above. Chimaeric mice
were immunised with DCs that were either unstimulated or activated with LPS alone
or in combination with IL-10, and then, five days later, were rechallenged with a
second injection of LPS-activated DCs. After a further five days, on day 10, the
mice were sacrificed and their splenocytes cultured in the presence of ova peptide for
an in vitro restimulation assay (fig 5.15). The results are shown in fig 5.16. As in
the adoptive transfer system, the strongest proliferation was shown by splenocytes
from chimaeras originally immunised with LPS-activated DCs. If the first
immunisation was given with unstimulated DCs, the proliferation was less
pronounced. IL-10 treated DCs resulted in a marked inhibition of the restimulation
response, leaving a level of proliferation below even that of the negative controls (fig
5.15). This suggests that DCs activated in the presence of IL-10 might be able to
induce an active suppression of the immune response. It remains very preliminary,
however. The experiment was done once with only two mice per group, and the
poverty of this approach was demonstrated by the two positive controls, only one of
which responded (fig 5.15).
5.4 Discussion
The combination ofDOl 1.10 adoptive transfers and the KJ126 monoclonal antibody
provides a powerful tool for investigating immune responses in a near-physiological
setting [437], Here the system was exploited to examine the impact of IL-10 treated
DCs on a T cell response in vivo. The data suggest that DCs activated in the
presence of IL-10 elicit a limited T cell expansion that confers a lasting suppression,
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leaving the T cells hyporesponsive to subsequent challenge. These results reinforce
those generated in vitro in chapter 4, and suggest an exciting therapeutic promise.
First, however, initial experiments confirmed that the adoptive transfer system could
work here as it does elsewhere [195, 443, 444], The original description of the
technique [195] reported a frequency of-0.5% transgenic T cells in the spleen and
lymph nodes following transfer of 2.5x106 T cells, and the percentages achieved here
were similar (figs 5.3 and 5.4). The transferred cells were shown to proliferate
strongly in response to a primary immunisation with antigen loaded DCs (fig 5.6),
but surprisingly weakly to a secondary challenge (fig 5.12). This was also detailed
by Jenkins's group [383] and it perhaps challenges a common perception that part of
the memory phenotype is an inherent propensity for rapid division upon stimulation
[446]. Merica et al. demonstrated that transferring the T cells into a naive host or
delaying the rechallenge by several weeks, presumably allowing residual
peptide:MHC complexes to disappear, resulted in a return to the slower but more
expansive proliferation typical of a primary response [383]. This was associated
with a reversion to a 'naive' surface phenotype with high levels ofCD45RB [383,
447], Their conclusion was that persistence of CD4+ mediated immunity after
elimination of the original antigen is due to the presence of both specific antibodies,
which efficiently target fresh antigen to APCs [448, 449], and an expanded
population of specific T cells, even though these share some functional
characteristics with naive cells [383, 450], This has two main implications for the
data presented here. The first is reassuring: the lack of T cell expansion seen in
response to secondary challenge is not a flaw in the system and should perhaps have
been expected. The second is intriguing: ifCD4+ T cell immunity is at least partly
due to environmental factors such as persistent antigen or specific antibodies, rather
than being an inherent property of the T cells, is the same also true ofCD4+ T cell
tolerance?
Another interesting point to emerge from these early experiments was the disparity in
the degree of expansion ofDOl 1.10 cells in spleen and lymph node, illustrated most
clearly in figs 5.6 and 5.7. The data is presented as a percentage of CD4+ cells, to
account for the different number of T cells in each tissue, so the explanation is more
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complex than this. The DCs were administered systemically, injected i.v. into the
tail vein, so the spleen is perhaps a natural destination. The transferred T cells were
delivered in the same way, however, and before immunisation there was no such
distinction between tissues. Nai've T cells express homing receptors to cany them
into lymph nodes, such as L-selectin, CD62L, which facilitates passage through high
endothelial venules [451], In contrast, the chemokine receptors on mature DC are
designed to take them into LNs from the lymph, not blood [398, 452], so systemic
delivery may well by default cause their accumulation in the spleen. Labelling the T
cells or the DCs with tracking dyes before injection would be revealing.
Although the primary T cell expansion generated by IL-10 treated DCs was
concentrated in the spleen, the inhibition of secondary responses was systemic,
evident even when the rechallenge was given as a s.c. immunisation in the thigh (tig
5.14). This presumably reflects the circulation of effector T cells. Interestingly,
while the suppression was apparent in splenic proliferation assays, it was more
pronounced in lymph node cultures (compare figs 5.13 and 5.14). Different degrees
of tolerance in spleen and lymph node have been reported elsewhere [453], but the
reason for these discrepancies is uncertain. The cellular composition of the spleen
and lymph node is quite different [454], but the predominance of B cells in the
spleen might be expected to encourage tolerance there [455, 456]. The drainage
systems that deliver antigen to the two tissues are also distinct, but again this offers
little explanation. Systemic antigens often elicit tolerance [195, 457] and many
localised, peripheral infections require strong immunity to clear them [458, 459]. It
may reflect the design of the experimental systems rather than a physiological reality,
but either way it remains puzzling.
The induction of tolerance by IL-10 treated DCs is not a new idea. Enk et al. first
described their ability to anergise a murine Thl clone in 1993 [351]. Steinbrink et al.
repeated this data using both human CD4+ [205] and CD8+ [460] cells, and more
recently the same group have attributed a suppressor function to these anergic cells
[349]. McBride et al. also used cocultures of human DCs and CD4+ T cells to
demonstrate that stimulation ofDCs in the presence of IL-10 inhibits T cell
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responses to subsequent challenge [461]. The data presented here have the
distinction of illustrating that the same suppression is possible in vivo.
The other key difference between these two sets of data is in the interpretation of the
status of the IL-10 treated DCs. All of these reports describe the effect of IL-10 as
an inhibition ofmaturation, so while their work is restricted to an in vitro setting, it
draws strength from the use of immature DCs in vivo. Dhodapkar et al. injected
autologous, immature DCs into two human volunteers and saw both the inhibition of
CD8+ cytolytic activity and the emergence of IL-10 producing CD4+ cells [325]. In
mice, immature DCs have been shown to temporarily [462] or indefinitely [463]
prolong cardiac allograft survival. The in vitro data presented in chapters 3 and 4
suggest that DCs stimulated in the presence of IL-10 are not immature, however.
They downregulate antigen uptake and rapidly increase their expression ofMHC and
B7. Even at the peak of their activation, though, IL-10 treated DCs fail to stimulate
T cell proliferation. Their activated state gives them a theoretical advantage over
immature cells: it implies a greater functional stability, and hence a smaller risk of an
unwanted immune response. Interestingly, the DCs that enabled seemingly
permanent acceptance of the murine heart transplant were generated by culture in
very low concentrations of GM-CSF [463], The stringency of these conditions
resulted in considerable apoptotic death, and the uptake of apoptotic cells by DCs has
been shown to induce an actively tolerogenic phenotype [464].
The difficulty with arguing that the suppression of T cell responses by IL-10 DCs in
vivo happens despite or even because of their high level expression ofMHC and B7,
is one of timing. In vitro, the DCs were stimulated for 6h, pulsed with peptide
antigen and immediately introduced to purified transgenic T cells (chapter 4). The
opening conversation between the DCs and responding T cells was therefore very
likely to occur while the IL-10 treated DCs were still phenotypically activated. In
contrast, the protocol used for the in vivo experiments meant that DCs were
expressing high levels ofMHC and B7 as they were injected. The time needed to
travel to secondary lymphoid tissue and then to encounter a specific T cell might
mean that, at the point ofT cell interaction, the IL-10 treated DCs had passed their
peak of activation and had begun to downregulate their surface markers (see fig 3.7).
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Labelling DCs with fluorescent dye before injection and monitoring their arrival in
the spleen or lymph nodes would allow a relevant assessment of the timing involved.
It may be surprisingly quick. Ingulli et al. injected ova peptide s.c. into the back of
mice and used microscopy to visualise physical contact between DCs that acquired
the antigen in vivo and T cells in the draining lymph node. Interaction began 6 hours
after immunisation and peaked at 12h, a time window that closely matched the
production of IL-2 by the T cells [384], Merica et al. measured IL-2 production by
na'ive DO 11.10 T cells in lymph nodes within 2h of i.v. injection of ova peptide, and
maximal levels were seen at 6h. In antigen experienced T cells, this peak occurred at
just 1.5h after injection [383]. The high levels ofMHC and B7 on IL-10 treated DCs
early after LPS stimulation may still be relevant to the in vivo experiments described
here. The absence of cytokine production by these DCs, the presence of actively
inhibitory signalling or perhaps the premature termination of T cell stimulation might
explain the lack of T cell expansion and the consequent suppression of secondary
responses observed (see figs 5.8, 5.13 and 5.14, and the discussion in chapters 3 and
4). In support, Taams et al. have demonstrated that anergic T cells can convert an
APC into one which is unable to stimulate proliferation in normal responder cells
and, importantly, that this happens without any reduction in surface levels ofMHCI,
MHCII, B7.1 or B7.2 on the APC [465],
Given that the kinetics ofDC activation are rapid (chapter 3)[117, 118], questions of
physiology and therapeutic potential perhaps need to be separated. While a 6h
stimulation may be ideal for in vitro modelling ofDC responses [382], a shorter
period might be better for in vivo application, allowing a greater window of
opportunity for interaction with specific T cells before the DCs reach exhaustion. It
would be interesting to compare the in vivo responses to DCs given LPS and IL-10
for perhaps only 30 minutes before injection, to those generated by DCs first
stimulated for 6 or even 24h. Would the suppression of subsequent T cell responses
be stronger if the DCs were delivered earlier?
The protocol for in vivo use of these DCs could be optimised on several levels. The
concentration of antigen used to coat the DCs, the number of cells injected and the
route of administration have all been reported to affect the type of immune response
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generated [466]. First, though, I wanted to confirm that IL-10 treated DCs could be
effective against pathological immune responses. A mouse model of autoimmunity
was used to examine their therapeutic potential.
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Chapter 6 - The impact of IL-10 DCs on EAE
6.1 Introduction
Most current therapies against unwanted or pathological immune responses involve
general immune suppression [467, 468], The manipulation of dendritic cells offers a
more targeted approach, potentially reducing side effects and increasing therapeutic
success. Several techniques have been used to enhance the ability ofDCs to elicit T
cell tolerance. Dhodapkar et ul. harvested human monocyte-derived DCs early to
promote their immaturity, and with them demonstrated antigen specific inhibition of
CD8+ T cell effector function [325], Min et al. transfected murine DCs with Fas
ligand and showed that responding T cells died by apoptosis. This suppressed
allogeneic responses in vitro and increased allograft acceptance in vivo [469], The
immunosuppressive functions of IL-10 [470, 471] have also made it an attractive
candidate for therapeutic manipulation. Adenoviral delivery of recombinant IL-10
into inflamed joints was able to inhibit delayed-type hypersensitivity systemically in
mice [472] and retroviral transfection of DCs in culture enabled selection of a highly
purified and suppressive DC population [473, 474], Data presented in chapter 5
suggested that DCs activated by LPS in the presence of IL-10 can limit T cell
responses in vivo. This chapter examines their therapeutic potential by asking
whether they can also suppress clinical disease.
Multiple sclerosis (MS) is caused by a T cell mediated, autoimmune attack which
destroys the myelin insulation of nerve axons [475], Saltatory conduction is lost and
patients suffer paralysis and sensual impairment [476]. Scotland has one of the
highest frequencies of the disease worldwide: prevalence in the Lothian and Borders
region was estimated in 1996 at approximately 1 in 500 [477, 478]. In mice, MS can
be mimicked in certain susceptible strains either by active immunisation with myelin
antigens in adjuvant [479, 480] or by passive transfer ofmyelin-specific T cells
[481], In both cases, the resulting disease is known as experimental autoimmune
encephalomyelitis (EAE). It is an established and well characterised model of
autoimmunity [482] in which the timing and course of disease are known and the
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assessment of symptoms is simple and non-invasive. It is an ideal system to
manipulate.
The T cell response in EAE is Thl dominated: IFNy and TNFa enhance T cell
pathogenicity [483, 484], IL-12 contributes to disease [485] and B cells can be
protective [486], Some reports have suggested that a Th2 response inhibits disease
[298, 300], but this remains controversial. Th2 cells are known to antagonise Thl
development: IL-4 prevents the differentiation of naive T cells into Thl effectors and
IL-4, IL-13 and IL-10 can suppress IFNy-induced macrophage activity [487, 488].
Expression of Th2 cytokines in the CNS correlates with EAE remission [489, 490].
IL-4 deficient mice are not any more susceptible to EAE than their wild-type
littermates [491, 492], however, and in immunodeficient hosts, myelin specific Th2
cells induce disease [493]. After comparing EAE in IL-4 and IL-10 knockout and
transgenic mice, Bettelli et al. suggested that it was the IL-10 component of a Th2
response that protects against disease, rather than a Th2 phenotype per se [492],
This is supported by a growing appreciation of the role of IL-10 dependent
regulatory cells in controlling autoimmunity [494, 495] [323], Even the importance
of IL-10 is debated, however. IL-10 deficient mice suffer accelerated disease and
fail to recover [492, 496]. In rats, s.c. injection of recombinant IL-10 suppressed
disease [497], In mice, adenoviral expression of IL-10 in the CNS blocked EAE
induction, but systemic delivery was ineffective [498]. Repetitive injections not only
failed to protect but markedly worsened disease [499].
While the involvement of IL-10 in the pathogenesis of EAE is complex, targeting its
action to a specific time or place may still have considerable therapeutic power [498,
500], In this chapter, IL-10 treated DCs are shown to be effective suppressors of
EAE when injected either before or after induction of disease. The data are yet
preliminary, but the effect is promising.
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6.2 Approach
These experiments used a model ofEAE in which disease is actively induced in
C57B1/6 mice by immunisation with the immunodominant epitope ofmyelin
oligodendrocyte glycoprotein (MOG35.55 peptide). It was first described by Mendel
et al. in 1995 [480] and is routinely used in Edinburgh by Steve Anderton and
colleagues [327], Disease was triggered by s.c. immunisation with MOG35.55
emulsified in CFA on day 0 of the experiment. Pertussis toxin was injected i.p., both
on day 0 and again on day 2. The pertussis toxin functions as an additional adjuvant
[501] and acts directly on the blood-brain barrier to allow leukocyte entry to the CNS
[502, 503]. Mice showed a monophasic disease with onset of symptoms around day
9 and recovery for most mice by day 28. Mice were checked daily and scored
according to the severity of their paralysis:
grade 0 = healthy
grade 1 = limp tail
grade 2 = impaired righting reflex
grade 3 = partial hind limb paralysis
grade 4 = total hind limb paralysis
grade 5 = total hind limb and partial fore limb paralysis
grade 6 = moribund or dead
To investigate the influence of IL-10 treated DCs on clinical disease, DCs were
grown from C57B1/6 bone marrow progenitors and harvested at day 7 of culture.
Cells were washed, stimulated with LPS and IL-10 for 6h, pulsed with MOG35-55 for
90min and injected i.v. into C57B1/6 hosts. This was done three times, either 7, 5
and 3 days before the same mice were immunised to induce EAE, as suggested by
Menges et al. [Ill], or on days 0, 2 and 4 after immunisation. Mice were then
monitored for the duration of disease before being sacrificed. Their spleens and
inguinal lymph nodes, the nodes draining the s.c. site of immunisation, were
harvested and cultured with MOG35.55 to assess their in vitro recall responses. The
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Clinical scoring of disease
In vitro restimulation assays
Figure 6.1 Experimental outline. A model of EAE was used to investigate whether
IL-10 treated DCs could inhibit autoimmune disease. DCs were injected three times,
normally 7, 5 and 3 days before EAE was induced by immunisation with MOG35.55
peptide and adjuvant. Disease became apparent around day 9. Mice were checked daily
from day 7 and graded according to the severity of their paralysis.
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6.3 Results
6.3.1 1L-10 treatedDCs limit the severity ofEAE
To determine whether the ability of IL-10 treated DCs to suppress T cell proliferation
in vivo (see fig 5.14) extended to an inhibition of pathogenic T cell activity, DCs
were stimulated with LPS and IL-10 before being pulsed with MOG35.55 and injected
into mice that were later immunised to induce EAE. DCs were given 7, 5 and 3 days
before immunisation. Their effect on the development of disease is illustrated in fig
6.2. Mice that were mock-injected with PBS showed a typical disease course, with
clinical symptoms becoming apparent 8-9 days after immunisation, reaching
maximum severity around day 14 and then steadily healing. Mice that received IL-
10 treated DCs pulsed with MOG35-55 appeared to be protected from disease. The
severity of their symptoms was reduced below that of the PBS controls, and their
recovery was accelerated. Unexpectedly, a similar suppression of disease was also
achieved with IL-10 treated DCs that had not been deliberately coated with peptide
(fig 6.2).
Figure 6.2 Pretreatment with IL-10 DCs suppresses EAE disease. DCs were harvested at day
7 of culture, stimulated in the presence of IL-10 and pulsed (IL-10 DCs + MOG) or not (IL-10
DCS alone) with MOG35.55. The DCs were injected into mice 7, 5 and 3 days before they were
immunised to induce EAE. The severity of disease was recorded daily using a discrete clinical
scoring system where grade 0 is healthy and grade 6 is moribund (see Materials and Methods,
chapter 2). The data is shown as the mean score within each group, ± SEM. For the PBS controls,
77=7; for IL-10 DCs + MOG, n=5, for IL-10 DCs alone, tt=3. The disease burdens for both DC
groups were significantly less severe than that of the PBS controls (P=0.0001 for both groups,
using the Mann Whitney rank sum test). This experiment was performed twice; the repeat is
illustrated in figure 6.6.
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6.3.2 In vitro restimulation responses
Recovery from EAE has been associated with expression of the cytokines IL-4 and
IL-10 [492, 504], To test whether the suppression of disease seen in fig 6.2
correlated with a Th2 bias, lymph node and spleen cells were harvested from these
mice and their proliferation and cytokine production measured in response to
restimulation in vitro. In keeping with the milder paralysis that they experienced,
cells from mice that had received IL-10 treated DCs either with or without antigen
proliferated less when rechallenged with MOG35.55 than those from control mice (fig
6.3). This was clear both in lymph node and spleen but again, there was little
difference between the two DC groups.
The lack of proliferation seen in restimulation cultures from mice given IL-10 DCs
could reflect either a smaller in vivo T cell expansion, leaving fewer specific T cells
in each well of the in vitro assay, or an initially equivalent expansion that, perhaps
through anergy or suppression, displays reduced proliferation on restimulation.
MHC:peptide-tetramer technology (reviewed in [505]) may soon be able to
distinguish the two possibilities directly, but for now, some direction can perhaps be
taken from the cytokine profiles of the cultures (fig 6.4). Cells from control mice
secreted IFNy but little IL-4, consistent with a Thl mediated disease [483, 484],
although interestingly the splenocytes also produced some IL-10. Cells from mice
that received IL-10 DCs secreted less IFNy but without any concomitant increase in
IL-4 production and, if anything, a loss of IL-10. The explanation for their reduced
severity of disease does not appear to be a Th2 skew. The general lack of cytokine
production is similar to that seen when DO 11.10 T cells originally activated by IL-10
treated DCs were restimulated in vitro (see fig 4.6) and, as discussed in chapter 4, it
















Figure 6.3 Restimulation in vitro. DCs were stimulated in the presence of EL-10 and
pulsed, or not, with MOG35.55. They were injected into mice 7, 5 and 3 days before
immunisation to induce EAE. The disease course for each group is shown in figure 6.2.
After recovery, mice were killed on day 30 and their spleens (A) and inguinal LNs (B)
collected. Cells were pooled within groups, plated with graded doses of MOG35.55 and
proliferation measured by 3H-thymidine incorporation during the last 16h of a 3d













































Figure 6.4 Cytokine profiles. DCs were stimulated in the presence of IL-10 and pulsed, or not,
with MOG35.55. They were injected into mice 7, 5 and 3 days before EAE induction. The disease
course for each group is shown in figure 6.2. After recovery, mice were killed on day 30 and
their spleens and inguinal LNs collected. Cells were pooled within groups, plated with graded
doses ofMOG35.55 and their cytokine production measured by a cell based Elisa method. Data is
shown as the mean of duplicate wells.
139
6.3.3 IL-10 treated DCs are effective after disease induction
While the suggestion that pre-treatment with IL-10 DCs can reduce the severity of
EAE is encouraging, particularly in its support of the suppression ofDO11.10 T cell
responses described in chapter 5, its therapeutic relevance is limited by the difficulty
in identifying people at risk ofmultiple sclerosis before symptoms occur. To move
towards an assessment of the potential of IL-10 DCs to treat rather than prevent
EAE, the DC injections were delayed and given instead on days 0, 2 and 4 of the
experiment, alongside the CFA and pertussis immunisations that provoke disease.
Their impact on the severity of symptoms is shown in fig 6.5. Disease was much
milder in mice that received IL-10 treated DCs coated with MOG35.55 than in the
PBS controls: onset was delayed, peak severity was reduced and recovery was
accelerated. IL-10 DCs without antigen also delayed the onset of disease slightly,
but the total disease burden was not significantly reduced below that of the controls
(fig 6.5). DCs activated in the presence of IL-10 can reduce the severity ofEAE
even when delivered after the induction of disease, and in this case it appears to be an
antigen specific effect.
Time after disease induction (days)
Figure 6.5 IL-10 treated DCs given after disease induction. DCs were harvested at day 7
of culture, stimulated in the presence of IL-10 and pulsed (IL-10 DCs + MOG) or not (IL-10
DCS alone) with MOG35.55. The DCs were then injected into mice on the same day as
immunisation to induce EAE and at 2 and 4 days afterwards. The severity of disease was
recorded daily and the data is shown as the mean score of the 5 mice in each group ± SEM.
IL-10 DCs + MOG significantly reduced the disease burden below that of the PBS controls
(P<0.0001, using the Mann-Whitney rank sum test), but IL-10 DCs alone did not (P=0.1).
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♦— IL-10 DC alone
♦— IL-10 DC + MOG
Figure 6.6 Disease suppression is non-specific. DCs were harvested at day 7 of culture and
replated in medium alone, with LPS or with LPS and IL-10 together. Cells were then
pulsed,or not, with MOG35.55 and injected into mice 7, 5 and 3 days before they were
immunised to induce EAE. The severity of disease was recorded daily, and the data is shown
as the mean score of 5 replicate mice ± SEM. The only groups to experience disease burdens
significantly below that of the PBS controls here were unstimulated DCs + MOG (P=0.015,
using the Mann-Whitney rank sum test) and IL-10 DCs alone (P<0.0001). This experiment
was performed once, although some groups repeat work shown in fig 6.2.
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6.3.4 Suppression is not specific
The two initial experiments using EAE to assess the impact of IL-10 treated DCs on
pathogenic T cell responses suggested considerable promise (see figs 6.2 and 6.5),
but a clearer understanding was needed of the specificity of their effect. The first
experiment was therefore repeated with additional control groups (fig 6.6). DCs
were activated with LPS and IL-10, with LPS alone or left unstimulated. Each group
was pulsed with MOG35.55 or left without antigen, before being injected into mice 7,
5 and 3 days before immunisation with CFA. As in fig 6.2, mice that received IL-10
treated DCs experienced much milder disease than those mock-injected with PBS,
and this was true irrespective of whether the DCs had been coated with MOG35.55
before injection. With the exception of unstimulated DCs without MOG35.55, all DC
groups appeared to suppress disease; the effect was neither antigen specific nor
dependent on the state of DC activation. The variation within groups in this
experiment was unusually high, however, as illustrated by the considerable error
bars. In comparison with the PBS controls, only unstimulated DCs with MOG35.55
and IL-10 DCs alone achieved a statistically significant reduction in disease (fig 6.6).
6.3.5 Clinical summary
To further examine the effect of IL-10 treated DCs in EAE, data were compiled from
both experiments in which mice were given DC before disease induction (table 6.7).
The incidence of disease was shown to be significantly reduced by pre-treatment
with IL-10 DCs, although this was more pronounced if the DCs were not pulsed with
MOG35-55. Those mice that received IL-10 DCs and still suffered paralysis appeared
to endure a similar disease course to the PBS controls: neither the onset of symptoms
nor their peak severity was significantly affected by the administration of DCs. Is
EAE an all or nothing event in which IL-10 DCs encourage the regulatory balance to
fall in favour of health rather than disease? Analysis ofmore mice will enable a
stronger conclusion.
142




Dav of onset3 Maximum
scoreb
PBS 12/12 (100%) 44.3 9.610.3 3.810.4
IL-10 DCs+ MOG 6/10 (60%)* 10.6*** 9.3 ±0.8+ 2.7 1 0.2X
IL-10 DCs alone 2/8 (25%)** 3.0*** 9.51 1.4 2.5 1 1.4
Data are compiled from two experiments, shown individually in figs 6.2 and 6.6
a,b Data refer only to those mice showing clinical disease
*, ** Statistically different to that of the PBS controls. P = 0.029 and 0.0007, respectively, using
Fisher's exact test.
Statistically different to that of the PBS controls. P < 0.0001 using the Mann-Whitney rank
sum test.
No statistical difference to that of the PBS controls. P = 0.45 using the Mann-Whitney rank
sum test.
No statistical difference to that of the PBS controls. P = 0.08 using the Mann-Whitney rank
sum test.
6.4 Discussion
The data presented in chapter 5 suggested that an in vivo interaction with DCs
stimulated in the presence of IL-10 elicits a muted proliferation and a lasting
suppression of T cell activity. This chapter demonstrates that IL-10 treated DCs can
inhibit pathogenic T cells as well as DOl 1.10 transgenic responses; tolerance can be
achieved not just in terms of limited proliferation in in vitro restimulation assays but
also as a reduction in clinical symptoms of disease.
The ability of IL-10 treated DCs to inhibit EAE even after CFA immunisation
implies that their effect is not just to anergise a cohort of responding cells, but to
establish an active suppression of the T cell response. This strengthens the data
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obtained in the DO 11.10 bone marrow chimaeras (see fig 5.15). In support, the
activated state of the DCs, at least at the time of injection, argues against induction of
classical anergy due to lack of costimulation [391], Albert et al. [375] and Menges et
al. [Ill] have both proposed that some degree of DC maturation is needed to
establish tolerance. Indeed, the protective effect of TGF(3 in an EAE model in rats
was attributed to stimulation ofDCs [506] and blood borne DCs from patients with
MS have been shown to express unusually low levels of the activation marker B7.2
[507, 508], Immature DCs have also been associated with pathology in autoimmune
diabetes [509, 510], lupus [511] and Graves' disease [512].
An argument based on the activation state of the DCs is perhaps undermined by the
equivalence of the different DC populations revealed in fig 6.6, however. The
experiment needs to be repeated before firm conclusions can be drawn, and it is also
true that the similar effects of the three DC populations do not necessarily reflect
similar mechanisms. While the unstimulated DCs used in these experiments do show
some degree ofmaturation (see fig 3.4, for example), probably encouraged by the
handling that they receive before injection [104], a comparable protocol was used by
Dhodapkar et al. to demonstrate CD8+ T cell tolerance in vivo [325], Inhibition of
disease by LPS activated DCs was more surprising. A similar result has been
described by Bettelli et al. in their comparison ofEAE in IL-4 A and IL-10"/_ mice
[492]. While the absence of endogenous IL-10 caused very severe EAE in response
to MOG35-55 in CFA, the same immunisation in combination with pertussis toxin
gave much milder symptoms. The additional stimulus of the second adjuvant
ameliorated disease. This negative feedback could be explained by the induction of
iNOS expression in strongly activated DCs, leading to nitric oxide release and
consequent T cell apoptosis [513, 514],
The other issue of specificity raised in this chapter is the intriguing ability of DCs
without antigen to mimic the effect of those pulsed with MOG35-55 (figs 6.2 and 6.6).
Initially I assumed that this was symptomatic of the same high background responses
that were afflicting the DOl 1.10 experiments at the same time (see fig 5.9). As
illustrated in fig 5.10, even unpulsed DCs were generating very strong, non-specific
proliferative responses and it was possible that these could overwhelm any MOG-
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specific proliferation and inadvertently protect their hosts from EAE [515]. Arguing
against this, the proliferation seen in in vitro restimulation assays from these EAE
experiments was peptide dose dependent and of the two EAE experiments completed
at this time (figs 6.2 and 6.5), only one appeared non-specific. Ironically, the
experiment set up after the serum issue had been solved with the intention of
demonstrating specificity (fig 6.6) showed particularly impressive disease
suppression by unpulsed, IL-10 treated DCs.
There are more interesting explanations. Tolerogenic DCs may be able to condition
their environment, perhaps through the secretion of cytokines such as IL-10 or TGF(3
[112, 330, 473, 516]. As long as the release of these cytokines is independent of T
cell engagement [259], IL-10 treated DCs both with and without antigen could
convert surrounding APCs into tolerogenic cells. When the CFA immunisation then
delivers a depot of specific antigen for endogenous presentation, the T cell response
would be limited and clinical disease suppressed.
Alternatively, DCs not pulsed with peptide in vitro might be able to acquire antigen
in vivo. In experiments in which mice were given DCs before EAE induction, this
would require the DCs to remain alive and capable of collecting and presenting
antigen 3 days after injection, when the MOG35.55 was delivered in the CFA
immunisation. This is possible (fig 3.8)[155], The DCs would also need to be able
to access the antigen. If endogenous APCs such as Langerhans cells carried the
peptide from the s.c. site of immunisation to the draining lymph node, it could be
transferred there onto DCs that originated in the injected population. Such hand-over
of antigen has been reported [217, 517], although data described in chapter 5
suggested that systemic delivery of DCs was relatively inefficient in reaching the
lymph nodes (see fig 5.7). The administration ofDCs several weeks before
immunisation with MOG35.55 might be revealing here, since DCs are unlikely to
survive that period [155] and so acquisition of antigen from the CFA deposit would
be prohibited.
The concept of in vivo acquisition of antigen has mixed implications. On the one
hand, it appears to defeat the aim of antigen-specific manipulation of the immune
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system for which DCs seemed such an attractive tool. On the other, the specific
antigens responsible for multiple sclerosis are not yet known, so pulsing DCs with
peptide in vitro is not currently an option in the treatment of human disease. MOG
constitutes only 0.01-0.05% ofmyelin proteins [518] and while there are more
abundant components, such as proteolipid protein and myelin basic protein, both of
which have immunodominant epitopes mapped [519, 520], there is little evidence
that these are clinically relevant [521, 522], Indeed, it has been suggested that the
relapsing and remitting disease so characteristic ofMS is a result of renewed waves
of autoimmune attack as the T cell response switches focus from one epitope to
another [523]. Although the EAE model used here is a monophasic disease, one
possible explanation for the apparently greater suppression of disease by IL-10
treated DCs without MOG35.55 than by the same DCs coated with peptide in vitro
(see figs 6.6 and 6.7) is that the unpulsed DCs are able to acquire an array of
biologically relevant antigens from the damaged CNS in vivo.
This is an idea that Xiao and colleagues have tried to exploit therapeutically.
Remarkably, they reported that bone marrow precursors taken from a rat that had
recovered from EAE and cultured for 7 days to generate DCs, can protect other rats
from subsequent attempts to induce disease [524], The authors argue that bone
marrow DCs are pulsed with CNS antigens in vivo and that the culture period merely
serves to expand the population, although how the antigens are also multiplied is
unclear. The same group have also described the use of CD8- splenic DCs, purified
from rats suffering EAE and treated in vitro with either IFNy or TGF(3, to inhibit the
development of disease in naive animals (quoted as unpublished data in [525]). It
would be very interesting to test whether DCs isolated from the lymph nodes or
spleens of the EAE mice used here, and ultimately from the blood ofMS patients,
could be activated in the presence of IL-10 in vitro and re-infused to achieve a
similar suppression of disease in vivo.
Current therapies for MS focus on general immune suppression, although this may be
mediated via the patient's endogenous DCs. Methylprednisolone, used to treat acute
relapses [526], is a potent corticosteroid shown to inhibit the differentiation of
monocytes into DCs [527], Related steroids have been reported to act on immature
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DCs to prevent their maturation [218, 528], In contrast, IFNJ3 is administered long-
term to prevent the occurrence of relapses and delay progression to disability [529],
IFN(3 appears to enhance DC activation while skewing their phenotype towards one
that favours the development of a Th2 response. DCs stimulated in the presence of
IFN(3 make little IL-12 [530] but instead release IL-10 [531] and consequently
encourage a T cell reaction dominated by IL-13, IL-5 and IL-10 [532],
Activating DCs in vitro in the presence of IL-10 has the advantage of concentrating
the action of the cytokine onto appropriate cells and with relevant timing. Systemic
administration of IL-10 has been reported to inhibit collagen induced arthritis [533],
but to aggravate EAE [499], Cua et al. have shown that targeting the IL-10 to the
site ofAPC:T cell interaction, by expressing recombinant IL-10 under an MHCII
promoter, completely protects the transgenic mice from EAE [500]. Interestingly,
this IL-10 is apparently sufficient to prevent disease: transgenic mice on an IL-10"/_
background are also protected. T cell release of IL-10 is not required. While little
IL-10 production was detected in the DCs used here (fig 3.11), IL-10 can act on DCs
in an autocrine manner [212], The transgenic IL-10 could be influencing the APCs
as well as the effector T cells. Cua et al. go on to demonstrate that therapeutic IL-10
must be able to enter the CNS [498], They achieve this by direct intracranial
injection, but circulating lymphocytes may provide an alternative means of access. If
T cell IL-10 is dispensable, B cells might be responsible [327, 534],
The data in this chapter suggest that IL-10 treated DCs can suppress pathogenic T
cell responses in a mouse model ofEAE, and hence reduce the severity of disease.
There are interesting experiments to be done, including the optimisation of the period
of DC stimulation and the timing of DC administration. Even at this preliminary
stage, however, the potential for therapeutic benefit looks exciting.
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Chapter 7 - Discussion and Conclusions
7.1 Summary
IL-10 is one of a number of factors reported to modulate DC function by trapping the
cells in an immature state. Others include apoptotic cells [83, 464], malaria-infected
erythrocytes [30] and steroidal anti-inflammatories [218], so the mechanism of
regulation is relevant to immunity, tolerance, infection and therapy. Data presented
in this thesis have shown that DCs activated in the presence of IL-10 do respond to
LPS stimulation, downregulating antigen uptake and increasing expression of MHC
and B7 (chapter 3), but that this activation is transient and does not stimulate strong
T cell proliferation (chapter 4). The T cell response is instead characterised by
limited proliferation and reduced cytokine production upon restimulation (chapters 4
and 5). The suppressive influence of IL-10 treated DCs is effective in vivo (chapter
5) and can limit the severity of disease in a mouse model of autoimmunity (chapter
6). These cells may have considerable therapeutic potential.
7.2 Discussion
7.2.1 DC activation in the presence ofIL-10
The observation that a combination of LPS and IL-10 can elicit an activated DC
phenotype, with high surface expression ofMHCII, B7.1 and B7.2 (fig 3.5), is in
contrast to the common perception of IL-10 as an inhibitor ofDC maturation [216],
The discrepancy may be a result of the kinetics ofDC activation: at 24h post
stimulation, IL-10 treated DCs do display lower levels ofMHC and B7 than
equivalent cells given LPS alone (fig 3.7). The idea that DC mediated regulation of
the immune response can occur despite or even because ofMHC and B7 expression
is not without support. A number of recent reports have described the suppression of
T cell responses by phenotypically activated DCs [111, 112, 330, 375], DC
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maturation is not a single event, and the different levels of DC activation that
contribute may each have a distinct influence on the consequent T cell response
[113]. Indeed, the 'steady-state' migration of peripheral DCs into lymph nodes that
is proposed to maintain peripheral tolerance [220], must be accompanied by some
degree of DC activation in order to trigger the upregulation ofCCR7 required for
entry into secondary lymphoid tissue. Steinman spoke of discrete stages of DC
maturation in which the change in chemokine receptors preceeded the surface
stabilisation ofMHCII, which in turn preceeded B7 expression (Steinman, 2002,
N1H/NIAID meeting, Airlie, Virginia, USA). The separation of the DC life cycle
into just two phenotypes, tolerogenic immature DCs and immunogenic mature cells,
may be over simplistic [535],
7.2.2 T cell anergy
The attraction of a decisive DC activation state in response to stimulation in the
presence of IL-10 is that it implies a greater functional stability than that of immature
cells. Hawiger et al. demonstrated that the T cell tolerance induced by immature
DCs could be broken by concomitant DC stimulation [328], Nelson et al. have
described cyclic DC activation in response to repetitive stimulation with TNFa
[536], but this is hard to reconcile with the limited life-span of DCs in vivo [155]. It
would be interesting to assess the dominance of the putative regulatory phenotype of
IL-10 treated DCs. Could IL-10 treated DCs maintain tolerance to the antigen they
present in the face of a strong immune response to a different peptide delivered on
co-injected LPS-activated DCs?
In vitro, IL-10 treated DCs alone elicit a limited T cell proliferation (fig 4.2) that
appears to leave the T cells hyporesponsive to rechallenge. Their proliferative
response to restimulation is weak (fig 4.5) and they make little cytokine (fig 4.6).
This phenotype is suggestive of T cell anergy [289], and analysis of T cell expression
of IL-2 would have been informative. In vivo, particularly in the lymph node, the
ability of IL-10 treated DCs to inhibit T cell proliferation in response to rechallenge
was clear (fig 5.14). The stronger result in vivo may reflect sub-optimal culture
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conditions in vitro. Exogenous IL-2 was added to the T cell cultures, which can
overcome T cell anergy [295], Alternatively, the explanation may lie in the different
timing of the two experiments. In vitro, the DCs were mixed with T cells at 6h after
stimulation, at the peak ofMHC and B7 expression on IL-10 treated DCs. In vivo,
the DCs were injected at this stage. Even if DC migration from the periphery to
secondary lymphoid tissue is rapid, possibly within 4-6h [382], this delay may mean
that the ex vivo IL-10 treated DCs have downregulated their expression ofMHC and
particularly B7 by the time they encounter specific T cells (fig 3.7). The T cell
suppression observed in figs 5.13 and 5.14 may then be an in vivo demonstration of
the same anergic tolerance seen in response to IL-10 treated DCs 24h after
stimulation, originally interpreted as a result of IL-10 mediated 'inhibition' of DC
maturation [205], Powerful microscopy techniques are now becoming available
which might allow direct visualisation of the levels of B7 expressed on injected DCs
during T cell engagement [377, 537].
7.2.3 Regulatory Tcells?
A pressing question that arises from the data presented in chapter 4 and particularly
in chapter 5 is whether the hyporesponsive T cells induced by IL-10 treated DCs are
also suppressive. The precedent for DC induction of regulatory T cells has been set:
both Akbari et al. McGuirk et al. have recently described the ability ofmature DCs
to elicit Trl like T cells [112, 330]. In contrast to these reports, however, the IL-10
treated DCs used here did not express any detectable IL-10 (fig 3.11). While IL-10
appears fundamental for the development ofTrl cells, other regulatory T cell
phenotypes exist and other molecules are important in their differentiation (reviewed
in [312, 314]). A comparison of the levels of TGF(3 secreted by DCs activated with
LPS alone and with LPS and IL-10 would be interesting [324],
The greatest need, however, is for some functional assessment of the responding T
cell populations. The simplest approach may be to mix the two DC populations and
measure the net T cell proliferation. If T cells responding to IL-10 treated DCs are
anergic but not suppressive, the proliferation in the combined culture should be
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equivalent to that induced by LPS-activated DCs alone. More elegantly, the
recovery of T cells from DC co-cultures for subsequent titration into nai've T cell
populations, either in vitro or in vivo, would enable a direct demonstration of T cell
suppression. Bone marrow chimaeras are particularly attractive hosts for this type of
experiment (figs 5.15 and 5.16), since the sustained thymic output of antigen specific
T cells provides the nai've targets for suppression and therefore negates the
requirement for successive T cell transfers. The preliminary experiment illustrated in
figure 5.16 may indicate that IL-10 treated DCs can elicit an active T cell
suppression. Although encouraging, the 5 day interval between primary
immunisation and secondary challenge may have been too short to allow the
accumulation of a significant nai've T cell population [538, 539]. Increasing the
period from 5 days to several weeks may be revealing.
7.2.4 Physiological context
The data in this thesis suggest that LPS and IL-10 together drive a tolerogenic DC
phenotype that can render T cells hyporesponsive to rechallenge. The combination
of LPS and IL-10 is important: DCs given IL-10 alone do not respond to subsequent
stimulation [540] and fully mature DCs are no longer affected by IL-10 addition
[117]. It is perhaps an unusual partnership, requiring either the presence of IL-10 in
the periphery or of LPS in the secondary lymphoid tissues. Both situations do occur.
In the liver, hepatocyte secretion of IL-10 may act on resident DCs to dampen local
immune responses [201]. In the skin, keratinocyte expression of IL-10 is markedly
enhanced by contact sensitisation or UV irradiation [85, 86]. The intracellular stores
that these cells accumulate mean that damaged keratinocytes may spill IL-10 into the
surrounding microenvironment. An infected cut therefore provides a good
opportunity for simultaneous LPS and IL-10 signals, but a tolerogenic response to
this situation is unlikely to be desirable. IL-10 production by keratinocytes may
instead be related to the suppression of immune reactivity against harmless
environmental antigens or commensal bacteria that live on the skin [39].
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The presence of LPS in secondary lymphoid tissue normally indicates a systemic
infection, either due to direct inoculation into the bloodstream or to the failure of the
immune system to contain the infection at the site of entry. Clinically, systemic
infections are serious [541] and it is perhaps counter-intuitive to discuss tolerance
induction at the same time as an urgent need for antibiotics. The life-threatening
pathology of septic shock syndrome or meningococcal septicaemia is associated with
extremely high levels of circulating IFNy and TNFa [542]. The ability of splenic or
lymph node DCs to respond to concomitant LPS and IL-10 by promoting T cell
tolerance or suppression may be critical to regulating the balance of effective
immunity and minimal immune damage. Indeed, splenic B cells have been shown to
react to IL-12 by releasing IL-10, which suggests that activated B cells in secondary
lymphoid tissues can downregulate Th 1 responses by dampening the stimulatory
capacity of DCs [271]. Any such B cell regulation would have to act on DCs
resident in the spleen or lymph nodes, or on those arriving from the periphery as part
of a sustained influx. Data shown in fig 3.10 suggests that, while DCs given LPS for
24h are resistant to the effect of IL-10, at 6h post-stimulation they remain responsive.
The window of opportunity during which the DC must receive signals from both LPS
and IL-10 in order to assume a tolerogenic phenotype may be sufficient to include
the time needed to travel from the periphery to the draining lymph node.
7.2.5 Therapeutic promise
Whatever its physiological setting, the capacity of LPS and IL-10 to elicit a DC
phenotype that limits T cells responses has considerable therapeutic promise. The
clinical applications of dendritic cells are becoming widely appreciated (reviewed in
[543]), although the majority of patient trials to date have focussed on the ability of
DCs to enhance anti-tumour immunity [345] [544], In mice, DCs can elicit complete
tumour rejection [433]; in man, similar efficacy can be achieved but as yet without
the same consistency [545], The use of cytokine conditioning to manipulate DC
function offers the potential to direct a range of different immune responses. DCs
cultured in GM-CSF and TGF(3 have been shown to prolong survival of experimental
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heart allografts [546] and those grown in GM-CSF and IL-4 reduce the incidence of
type 1 diabetes in non-obese diabetic (NOD) mice [547], Results presented here
have demonstrated that DCs activated in the presence of IL-10 can generate a limited
T cell response that leaves the T cells hyporesponsive to subsequent challenge
(chapter 4). These DCs are effective in vivo (chapter 5) and can reduce the severity
of disease in a mouse model ofmultiple sclerosis (chapter 6). The data are
preliminary but promising. The early clinical trials of DCs as cancer therapy have
served to confirm the safety and feasibility of using protocols based on antigen
pulsing of cultured DCs to combat disease [545, 548],
7.2.6 Therapeutic challenges
One of the major hurdles in translating data from animal models into human
relevance is the need not just to prevent disease, but to treat established symptoms.
Fig 6.4 demonstrates that IL-10 treated DCs are effective in suppressing EAE when
given at the time of disease induction, but it would be valuable to delay DC
administration until the onset of symptoms and even into established disease. Both
mice that lack B cells and those whose B cells are IL-10 deficient suffer a severe,
non-remitting form ofEAE [327], and such animals might provide a means of
assessing the ability of IL-10 treated DCs to promote recovery. A comparison of the
efficacy of DCs when used as prophylaxis, to treat active disease and to prevent
relapses would be interesting, both to assess potential clinical benefit and to
understand more about the influence of the different immune system environments
into which the DCs are delivered.
In multiple sclerosis, successive relapses have been associated with epitope
spreading and renewed waves of autoimmune attack [523], A critical question then
is whether administration of IL-10 treated DCs loaded with one antigen can suppress
T cell responses to another. EAE can be induced in different strains of mice using
encephalitogenic peptides derived from myelin basic protein (MBP) and proteolipid
protein (PLP) as well as the MOG35-55 used here. Attempts to modulate disease
induced with one peptide by injection of DCs pulsed with another would be
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instructive. Tumour vaccination strategies have often used DCs pulsed with whole
tumour lysates in order to include a range of clinically relevant epitopes [545, 548].
Oral administration of bovine myelin to multiple sclerosis patients has been reported
to induce regulatory Th3 cells against epitopes of both MBP and PLP [323], but
safety concerns over BSE must now prohibit this approach. The ability of DCs to
pick up antigen in vivo is intriguing and a rigorous investigation is needed. This
approach also has inherent dangers, however. Human patients will inevitably carry
unrelated antigens, such as those of latent viruses or sub-clinical bacterial infections,
which a scavenging DC may also be able to access and to which tolerance may be
disastrous. The use of IL-10 treated DCs in deliberately infected mice would be
interesting.
7.3 Conclusions
The data presented in this thesis have demonstrated that IL-10 treated DCs do
respond to stimulation. They show an early upregulation of surface MHC and B7
but, even when phenotypically active, they fail to elicit strong T cell proliferation.
Both in vitro and in vivo, the interaction with DCs activated in the presence of IL-10
leaves specific T cells hyporesponsive to rechallenge. In a model of autoimmunity,
these DCs reduce symptoms of disease. Together, the data suggest that, rather than
inhibiting DC maturation, IL-10 directs an active DC phenotype that can regulate
immune responses. In vitro manipulation ofDC function can influence the outcome
of immune responses in vivo.
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